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Abstract 
 
β-alanine is a relatively new ergogenic aid and a number of questions relating to its 
effectiveness in enhancing high intensity exercise performance remain to be addressed. The 
five studies described in this thesis examined the influence of β-alanine supplementation 
and high intensity training on exercise capacity and considered factors that potentially 
influence dosage compliance and side effects – factors that may impact on the ergogenic 
value of β-alanine supplementation. Study 1 examined the efficacy of β-alanine 
supplementation in conjunction with repeated sprint and sprint interval training (and 
combined with a pre-exercise dose of sodium bicarbonate), on repeated-sprint ability and 
high intensity cycling capacity (time to fatigue at 110% of maximum power output).  β-alanine 
supplementation, when combined with sprint and interval training, improved repeated sprint 
ability but did not influence high intensity cycle capacity. Furthermore, acute sodium 
bicarbonate ingestion improved high intensity cycle capacity before training but had no 
influence on either repeated sprint ability or exercise capacity after training.  It is likely that 
intramuscular buffer capacity increased as a result of training and that this may have 
outweighed the potential ergogenic buffering effects of β-alanine and sodium bicarbonate 
(i.e., both alone and in combination).   
 
Study 2 investigated β-alanine supplementation use and level of knowledge amongst 
professional rugby union (n = 87), rugby league (n = 180) and Australian Rules Football (n 
= 303) players. Over half the professional footballers surveyed used β-alanine, yet most 
supplemented in a manner inconsistent with recommendations. A better understanding of 
the environment and culture within professional football codes is required before supplement 
use aligns with evidence-based β-alanine supplementation recommendations. In light of 
these findings, Study 3 examined compliance levels to β-alanine supplementation in an 
applied setting.  Compliance over a 28 day period was 59% (± 24%) which was significantly 
lower than the mean compliance rate reported by others (96%) (p < 0.0001).  It was 
concluded that the determinants of β-alanine (non-) compliance in athletes needed to be 
further investigated. Study 4 examined potential relationships between different β-alanine 
dosages and side effects. Healthy male participants were divided into low (< 75 kg) and high 
(> 85kg) body mass groups and completed three supplementation treatments: 1. a placebo, 
2. β-alanine as a relative dose of 0.02 g·kgBM-1 and 3. β-alanine as an absolute dose of 1.6 
g. For 90 min following supplementation in each condition, participants completed a 
questionnaire that sought responses to side effects. It was found that lighter individuals 
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experienced fewer side effects when they supplemented with β-alanine as a dose relative 
to body mass; heavier individuals experienced fewer side effects when they consumed an 
absolute dose of 1.6 g.  It was concluded that individualising the supplementation of β-
alanine is likely to reduce side effects and in turn improve compliance. Finally, Study 5 
assessed whether the paraesthesia experienced following acute β-alanine supplementation 
was related to high intensity exercise performance. There was no relationship between the 
level of paraesthesia experienced by participants and exercise capacity. However, individual 
differences in side effects were found after repeated doses of β-alanine and some 
participants experienced side effects after consuming the slow release β-alanine formula. 
The findings of Study 5 highlight the need to further understand the underlying mechanism 
of side effects and impress the need to monitor and report side effects in future studies – 
particularly in β-alanine supplementation studies where participant blinding is required.   
 
Collectively, the studies described in the present thesis extend knowledge relating to β-
alanine supplementation; specifically how supplementation practices can be individualised 
to improve compliance by practitioners and sport scientists in applied settings. 
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CHAPTER 1: INTRODUCTION 
 
β-alanine is an amino acid involved in the synthesis of carnosine, an intramuscular 
compound that buffers pH and has been associated with improvements in high 
intensity exercise performance.  Saunders et al. [1] [2] completed a meta-analysis 
examining the effects of β-alanine supplementation on 65 exercise tests; assessing 
70 measures, they found a significant overall effect size of 0.18.  Subgroup analyses 
also identified the type ofexercise as a significant (p=0.013) moderator of effect sizes 
within an exercise time frame of 0.5–10 min with greater effect sizes for exercise 
capacity. Whilst a variety of studies have been completed examining the efficacy of β-
alanine, there are a number of unanswered questions relating to its effectiveness; 
current usage habits, side effects following acute supplementation and whether β-
alanine can enhance repeated-sprint exercise performance when supplementation is 
combined with high intensity training.    
 
While research to date generally suggests that high intensity exercise performance 
can be improved following chronic β-alanine supplementation, current evidence 
regarding the efficacy of β-alanine supplementation when combined with a training 
intervention is equivocal [3-5].  It is important that when β-alanine supplementation 
randomised control trial (RCTs) findings are implemented into real-world sports 
settings, rather than just contrived laboratory settings, that they are used by the target 
group in the way that was intended.  The efficacy of supplements and the 
dissemination of their findings is needed to determine if athletes are adhering to 
recommended dosages and protocols and therefore providing the best opportunity to 
gain maximum ergogenic benefit.  The current supplementation practices and level of 
knowledge relating to the benefits of supplementing with β-alanine among elite 
athletes is unclear. Given that greater adherence to a supplement correlates strongly 
with an individual’s knowledge of the therapy [6], poor knowledge of the benefits and 
correct dosages of β-alanine may influence adherence.  This is especially relevant to 
β-alanine supplementation, as multiple daily doses of β-alanine over several weeks 
are necessary to optimise increases in muscle carnosine levels over a period of time; 
non-compliance is thus likely to reduce the potential of β-alanine supplementation to 
improve performance.  Oral free powder β-alanine doses that exceed 800 mg are 
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generally associated with side effects that include paraesthesia. The level of these 
acute side effects following ingestion may also influence compliance.  To date, factors 
that influence compliance to a β-alanine supplementation program and strategies that 
may minimise the side effects have not been investigated.  An improved understanding 
of these factors will inform recommendations for individualising β-alanine 
supplementation that in turn may improve its effectiveness in applied settings. Finally, 
free powder β-alanine induced paraesthesia may induce a placebo effect, defined as 
a positive impact on performance resulting solely from the belief that beneficial 
treatment has been received. Although there is no current underlying mechanism to 
explain how acute β-alanine supplementation could acutely enhance performance, it 
is plausible that athletes believe that the sensations associated with supplementation 
are suggestive of an ergogenic aid and that this is sufficient to improve performance. 
 
The aim of this thesis was to examine the efficacy of β-alanine supplementation 
combined with high intensity training and consider factors that potentially influence an 
athlete’s decision to use β-alanine and factors that may influence their decision to keep 
using it, such as side-effects and dosage compliance.  From a practical perspective 
the aim was to consider factors that influence how the findings of β-alanine research 
are likely to be translated into practice.  The thesis is presented as a sequence of 
individual chapters for clarity and coherence. Chapter 2 reviews the current literature 
relating to β-alanine supplementation.  Five original investigations are then presented 
(Chapters 3 – 7), each addressing different research questions relating to β-alanine 
supplementation.  Firstly, in Chapter 3 the efficacy of β-alanine supplementation, in 
conjunction with sprint and interval training in addition to acute sodium bicarbonate 
intake, on repeated-sprint ability and high intensity cycling capacity is examined.  
Following this, in Chapter 4 the prevalence of β-alanine supplementation and the 
knowledge and attitudes to using β-alanine amongst professional football players is 
examined. In Chapter 5, the compliance to β-alanine supplementation in an applied 
setting to determine whether current practices are meeting recommendations is 
investigated while in Chapter 6 the influence of different β-alanine doses on side 
effects, again in the context of addressing compliance is investigated.  The final 
investigation, described in Chapter 7, assesses whether the paraesthesia experienced 
following acute β-alanine supplementation influences exercise performance.  Chapter 
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8 summarises the findings of the thesis, provides practical applications for the use of 
β-alanine and briefly outlines directions for future research. 
 
Outlined below are the specific aims and significance of the original investigations. 
 
CHAPTER 3 (Study 1): EFFECT OF REPEAT SPRINT TRAINING, β-ALANINE AND 
SODIUM BICARBONATE ON REPEAT SPRINT ABILITY AND HIGH-INTENSITY 
CYCLING CAPACITY 
 
AIM 
The aim of Study 1 was to investigate whether supplementation of β-alanine for 28 
days, in conjunction with repeated sprint and sprint interval training and when 
combined with a pre-exercise dose of sodium bicarbonate, could improve repeated-
sprint ability and high intensity cycling capacity in healthy males. 
 
SIGNFICANCE 
To date, research has shown that β-alanine and sodium bicarbonate supplementation 
can independently improve high intensity exercise performance and some studies 
have found that when combined, performance may be further improved.  The findings 
from those few studies that have combined β-alanine supplementation with sprint 
interval training have not shown any additive benefits compared to single 
interventions.  Research is yet to examine the potential combined influence of β-
alanine and sodium bicarbonate in addition to repeat sprint and interval training on 
high intensity exercise performance.  The purpose of this study was to provide insight 
into the influence of training on performance compared to the potential ergogenic 
effects of β-alanine and/or NaHCO3 (i.e., alone or in combination).   
 
CHAPTER 4 (Study 2): PREVALENCE, KNOWLEDGE AND ATTITUDES RELATING 
TO β-ALANINE USE AMONG PROFESSIONAL FOOTBALLERS 
 
AIM 
The aim of Study 2 was to investigate the prevalence of β-alanine supplementation 
amongst professional football players and to evaluate the knowledge and attitudes of 
those athletes using β-alanine.  
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SIGNFICANCE 
The purpose of this study was to gain insight into the current habits and level of 
knowledge of β-alanine with a view to informing ‘current best practice for this 
population’ amongst professional sporting staff for their athletes in relation to effective 
β-alanine supplementation. 
 
CHAPTER 5 (Study 3): COMPLIANCE OVER 28 DAYS OF β-ALANINE 
SUPPLEMENTATION  
 
AIM 
The aim of Study 3 was to examine compliance to 28 days of β-alanine or placebo 
supplementation during a rugby league pre-season training period. 
 
SIGNFICANCE 
This study addressed the need to improve understanding of determinants of β-alanine 
(non-) compliance in athletes. The findings would facilitate the development of more 
individualised supplementation protocols.   
 
CHAPTER 6 (Study 4): THE INFLUENCE OF BODY COMPOSITION ON ACUTE 
SIDE EFFECTS FOLLOWING β-ALANINE SUPPLEMENTATION 
 
AIM 
The aims of Study 4 were: 1. to determine if the acute side-effects resulting from β-
alanine supplementation differed between absolute and relative doses, and 2. to 
consider if body mass and body composition were related to reported side effects.  
 
SIGNFICANCE 
Understanding the acute doses that can be taken without side effects is important to 
optimising the capacity of individuals to consume the recommended daily doses of β-
alanine.  
 
CHAPTER 7 (Study 5): THE INFLUENCE OF PARAESTHESIA FOLLOWING β-
ALANINE SUPPLEMENTATION ON HIGH-INTENSITY CYCLING CAPACITY. 
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AIM 
The aim of Study 5 was to determine whether paraesthesia experienced following 
acute β-alanine supplementation was related to high intensity exercise performance. 
 
SIGNFICANCE 
Although there is no current underlying mechanism to explain how β-alanine-induced 
paraesthesia could enhance performance, some athletes (and indeed some research) 
suggest that the sensations associated with acute supplementation may improve 
subsequent exercise performance.  The purpose of this study was to consider whether 
sensations of paraesthesia were related to high intensity exercise capacity.
 6 
 
CHAPTER 2: LITERATURE REVIEW 
 
Overview 
The following literature review will examine carnosine as an organic compound 
including discussion about physiological role of carnosine along with the determinants 
of muscle carnosine content. This will be followed by a review of the current literature 
on the effect β–alanine supplementation has on muscle carnosine along with the 
changes in exercise performance following a period of β–alanine supplementation.   
 
Carnosine  
In 1900, the Russian scientist Vladimir Gulevitch discovered an unidentified organic 
nitrogen-containing non-protein compound and named it carnosine [7].  In 1906, 
Krimberg described carnosine as a dipeptide containing β-anayl-L-histidine and 
classified it as a histidine containing dipeptide (HCD) [8, 9].  Carnosine is formed by 
binding histidine and β–alanine in a reaction catalysed by carnosine synthase.  It is 
found in high concentrations in vertebrate and invertebrate skeletal muscle and its 
primary physiological role is to maintain acid-base homeostasis within muscle [10].   
 
Histidine-containing dipeptides (HCD) are peptides consisting of a histidine and the 
atypical amino acid β–alanine and are predominantly and abundantly present in 
skeletal muscle, but they are also measurable in other tissues such as brain, kidney 
and liver. Human skeletal muscles only possess the HCD carnosine (beta-alanyl-L-
histidine). Carnosine is a small molecular weight compound occurring in the millimolar 
range in muscle and is categorised as a muscle histidine-containing dipeptide (M-
HCD).  The M-HCD’s provide a means to accumulate high, stable concentrations of 
histidine in muscle fibres and are the only means available to significantly change the 
intracellular buffering capacity [11].  The imidazole chemical group is found in histidine 
residues of proteins and the imidazole ring of histidine (pKa 6.21) is a good pKa to 
function as a buffer in the physiological range.  The pKa is the acid dissociation 
constant, which is ideal when it lies within the physiological pH range (6.5 – 7.1).  All 
compounds containing an imidazole group may act as intracellular buffers as the 
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nitrogen of imidazole rings can be protonated at physiological pH [12, 13].  The pKa of 
histadine is 6.10 and when combined with β–alanine to form  the carnosine pKa is 6.83 
which means it has the ability to bind protons and provide one mechanism to prevent 
acidification of the intracellular medium [14, 15]. 
 
Physiological roles of carnosine 
pH Buffer 
It is generally assumed that a decrease in intracellular pH significantly contributes to 
fatigue and impairs performance during high intensity ‘anaerobic’ exercise.  Several 
studies have shown that by increasing the muscle buffer capacity, high intensity 
exercise performance can be enhanced [16, 17].  As pH buffering is one of several 
functions of the M-HCD’s, increasing muscle carnosine (M-Carn) concentrations 
would increase the buffering capacity of muscle and thus potentially improve high 
intensity exercise performance [18].    
 
Ca2+ ion sensitivity 
In addition to supporting acid-base balance, carnosine also has a role in excitation-
contraction (E-C) coupling in skeletal muscle and the generation of force.  Lamont and 
Miller [19] added 15mM of carnosine to frog Sartorius muscle and rat cardiac muscle 
and found an increase in Ca2+ sensitivity in the muscle fibres.  They also noted that 
different muscle fibre types had varying levels of carnosine content and fast titch fibres 
were generally higher in carnosine.  Lamont and Miller [19] concluded that a carnosine 
deficit reduces Ca2+ sensitivity and contributes to diminished muscle performance.  
 
This work was extended by Dutka and Lamb [20] who were the first to examine the 
effect of carnosine on the E-C coupling in mammalian skeletal muscle fibres.  They 
added carnosine to the cytoplasmic environment of mechanically skinned extensor 
digitorum longus and soleus rat muscle fibre and showed an increase in the Ca2+ 
sensitivity of the contractile apparatus in a concentration-dependent manner (with 4, 
8 and 16mM respectively).  When caffeine was added and force production measured, 
Ca2+ release from the sarcoplasmic reticulum was potentiated in the presence of 
carnosine.  The authors concluded that carnosine’s action in increasing the Ca2+ 
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sensitivity of the contractile apparatus to Ca2+ ions, could aid in maintaining a higher 
level of force during the later stages of exercise when Ca2+ release generally declines. 
 
In the first study to examine the effect of physiological levels of carnosine in human 
muscle, Dutka, et al., [21] found that an increase in M-Carn in the vastus lateralis 
muscle from normal (~8mM) to supplemented levels (~16mM), increased the Ca2+ 
sensitivity of the contractile apparatus in both type I and type II fibres.  These findings 
are consistent with the results found with chemically skinned rat [19] and frog [20] 
muscle.  Differences between type I and type II fibres were evident when caffeine-
induced force responses were potentiated by 8mM of carnosine.  The potentiation in 
type II fibres was explained by the increase in Ca2+ sensitivity of the contractile 
apparatus caused by carnosine.  In type I fibres, the potentiation of caffeine-induced 
responses caused by carnosine was beyond the expected increase in Ca2+ sensitivity 
of the contractile apparatus and this suggests an increase in Ca2+-induced Ca2+-
release.  The authors concluded that an increase in M-Carn can help reduce the 
decline in muscle performance during fatiguing contractions through maintaining Ca2+ 
sensitivity of the contractile apparatus, and in type I fibres by possibly decreasing Ca2+ 
release.  In support of these findings, Everart et al. [22] were the first to show a leftward 
shift of the force-frequency relationship, in vivo, in extensor digitorum longus muscle 
of mice who supplemented with 1.2% β-alanine with water for eight weeks.  This 
resulted in an increase of force produced at low stimulation frequencies by 10 – 31%. 
 
This potential effect was recently tested in human skeletal muscle in vivo [23].  β-
alanine supplementation (6.4 g·day-1 for 28 days) did not influence electrically evoked 
contractile properties. Specifically, β-alanine had no effect on knee extensor force 
production across a range of frequencies (1 – 100 Hz).  The authors concluded that 
β-alanine did not influence Ca2+ sensitivity or Ca2+ release and these are not the 
mechanisms by which β-alanine supplementation influences exercise performance.  
However, they did find a reduced half-relaxation time, which may be explained by 
reuptake of Ca2+ into the sarcoplasmic reticulum, that may improve the efficiency of 
muscle contraction following β-alanine supplementation. 
 
Another possible mechanism, called the ‘carnosine shuttle’, has recently been 
suggested to explain the ergogenic benefits of M-Carn loading [24].  It is hypothesised 
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that carnosine can act as a Ca2+/H+ exchanger [25, 26].  During muscle contraction, 
Ca2+ is required for cross-bridge formation whilst adenosine-tri phosphate (ATP) is 
used to provide energy.  During anaerobic glycolysis, H+ ions need to be transported 
to the sarcolemma. However, the Ca2+ needs to diffuse from the sarcoplasmic 
reticulum to the sarcomeres [24].  As both Ca2+ and H+ can bind to proteins such as 
carnosine, the increased accumulation of H+  causes an unloading of H+ which then 
increases cross-bridge formation and muscle force [24].  
 
The effects of carnosine on both pH buffering and Ca2+ sensitivity suggest that 
carnosine may play an important role in exercise capacity and performance. 
 
Other roles of carnosine  
Carnosine is present in the olfactory lobe of the brain, heart and also in the eye and 
may have many other physiological roles including activation of carbonic anhydrase 
activity [27], as an antioxidant [28-33], in anti-aging [34, 35], in enzyme regulation [36], 
in protein-protein cross-linking [35] and assisting in the pathology of diabetic [37, 38], 
aging [34] and cataract complications [39].  Other functions of carnosine in neural 
tissue include it being a histidine reservoir for histamine synthesis [40] and to protect 
against copper- and zinc-induced neurotoxicity [41].  The chemical properties and 
therapeutic benefits of carnosine have been extensively reviewed previously [7, 39, 
42-45].  
 
Determinants of muscle carnosine content 
To gain an understanding of the physiological benefits of M-Carn in humans, 
examining the role it plays in the animal world can assist in providing an understanding 
of its potential benefit.  
 
Species 
The Balaenoptera acutorostrata whale has the greatest M-HCD content of any animal, 
reaching levels of approximately 400 mmol·kg-1 [46].  Whales are regularly exposed 
to hypoxic environments, diving for over 30 min without taking a breath.  Similarly, high 
M-HCD levels are found in deep sea fish who also live in a hypoxic environment and 
require an efficient buffering system [13]. 
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In birds such as chickens and turkeys, higher levels of M-Carn  are found in the breast 
muscles versus the leg muscles, where a higher buffering capacity is required to assist 
flight, especially when they are trying to escape a predator [13].   Geese and pigeons 
that fly for longer periods, are more aerobic in nature and have a decreased need for 
an efficient buffering system and therefore have lower levels of M-HCD [47]. 
 
In mammals, anaerobically active animals have higher M-Carn levels when compared 
to less active species.  For example, animals that are required to hunt (canines) and 
race (greyhounds, camels and thoroughbred horses) have greater M-HCD levels than 
the sedentary ox or pig [13, 48, 49].  In the animal kingdom the increased levels of 
muscles carnosine and M-HCD appear to maintain intramuscular pH during physical 
activity.  
 
In humans, M-Carn content can be measured via muscle biopsy where individual 
fibres are separated and quantified by high performance liquid chromatography 
(HPLC) [50, 51] or through non-invasive methods using proton magnetic resonance 
spectroscopy (proton MRS) [52-54].  The following sections will describe various 
factors that contribute to M-Carn content measured by these methods. 
 
Age 
M-Carn concentration has been shown to decrease with age in rats [55-57].  Similarly, 
a decline of 63% of M-HCD concentration in human patients with neuromuscular 
disease aged between 10 and 70 years has been reported [56].  Everaert et al., [58] 
found a negative correlation between age and carnosine concentration in the soleus 
muscle in humans.  This represents a decline of soleus carnosine concentration of 
1.2% each year, however the majority of participants were younger than 30 years of 
age.  In the most comprehensive cross-sectional investigation into the changes in M-
Carn content with age, [59] M-Carn  content of children, adolescents, adults and 
healthy elderly participants was compared.  Using proton magnetic resonance 
spectroscopy (1H-MRS) to measure carnosine content in the soleus and 
gastrocnemius muscles they found that puberty resulted in a significant increase in M-
Carn concentration in boys but not girls.  Another unique finding of this study was that 
M-Carn levels started to decline during adulthood, shortly after puberty and this decline 
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appears much greater than the decline from adulthood into old age.  The authors 
suggest that this decline in M-Carn is either an indirect marker or even a direct 
contributing cause of the decline in anaerobic capacity seen at approximately 25 – 30 
years of age [59]. 
 
Growing older is also associated with a transition from type II to type I muscle fibres 
and this may relate to the decline in M-Carn with age.  Tallon et al [60] found a 53% 
reduction in M-Carn in the type II fibres of elderly patients with osteoarthritis of the 
knee, however there was no change in type I M-Carn content. 
 
The decline in M-Carn  levels with age was not shown in a recent study by Kim [61].  
They compared elderly Korean males (58 – 67 years) with younger elite Korean 
swimmers and found no difference in M-Carn content.  Whilst the small sample size 
(n = 8) may have contributed to this finding, the authors suggested that the typical 
Korean diet of chicken, pork, fish and beef was sufficient in the older group to supply 
adequate levels of β–alanine for M-Carn synthesis [61].  
 
Gender 
Sexual dimorphism is evidenced in rats with a lower M-HCD content of females in the 
hind legs, fore legs and pectoral region compared to males [62].  The male rodents 
doubled their M-Carn content during puberty and the authors speculated that 
androgens may play a role in carnosine synthesis.  In support of this hypothesis, 
Penafiel et al [62] showed that M-Carn content was reduced by ~40% when the male 
rats were castrated and that exogenous testosterone administration to the female rats 
resulted in a 268% increase in M-Carn  content.  Consistent with this finding, Tallon et 
al. [63] reported M-Carn levels of bodybuilders to be twice as high as the normal 
population.  In their study, five of the six bodybuilders reported using anabolic steroids 
in the previous six months. 
 
The male/female M-Carn content ratio of 3.5:1 found in rats has not been found in 
horses.  There were no obvious sex differences in the M-Carn  content of the gluteus 
medius of 1 year old male and female thoroughbred horses [64].  In humans, males 
have approximately 21% greater M-Carn  content than women in the quadriceps 
femoris muscle [65], 28% in the gastrocnemius, 36% in the soleus and 82% in the 
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tibialis anterior [58].  The authors suggest that the differences in M-Carn content may 
be a contributing factor to the gender differences in performance during high-intensity 
exercise. 
 
A recent study by Baguet et al [59] found that males experience an approximate 
increase of 23 – 45% in M-Carn levels during puberty whereas females have no 
change.  This is consistent with the increases in muscles carnosine found in rodents 
during puberty [62].  These findings, in conjunction with dimorphic differences in 
testosterone (no difference before puberty [66] and a ten-fold increase during 
adulthood [67]) support the theory that androgens may influence M-Carn content.  
However, there was no correlation between free testosterone and M-Carn content 
found by Everaert et al. [58] in young men.  Also, the age-related changes in 
testosterone [67, 68] are not the same as the age-related changes in M-Carn. 
 
The differences in M-Carn content found by Everaert et al. [58] were from whole 
muscle and did not account for muscle fibre composition.  The gender differences in 
M-Carn during puberty may be explained by the larger cross sectional area of type II 
fibres present in males versus females [69, 70].  Type II fibres in humans have 30 – 
100% greater levels of M-Carn than type I fibres [71-73].  When the M-Carn levels of 
type I and II fibres were compared by Tallon et al. [60], no differences were found 
between males and females aged 20 – 35 years.  Everaert et al. [58] suggest that 
females may have lower M-Carn levels due to a higher ratio of type I:II muscle fibres 
compared to males.  Future studies examining the gender differences of type I and 
type II fibres are required to determine if males do have greater M-Carn than females. 
 
Fibre type 
In both animals and humans, type II fibres have a greater M-Carn compared to type I 
fibres.  In horses and camel gluteus medius muscle, the ratio in M-Carn of type I/II is 
5 and 2.3 respectively [50, 74].  In humans, using HPLC-based single fibre analysis 
the ratio is 1.3 to 2.0 [60, 71-73].  Muscles with a greater ratio of type II fibres have a 
greater M-Carn content than muscles which have the majority of type I fibres.  For 
example, the gastrocnemius has a greater M-Carn content than the soleus muscle 
however, this is most likely due to the higher number of fast twitch fibres in the 
gastrocnemius.  Recently, Baguet et al. [75] reported a positive correlation between 
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M-Carn, measured by 1H-MRS, and percentage area occupied by type II fibres.  This 
quick, valid and non-invasive method could be used in the future with interventions 
that alter muscle fibre composition. Also, the change in M-Carn in vivo is difficult to 
verify compared to changes in single fibre and this may have influenced the findings 
of this study. 
 
Training: chronic 
Anaerobically-trained athletes have a greater muscle buffer capacity and also a 
greater M-Carn content than endurance athletes.  Whether this increased level of M-
Carn is due to genetic factors or chronic training has yet to be determined.  Parkhouse 
et al. [76] compared the M-Carn concentration of Canadian sprinters, rowers, 
marathoners and untrained individuals and found that M-Carn was markedly higher in 
the sprinters and rowers.  Trained 400m runners from Belgium also showed greater 
M-Carn than physically active students [52].  Similar findings were reported by Tallon 
et al. [63] who found significantly greater M-Carn content in the vastus lateralis of 
bodybuilders compared to untrained participants. However, a number of these 
bodybuilders reported using steroids and steroid use has been shown to increase M-
Carn, however this was in murine muscle which may not be directly related to humans 
[62].  All of the previously reviewed studies did not take diet into consideration and 
therefore it is difficult to conclude if high M-Carn levels are due to training adaption 
alone, as the consumption of histidine dipeptide rich foods may also influence M-Carn 
content. 
 
Tallon et al. [60] examined the M-Carn levels of Korean breath-hold divers to 
determine if intermittent hypoxia immersion during breath-hold diving could result in 
adaptations to facilitate muscle activity in these conditions.  However, they determined 
that intermittent hypoxia was insufficient to cause tissue de-oxygenation to the extent 
believed necessary to increase M-Carn compared to previously published values for 
untrained participants. 
 
In a recent investigation by Baguet et al. [75], 1H-MRS was used to measure M-Carn 
content in different fibres types within the gastrocnemius muscle of 51 elite athletes; 
values were compared to estimates in fibres from 83 active individuals.  The athletes 
were competing in the following disciplines; 100-200m, 400m, 800m, 1500m, 3000m-
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marathon, jump, throws, decathlon and triathlon.  M-Carn was ~30% higher in the 
sprinters than the control group and the endurance athletes were ~20% lower than the 
control group.  See Figure 2.1 for a complete comparison of all athlete groups. 
 
In addition to the differences between elite athletes, Baguet et al. [75] also compared 
the M-Carn content between three groups of sprinters and endurance athletes.  They 
compared young talented athletes with active elite athletes and finally ex-athletes.  A 
significant difference in M-Carn levels between sprinters and endurance athletes was 
shown in all three groups.  Despite the young group being only 14 – 18 years old and 
with a very short training history, the sprinters in this group had greater M-Carn than 
the age matched endurance athletes.  This evidence is somewhat in contrast to the 
theory that chronic training will increase M-Carn levels and the authors concluded that 
M-Carn  content is largely genetically determined, as is muscle fibre type composition 
[77].   
 
 
Figure 2.1 Carnosine content of gastrocnemius muscle in track and field and 
triathletes compared to an untrained male control.  From [75] 
 
Training: acute 
Suzuki et al. [78] showed an extremely large (+113%) increase in M-Carn in the vastus 
lateralis muscle of six untrained males after eight weeks of high intensity sprint 
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training.  The participants were required to complete one or two 30sec Wingate tests 
per week and completed a total of 14 min of training over eight weeks.  These results 
are questionable as they have not been replicated despite numerous studies 
examining changes in M-Carn levels following high intensity training, performed for 4 
– 16 weeks and found no change in M-Carn levels.  No change in M-Carn levels was 
found following 10 weeks of whole body strength training [79] or 4 weeks [73], 5 weeks 
[59], or 16 weeks [80] of sprint training.  In the study by Baguet et al. [59], there was a 
small but non-significant increase (11%) in M-Carn in the soleus muscle in the group 
that consumed a β-alanine rich diet but in the group that consumed a vegetarian diet 
the change M-Carn was a small non-significant decrease (9%).  An increase in a β-
alanine rich diet may be one explanation for the findings of Suzuki et al. [78] or that 
there was an error in the measurement of M-Carn in the muscle samples [18]. 
 
Nutrition 
Ingestion of HCD contained in meat or fish will increase circulating carnosine 
concentrations after being absorbed from the gut [81, 82].  It will also have an impact 
on the availability of β-alanine, the rate limiting factor for carnosine synthesis and 
subsequently the skeletal M-Carn content.  Harris et al. [83] showed that the M-Carn 
content was greatest in participants who consumed a high meat diet.  In habitual male 
vegetarians, M-Carn content is 17 – 26% lower compared to male omnivores [58] and 
female vegetarians have been shown to have a 45% lower M-Carn content than male 
sport science students [83].  In vegetarians, the supply of β-alanine from dietary 
sources is reduced, therefore, M-Carn content is limited by hepatic synthesis of β-
alanine from uracil degradation [11].  Therefore it may be beneficial for vegetarians 
involved in high-intensity exercise to supplement their diet with β-alanine to 
compensate for the lack of β-alanine in their normal diet.    
 
Everaert et al [58] reported no difference in M-Carn content in individuals with either a 
high or low β-alanine content in their diet, but this was only in a small population from 
one ethnic background.  Similar findings were reported by Kim [61] who compared the 
M-Carn content of young and elderly Korean males.  The author concluded that the 
normal Korean diet high in meat and fish was adequate in providing sufficient levels 
of β-alanine to maintain carnosine synthesis.   
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It may be possible to increase the amount of β-alanine consumed in the diet by 
manipulating the β-alanine content in meat.  Jones et al. [84] analysed the imidazole 
dipeptides of ten commonly consumed foods in the British diet to use as reference 
values.  For example, 800 mg of β-alanine was contained in approximately 150 g of 
turkey.  The same research group then attempted to manipulate the β-alanine content 
in turkey meat; turkeys were fed β-alanine over a nine week period (Jones, 
unpublished PhD thesis).  After manipulation, the amount of turkey meat required for 
a person to consume 800 mg of β-alanine had reduced to 75 – 80 g.  Similarly, 
supplemental β-alanine was effective in increasing M-Carn levels in broiler chicks [85].  
Therefore, it may be possible for individuals to increase their M-Carn content by 
consuming “β-alanine supplemented” meat.  Whether the consumption of this modified 
meat can affect the M-Carn content in humans is yet to be determined and more work 
is needed in to determine the exact effect of meat ingestion on M-Carn content in 
humans.  In addition, the influence of increased M-Carn from supplemented meat on 
exercise capacity and performance is currently unknown. 
 
β-alanine  
β-alanine is a relatively new supplement available to athletes to improve performance.  
Whilst there is currently no research that describes the level of use, based on exercise 
performance studies it is assumed that athletes participating in events that have a 
duration of on to two minutes may benefit from β-alanine supplementation.  It is 
feasible that athletes who participate in intermittent team sports that have periods of 
play that involve high intensity repeated sprint may also benefit from supplementing 
with β-alanine. 
 
 β-alanine is endogenously produced by the liver from the degradation of uracil [86] 
and is described as a ‘nonprotogenic’ amino acid [87].  β-alanine is also present in the 
blood when carnosine is hydrolysed by the enzyme, carnosinase [88, 89].  Uptake of 
β-alanine into skeletal muscle is mediated by a single protein, whose Km for β-alanine 
is approximately 40 μM [90].  Transport of β-alanine into muscle occurs through 
stoichiometric concentrations in a ratio of 2:1:1 of sodium, β-amino acid, and chloride 
[91, 92].  Synthesis of carnosine inside the muscle tissue is limited by the very low 
concentration of β-alanine and the high saturation point (Km 1.0-2.3 mM) of carnosine 
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synthase [93, 94].  Therefore, the presence of β-alanine is the rate limiting factor for 
carnosine synthesis in skeletal muscle and it may be influenced by the availability of 
β-alanine in the blood stream.  
 
β-alanine supplementation  
One of the earliest studies to show an increase in M-Carn through β-alanine 
supplementation was with thoroughbred horses.  Dunnett and Harris [95] 
supplemented horses for 30 days with β-alanine (3x·day-1 with 100 mg·kgBM-1) and 
histidine (3x·day-1 with 12.5 mg·kgBM-1) and observed a significant increase in the M-
Carn of the type IIA (16%) and type IIB (22%) gluteal muscle fibres.  The increased 
M-Carn content led to an increased intramuscular hydrogen ion (H+) buffering capacity 
ranging from 1-8 – 13.7%.  
 
The seminal paper examining β-alanine supplementation in humans described three 
studies examining the effect of β-alanine, taurine and carnosine concentrations in 
plasma, urine and skeletal muscle [10].  The first study compared the pharmacological 
profile of 40 mg·kgBM-1 of β-alanine with a chicken broth that contained an equivalent 
dose of free β-alanine in the dipeptide form.  Within 20 min of ingestion, participants 
complained of symptoms of paraesthesia, flushing, irritation and prickly skin that lasted 
up to one hour.  The possible causes of this paraesthesia will be discussed in detail 
later.  As a result of the paraesthesia, the effect of two lower doses of 10 and 20 
mg·kgBM-1 were examined.  The plasma concentration of β-alanine increased rapidly, 
peaking at approximately 30 – 45 min after β-alanine supplementation; the half-life of 
disappearance in all three doses was approximately 25 min [10].  The peak plasma 
concentration of β-alanine following ingestion of the chicken broth was approximately 
50% lower than the other free β-alanine in solution and occurred about 50 min later 
compared to the other conditions.  No symptoms of paraesthesia were experienced 
following the ingestion of the chicken broth despite it containing 40 mg·kgBM-1 of β-
alanine.  A small percentage (0.6 – 3.6%) of β-alanine was lost in the urine up to nine 
hours post ingestion.  Reasons for the differences in peak concentrations and 
symptoms of paraesthesia between the conditions were not discussed. 
 
A ‘slow-release’ β-alanine supplement has been developed in an attempt to minimise 
the symptoms of paraesthesia.  A small pilot study was performed with three females 
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to examine the plasma concentration-time profile of β-alanine using the controlled-
release formulation.  Consuming 1.6 g of β-alanine in slow-release tablets compared 
to 1.6 g of β-alanine in solution resulted in no paraesthesia symptoms and the peak 
plasma concentration of β-alanine was lower but remained elevated above baseline 
for longer [96].  The area under the plasma concentration curve was significantly 
greater for the slow-release tablet compared to the β-alanine in solution.  This pilot 
study was recently replicated and extended to include a greater participant number 
[97].  Questionnaires seeking responses of paraesthesia symptoms were 
administered with no significant differences found between the slow-release tablets 
and the placebo.  The peak plasma concentration of β-alanine in the slow-release 
condition was 33% less than the β-alanine in solution and occurred approximately 30 
min later. Both of these findings support the preliminary findings of Harris et al. [96].  
A novel finding of this study was that the urinary content of β-alanine was less in the 
slow-release condition which resulted in approximately 99% of the β-alanine being 
retained [97].  This retention of β-alanine in the body adds value to the use of a slow-
release formulation as the benefits of β-alanine supplementation are gained by the 
accumulation of M-Carn over several weeks. 
 
Harris et al. [10] were the first to supplement β-alanine for an extended period in 
humans.  Participants consumed 10 mg·kgBM-1 of β-alanine three times a day for two 
weeks.  Plasma peak β-alanine concentration and time to peak concentration were 
the same on days one and 15 and was also the same as the concentrations reported 
in study one of this paper following supplementation with 10 mg·kgBM-1.  The final 
study described in this paper examined the effect of four weeks of supplementation 
with β-alanine or carnosine on M-Carn content.  Participants were assigned to one of 
four groups; I) ingested 800 mg β-alanine four times per day, a total four week dose 
of 89.6 g, II) ingested 4 g·day-1 in week one increasing to 4 g·day-1 in week four, a total 
four week dose of 145.6 g) ingested 364g of L-carnosine which corresponds to a total 
four week dose of 143.3 g of β-alanine, and IV) placebo.  After one outlier was omitted, 
the mean percentage increase in M-Carn in the four groups were I) 42%, II) 64%, III) 
66% and IV) 10% respectively [10]. 
 
Since the first series of investigations were published by Harris et al. [10], every 
subsequent study examining the effect of β-alanine supplementation (1.6 – 6.4 g for 
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>4 weeks) on M-Carn has shown a significant increase of greater than 40% from 
baseline levels.  This is highlighted in Figure 2.2, which shows the relationship 
between β-alanine consumption and the percentage increase in M-Carn.  
 
Figure 2.2 Correlation of all published studies between the relative percent increase 
in muscle carnosine compared to the total β-alanine consumed by participants.  
From [98]. 
 
Researchers have used different supplementation protocols and measurement 
techniques to monitor the changes in M-Carn.  Hill et al. [72], and Kendrick et al. [73, 
79] supplemented with 4 – 6.4 g·day-1 for 10 weeks,  6.4 g·day-1 for 10 weeks and 6.4 
g·day-1 for 4 weeks, respectively and showed M-Carn increases of 80%, 59%, and 
69% using HPLC with muscle sampled through biopsies.  Derave et al. [52] validated 
the use of 1H-MRS proton MRS to quantify M-Carn content and this non-invasive 
technique has since been used in a number of studies to monitor changes in M-Carn 
following β-alanine supplementation.  Using 1H-MRS, increases in M-Carn of 39% [99], 
45% [100], 47% [52] and 44% [101] have been shown when β-alanine was 
supplemented, with 4.8 g·day-1 for 5 – 6 weeks, 5 g·day-1 for 7 weeks, 2.4 – 4.8 g·day-
1 for 4 – 5 weeks and 1.6 – 3.2 g·day-1 for 8 weeks, respectively. 
 
It is not clear whether there is a peak attainable M-Carn level and if there is a “ceiling 
effect” as seen with creatine supplementation [102-104].  The highest recorded 
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change in M-Carn to date is 80% [72], after ten weeks of supplementation ranging 
from 4 g·day-1 in week one up to 6.4 g·day-1 in weeks 5 – 10.  The long term 
performance benefits and/or health outcomes of such an increase are also currently 
unknown. 
 
The different methods of measuring M-Carn result in varying levels of absolute and 
relative changes after supplementation with β-alanine.  The percent increase in M-
Carn is greater in muscle biopsy compared to 1H-MRS [98].  One explanation for this 
is that the biopsy studies [10, 72, 73, 79] all examined samples from the vastus lateralis 
muscle and the 1H-MRS data measured M-Carn in the tibialis anterior, soleus and/or 
gastrocnemius muscle [52, 99-101].  Stellingwerf et al. [101] recently showed that 
despite an equal absolute change in M-Carn levels in different muscles, the relative 
change varies because of different baseline levels.  Therefore there will always be 
differences in baseline M-Carn levels when comparing biopsy and 1H-MRS data [98].  
 
Recently, Bex et al. [105] showed that M-Carn can be reliably measured in the upper 
body via 1H-MRS with the best CV (6.6%) for measured levels in the deltoid muscle.  
This enabled the researches to compare β-alanine supplement induced changes in M-
Carn in different parts of the body in the same person.  In non-athletes M-Carn levels 
were increased equally in the upper and lower body following β-alanine 
supplementation.   
 
Differences in muscle fibre type between individuals who have participated in various 
studies may also have contributed to reported differences in M-Carn content; type II 
fibres contain approximately twice the amount of M-Carn of type I fibres [71].  However, 
both Hill et al. [72] and Kendrick et al. [73] showed similar increases in the M-Carn 
content of type I and type II fibres following β-alanine supplementation despite the type 
II fibres having greater pre-supplementation levels of M-Carn.   
 
It is currently unclear whether baseline M-Carn levels influence the increase in M-Carn 
following β-alanine supplementation.  Increases in muscle creatine have been 
negatively correlated to high baseline creatine values [102].  Stellingwerf et al. [98] 
hypothesised that individuals with low baseline carnosine levels such as vegetarians, 
females or the elderly [58], might respond to a greater extent to β-alanine 
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supplementation than those having higher resting concentrations.  However, contrary 
to this hypothesis Baguet et al. [100] found a positive correlation between high 
baseline levels and the increase in M-Carn in eight elite rowers.  In addition, no 
relationship between baseline carnosine levels and increases in M-Carn was found in 
21 young males [101].  However, in this study, individuals with high baseline M-Carn 
levels were excluded, making comparisons difficult.  
 
Recently, researchers compared M-Carn loading of trained and untrained muscles of 
swimmers, cyclists and kayakers.  They found that M-Carn content increased almost 
twice as much in specifically trained muscles (77.95%) compared to untrained muscles 
(42.88%) following supplementation.  Cyclists increased more M-Carn in their trained 
leg muscles (soleus and gastrocnemius) than their untrained arm muscles (deltoid) 
while the reverse was observed in kayakers.  Swimmers increased M-Carn levels 
more than non-athletes in both their gastrocnemius and deltoid muscles. Whilst the 
underlying physiological mechanisms for this finding were not assessed, the authors 
speculated that increased blood flow to contracting muscles may increase β-alanine 
delivery during acute exercise.  Conversely, as the athletes examined were endurance 
trained, another possible explanation may be the increased capillary density caused 
by endurance training which may enhance β-alanine delivery to the trained muscles.  
The practical application of this finding is to recommend to athletes to supplement with 
β-alanine during high volume training periods as opposed to during rest or recovery 
phases of training [105]. 
 
Following on from their previous work, Bex et al. [106] investigated whether M-Carn 
loading could be increased by concurrent β-alanine supplementation and high 
intensity training or high volume cycle training.  Twenty-eight non-trained males 
supplemented 6.4 g·day-1 of β-alanine for 23 days.  The control group (n = 10) did not 
train at all whilst the other two groups completed nine training sessions over 21 days.  
The high intensity group completed 3 – 5 repetitions of all out 30 sec efforts at 165% 
Wmax with 4 min active recovery between sets.  The high volume group completed 75-
90 min of continuous cycling at 35 – 45% of Wmax.  There was no difference between 
groups in the absolute increase in M-Carn content between the groups in soleus and 
gastrocnemius muscle [106].  However, a small, non-significant improvement in 
efficiency of β-alanine uptake was noted in the exercising groups. 
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β-alanine dosage  
Agreement is yet to be reached as to the most effective dosage protocol of β-alanine 
supplementation to increase M-Carn.  Early supplementation protocols were based 
around limiting the symptoms of paraesthesia experienced when doses greater than 
10 mg·kgBM-1 (approximately 800 mg) were consumed [10].  After consuming this 
dose, the plasma β-alanine concentration returned to baseline after three hours, 
therefore the recommendation was to spread up to eight doses throughout the day to 
achieve a total daily dose of 4.8 – 6.6 g·day-1.   
 
Others have recommended that the dosage should be relative to the individual’s body 
mass and this would require dosages of approximately 50 – 80 mg·kg-1.day-1 [107].  
Stegen et al. [108] extrapolated the data from four studies that showed both an 
increase in M-Carn levels and an increase in exercise performance [52, 72, 109, 110].  
They extrapolated and interpolated the daily β-alanine dose that would be required to 
increase M-Carn by 50% over a 6 week supplementation period.  These calculations 
highlight the wide variation in required doses relative to body mass for both males and 
females.  For example a 56 kg female would require only 2.5 g·day-1 whereas an 84 
kg male would require up to 5.5 g·day-1.  Doses of 6.4 g·day-1 were still recommended 
for those who require faster loading. 
 
The introduction of the “slow-release” capsules influenced the supplementation 
recommendations, as the single dose could now be doubled from 800 mg to 1600 mg 
with no symptoms of paraesthesia [96].  Four daily doses of 1600 mg slow release β-
alanine may be more practical than eight daily doses and potentially could influence 
compliance [111].   
 
Finally, Stellingwerf et al. [101] suggested a simplified dosage recommendation based 
on a strong correlation (R2 = 0.921) found between the increase in M-Carn content 
and total grams of β-alanine consumed.  When pooling the data from eight studies 
they concluded that a 30% or 50% increase in M-Carn could be achieved through the 
ingestion of a total of approximately 100 g and 230 g of β-alanine, respectively [98]. 
 
Stegen et al. (2014) recently attempted to determine the optimal maintenance dose by 
supplementing participants with either 0.4 g·day-1 (n = 7), 0.8 g·day-1 (n = 6) or 1.2 
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g·day-1 (n = 6) for six weeks, after an intimal loading period of 3.2 g·day-1 for 46 days. 
They determined that an average dose of 1.2 g·day-1 day is considered optimal to keep 
M-Carn content elevated at 30 – 50% above baseline.  However, they again suggested 
that heavier individuals need a higher maintenance dose and a dose of 18 mg·kgBM-
1 was recommended to ensure M-Carn levels remain elevated.  
 
Despite the large doses of β-alanine consumed to increase M-Carn, Stegen et al. [112] 
showed that the amount of β-alanine that is actually incorporated into the muscle was 
only 2.8% (assuming that 40% of body mass is muscle mass).  Known as the efficiency 
of supplementation, this can be calculated by dividing the molar increase in M-Carn 
by the total ingested molar amount of β-alanine.  Stegen et al. [112] showed that only 
1.6% of the ingested β-alanine is excreted in the urine and commented that 
approximately 95% of the ingested β-alanine has an unknown fate.  One possible 
explanation may be that the remaining β-alanine is metabolised through oxidation 
possibly in skeletal muscle and also liver, kidney and brain [112]. 
 
The influence of coingestion of carbohydrate and proteins with β-alanine 
supplementation on β-alanine efficiency was recently investigated.  Sixteen men and 
18 women supplemented with 3.2 g·day-1 of pure β-alanine in between meals or pure 
or slow release β-alanine at the start of meals for 6 – 7 weeks to examine the effect of 
meal induced insulin release [112].  Using 1H-MRS, this group showed that the 
efficiency of M-Carn loading in the soleus muscle was significantly higher (+64%) in 
the pure β-alanine plus meal condition compared with puree β-alanine in between 
meals (+41%).  There was no significant difference in β-alanine efficiency when pure 
or slow release β-alanine was ingested with a meal.  This study showed that 
regardless of the form of β-alanine used, insulin may play an important role in the 
synthesis of M-Carn and the practical recommendation for those trying to increase M-
Carn levels would be to ingest β-alanine with a meal. 
 
Other influences on the efficiency of loading include training status (5.82% efficiency 
in trained muscles) [105], high intensity training (5.67%) or high volume training 
(5.17%) in conjunction with β-alanine supplementation  
 
 24 
 
β-alanine washout 
Once β-alanine supplementation ceases, carnosine washout will result when 
degradation/elimination exceeds the synthesis [98].  Harris et al. [96] reported that M-
Carn of vastus lateralis, measured in biopsied muscle, declined with a half-life (t½) of 
approximately nine weeks.  Using 1H-MRS, Baguet et al. [99] and Stellingwerf et al. 
[101] estimated the M-Carn t½ in the tibialis anterior, gastrocnemius and soleus was 
between 5 – 8 weeks.  The results of Danaher et al. [4], who showed that M-Carn 
concentrations were still elevated six weeks after cessation of supplementation, 
support these findings.  The length of washout may be related to the efficacy of β-
alanine supplementation.  Baguet et al. [109] assessed their participants as either 
responders (mean M-Carn increase = 55%) or non-responders (mean M-Carn 
increase = 15%) and found that the washout in responders was ~ 15 weeks compared 
to ~ 6 weeks in the non-responders.  Based on these results, complete washout of M-
Carn following β-alanine supplementation is believed to be somewhere between 10-
20 weeks, or ~ 2 – 4% per week [99].  The washout rates for type I and II muscle fibres 
are currently unknown, as are the determinants of M-Carn regulation.  Harris et al [11] 
hypothesised that the M-Carn may be slowly released from the muscle fibres or 
destroyed within the fibres due to a reaction with free radicals or carbonyl groups [113, 
114]. 
 
β-alanine side effects 
Current recommended dosage protocols relating to β-alanine supplementation are 
provided as absolute doses, not relative to body mass.  It is not currently known if total 
body mass, or even body composition, is related to the amount or severity of 
symptoms.  It is possible that heavier individuals ingesting the absolute recommended 
dose may experience little or no symptoms and may be able to tolerate higher 
dosages.  They may be able to achieve the recommended daily dose of 3.2 – 6.4 g 
with a lower number of doses and this would improve compliance.  In studies involving 
medications there is an inverse relationship between number of doses per day and 
rate of compliance [115].  The side effects experienced when consuming an absolute 
of relative dose and the influence of body mass and composition on side effects 
following β-alanine supplementation warrants further investigation. 
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As previously reviewed, when participants ingest 40 mg·kgBM-1 of β-alanine in free 
solution they generally experience paraesthesia, described as flushing, and prickly 
skin [10].  These sensations last for approximately one hour after β-alanine ingestion 
and are dose dependent; participants report similar but less intense sensations after 
ingestion of 20 mg·kgBM-1 and only mild sensations after consumption of 10 mg·kgBM-
1 of β-alanine.  Table 2.1 shows the amount of β-alanine provided per dose and the 
different side effects experienced by participants from a number of studies where side 
effects were reported 
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Table 2.1 Side effects following different doses of β-alanine. 
Study Single dose Form of β-alanine  Side effect 
Bellinger et al. [116] ~16 mg∙kgBM-1 Free form paraesthesia  
Bellinger and 
Minahan [117] 
30 mg∙kgBM-1 Free form paraesthesia – pins and needles 
Bellinger and 
Minahan [118] 
1600 mg  Slow release paraesthesia – d burning, pins and needles, prickling, and/or 
stinging sensation 
Chung et al. [119] 1600 mg Slow release mild paraesthesia 
Decombaz et al. 
[97] 
1600 mg 
 
1600 mg  
Free form  
 
Slow release 
pins and needles; tickling, itching; numbness, insensitivity; 
pain, soreness; tactile hypersensitivity; and flush, shiver 
all symptoms above were reported however were not different 
from placebo   
de Salles et al. [120] 1600 mg  Slow release mild paraesthesia 
de Salles et al. [121] 1600 mg Slow release mild paraesthesia 
Glenn et al. [122] 1600 mg Free form paraesthesia 
Glenn et al. [123] 1600 mg Free form paraesthesia 
Gross et al. [124] 1600 mg Free form paraesthesia 
Harris et al. [10] 10 mg∙kg-1 
20 mg∙kg-1 
40 mg∙kg-1 
Free form 
Free form 
Free form 
irritation of the skin and prickly sensation (mild) 
irritation of the skin and prickly sensation (less intense then 
flushing (described variously as an irritation of the skin and 
prickly sensation) 
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Harris et al. [96] 3200 mg Slow release trace symptoms of paraesthesia 
Hill et al. [72] 800 mg Free form Infrequent and mild paraesthesia 
Hoffman et al. [125] 2000 mg  Slow release paraesthesia 
Howe et al. [126] ~16 mg∙kgBM-1 Free form paraesthesia 
Jordan et al. [127] 2000 mg Free form tingling in fingers and hands 
MacPhee et al. 
[128] 
3000 mg Free form pin and needles, flushing (reddening and/or feeling of heat) 
 
McCormack et al. 
[129] 
800 & 1200 mg Free form paraesthesia 
Mero et al. [130] 1200 mg Free form paraesthesia 
Smith-Ryan et al 
[131] 
1600 mg Free form paraesthesia 
Stellingwerf et al. 
[101] 
1600 mg Slow release ‘‘warmth’’, ‘‘redness’’, ‘‘pins and needles’’ and ‘‘itching’’ were 
reported however were not different from placebo   
Sweeney et al. [132] ~1300 mg Free form prickly sensation 
Tobias et al. [133] 6400 mg Slow release paraesthesia 
Free form = β-alanine either in solution or in tablet form 
Slow release = Carboxymethyl cellulose was added to free form β-alanine 
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Decombaz et al. [97] examined the side effects of 1.6 g of β-alanine in solution 
compared to 1.6 g in slow release β-alanine tablets and a placebo in five females and 
six males.  Participants were required to complete questionaries relating to intensity 
and type of sensations they experienced and the effect of these sensations on their 
mood and anxiety at regular interval after ingestion.  Blood was sampled at regular 
intervals up until six hours post-supplementation to compare the kinetics of plasma β-
alanine with the paraesthesia symptoms.  Only the β-alanine in solution produced 
unusual sensations which were generally described as ‘pins and needles’ and followed 
a pattern of response in parallel to plasma β-alanine concentration. The quicker the 
plasma β-alanine peak, the more symptoms of pins and needles were observed.  
Approximately 80% of participants experienced some level of unusual sensation, with 
32% of these sensations being described as either moderate- or low-intensity 
symptoms.  In the first two hours after supplementation, 40% of the reported 
sensations were for “pins and needles”, 24% for tickling, itching” and the remainder 
were spread across “numbness, insensitivity”, “pain, soreness”, “tactile 
hypersensitivity” and “flush, shiver”.   
 
Possible reasons why 20% of the participants in this study did not experience any 
symptoms were not discussed.  The amount of β-alanine supplemented was an 
absolute dose compared to the dose relative to body mass provided by Harris et al. 
[10].  The lack of symptoms may be due to the absolute dose provided being not large 
enough to affect the heavier participants in the study.  Also the difference in side 
effects between males and females was not reported.  This would be of interest as the 
female participants were, on average, 16 kg lighter than the male participants.  When 
ingesting an absolute dose of 1.6 g of β-alanine, this equates to approximately an 
extra 7 mg·kgBM-1.  Previously an increase of similar magnitude caused the severity 
of symptoms to increase from ‘mild’ to ‘moderate’ [10].  
 
Hoffman et al. [134] suggested that the paraesthesia side effects are negated when 
β-alanine is consumed with a carbohydrate and electrolyte solution but did not provide 
any mechanistic explanation why.  Recently, Donovan et al. [135] required participants 
to take their β-alanine with a meal containing protein and reported no side effects 
however, no explanation was provided why this may have occurred. The possible 
slower digestion and absorption of β-alanine may have reduced side effects. 
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The first study to monitor long term paraesthesia symptoms when β-alanine was 
chronically supplemented over eight weeks showed no change in symptoms when 
ingesting slow-release β-alanine [101].  Participants ingested 1.6 – 3.2 g·day-1 of slow-
release β-alanine and completed a questionnaire every two weeks relating to the 
amount and intensity of symptoms.  Only trivial paraesthesia symptoms were reported 
in week one and no differences in these symptoms were reported after eight weeks of 
supplementation. However, research is still required to determine whether a similar 
pattern exists when standard β-alanine is supplemented long term.  It is unknown 
whether the paraesthesia symptoms experienced after ingesting free form β-alanine 
reduce or become more tolerable over time.    
 
Sale et al. [18] considered possible mechanisms responsible for the paraesthesia 
experienced following β-alanine supplementation.  These included β-alanine-activated 
strychnine-sensitive glycine receptor sites, in association with glutamate sensitive N-
methyl-D-aspartate receptors in the brain and central nervous system.  Mori et al. [136] 
showed that that modulation of transporters for β-alanine and taurine can regulate 
tonic activation of glycine receptors, which may function in maintenance of inhibitory 
tone in the hippocampus. Also β-alanine as well as taurine, may act as a functional 
inhibitory neurotransmitter in the mammalian sacral dorsal commissural nucleus [137]. 
 
Other mechanisms may be related to the mas-related gene family of G protein-coupled 
receptors, in dorsal root ganglia neurons ending in the skin, which are triggered by 
interactions with specific ligands such as β-alanine [138].  β-alanine binds with and 
activates one of these G protein receptors, MrgprD [139].  MrgprD is present in dorsal 
root ganglion neurons that exclusively innervate the epidermis of hairy and glabrous 
skin [140].  
 
A recent paper investigating the mechanism of the “itching” invoked by β-alanine 
supports the theory relating to G protein-coupled receptors.  Eleven healthy 
participants were intradermally injected with 90 μg of β-alanine and rated the 
perceived intensity of itch, pricking/stinging and burning [141].  The pattern of 
symptoms was similar to those previously reported by Harris et al. [10] and Decombaz 
et al. [97].  Following an early peak, sensations dissipated over time and the level of 
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intensity was dose dependent.  This study provides evidence that β-alanine-induced 
itch-mediating neural activity originates in the peripheral and not the central nervous 
system.   
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Table 2.2 A summary of β-alanine supplementation studies that report compliance rates. 
Study Daily Dosage Compliance Reporting Method 
Bellinger and Minahan 
[142] 
 
6.4 g∙day-1 
4 weeks 
β-alanine (n = 7) 100% 
Placebo (n = 7) 100% 
 
Verbal confirmation 
Chung et al. [143] 
 
6.4 g∙day-1 
6 weeks 
β-alanine (n = 14) 100% 
Placebo (n = 13) 100% 
 
Verbal confirmation 
de Salles Painelli et al. 
[121] 
 
6.4 g∙day-1 
4 weeks 
β-alanine (n = 20) 100% 
Placebo (n = 19) 100% 
 
Returned 
supplementation 
container 
del Favero et al. [110] 
 
3.2 g∙day-1 
12 weeks 
 
β-alanine (n = 12) 100% 
Placebo (n = 6) 100% 
Daily phone call 
Gross et al. [3] 
 
3.2 g∙day–1   
38 days 
β-alanine (n = 8) 99.4 ± 1.7%  
Placebo (n = 9) 99.9 ± 0.2%  
 
Supplementation logs 
Hannah et al. [23] 
 
6.4 g∙day-1 
4 weeks 
β-alanine (n = 11) 91 ± 7% 
Placebo (n = 12) 88 ± 10%  
 
Supplementation logs 
 32 
 
Hoffman et al. [144] 
 
4.8 g∙day-1 
4 weeks 
 
β-alanine (n = 8) 100% 
Placebo (n = 8) 100% 
Cross-over design 
 
Participant written 
confirmation  
Hoffman et al. [125] 
 
6 g∙day-1 
4 weeks 
β-alanine (n = 10) 97% 
Placebo (n = 10) 97% 
 
Returned 
supplementation 
container 
Sale et al. [145]  
 
6.4 g∙day-1 
4 weeks 
β-alanine (n = 7) >95% 
Placebo; (n = 6) >95% 
 
Supplementation logs 
Saunders et al. [146] 
 
6.4 g∙day-1 
4 weeks 
 
β-alanine (n = 8) 87 ± 10 % 
Placebo (n = 8) 94 ± 5 % 
β-alanine (n = 10) 96 ± 6 % 
Placebo (n = 10) 96 ± 4 % 
 
Supplementation logs 
Saunders et al. [147] 
 
6.4 g∙day–1 for 4 weeks 
3.2 g∙day–1 for 1 week 
β-alanine (n = 8) 96 ± 8% 
Placebo (n = 8) 99 ± 3% 
 
Supplementation logs 
Saunders et al. [148] 3.2 g∙day-1 
12 weeks 
β-alanine (n = 9) 90% 
Placebo (n = 8) 89% 
 
Supplementation logs 
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Smith et al. [149] 
 
3.2 g∙day-1 
4 weeks 
 
β-alanine (n = 15) 100% 
Placebo (n = 15) 100% 
 
Supplementation logs 
Smith-Ryan et al. [150] 
 
 
4.8 g∙day-1 
4 weeks 
 
β-alanine (n = 15) 100% 
Placebo (n = 15) 100% 
 
Not stated 
Solis et al. [151] 
 
6.4 g∙day-1 
4 weeks 
β-alanine (n = 15) 100% 
Placebo (n = 15) 100% 
 
Returned 
supplementation 
container 
Stout et al. [152] 
 
3.2 g∙day–1 for 1 week 
6.4 g∙day–1 for 3 weeks 
 
β-alanine (n = 11) 89.5% 
Placebo (n = 11) 91.7% 
 
Not stated 
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Effect of β-alanine supplementation on exercise performance 
Several comprehensive reviews have described in detail the relationship between β-
alanine supplementation and exercise performance [18, 111, 153].  Recently, 
Saunders et al. [1] completed a meta-analysis examining the effects of β-alanine 
supplementation on 65 different exercise protocols and 70 exercise measures and 
found a significant overall effect size of 0.18 (95% CI 0.08 to 0.28).  Meta-regression 
demonstrated that exercise duration significantly (p=0.004) moderated effect sizes 
and subgroup analyses identified the type of exercise as a significant (p=0.013) 
moderator of effect sizes within an exercise time frame of 0.5–10 min with greater 
effect sizes for exercise capacity (0.4998 (95% CI 0.246 to 0.753)) versus performance 
(0.1078 (95% CI −0.201 to 0.416).  Several exercises measures have been 
investigated and for full details on the majority of studies the reader is directed to the 
reviews mentioned previously.  The remainder of this review will focus on tests of 
repeated contraction and repeat sprint ability, maximal all out tests between 30 and 
60 sec and finally exercise capacity tests lasting between 60 and 240 sec.  Finally, 
studies that have incorporated training programs in addition to β-alanine 
supplementation will be examined. 
 
Effect of β-alanine supplementation on repeated contractions and repeated-
sprint performance 
Muscle buffer capacity has been associated with multiple sprint ability [154-157] and 
several studies have examined whether an increase in M-Carn via β-alanine 
supplementation has an effect on repeated sprint performance.  Suzuki et al. [158] fed 
eight healthy, active male participants an acute dose of chicken breast extract rich in 
HCDs 30 min prior to the completion of 10 x 5 sec maximal cycle ergometer sprints 
(each separated by 25 sec rest intervals) and found no ergogenic benefit.  In contrast, 
four weeks of 2.4 – 4.8 g·day-1 β-alanine supplementation led to a significant reduction 
in fatigue during repeated isokinetic knee extensions in trained male 400 m runners 
[52].  β-alanine supplementation also reduced fatigability in isolated soleus muscles in 
mice during repeated tetanic contractions [22].  However, during repeated sprints (2 
sets of 5 x 5 sec, 45 sec rest) on a non-motorised treadmill, there was no change in 
performance for nine physically active college men after four weeks of β-alanine 
supplementation of 4 – 6 g·day-1 [132].  When multiple repeated sprints were 
interspersed with walking and jogging to replicate a team sport game demands, four 
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weeks consumption of 6.4 g·day-1 β-alanine showed no additional benefit in ten elite 
male hockey players and eight non-elite male participants.  Despite completing 66 
sprints throughout the Loughborough Intermittent Shuttle Test, participants showed no 
deterioration in performance prior to supplementation which may have masked the 
benefits of any increased muscle buffer capacity due to an increase in M-Carn levels 
[146].    
 
Effect of β-alanine supplementation on high intensity intermittent exercise (30 – 
60sec) 
Suzuki et al. [159] showed, in eleven healthy males, a positive correlation between M-
Carn content and mean power per body mass during a 30 sec all out cycle sprint, in 
particular, the last two 5 sec periods.  In contrast to these findings, Hill (2007, 
unpublished thesis) did not find any change in peak and mean power output or fatigue 
index during three consecutive bouts of 30 sec cycle ergometer sprints after four 
weeks of supplementation with β-alanine.  These different findings, as Sale et al. [18] 
suggest, may be due to a significant relationship between carnosine and muscle fibre 
type shown by Suzuki et al. [159], explaining the relationship found between M-Carn 
concentration and exercise performance.  Specifically, the area occupied by type II 
fibres was more important than pH buffer capacity during 30 sec maximal sprints 
explaining why Hill (2007, unpublished thesis) did not find any effect of β-alanine 
supplementation on repeated 30 sec sprint performance.  
 
There is further evidence to suggest that short duration exercise, less than 60s, may 
not benefit from β-alanine supplementation.  Lindsay (2011, unpublished thesis) found 
no significant difference between control and β-alanine (8 weeks x 6.4g.day-1) groups 
for peak power, minimum power average 30 sec maximum power, and average W·kg-
1 of 30 sec maximum power during a 30 sec Wingate test in 14 elite male cyclists.  
Also, no differences were found in peak and mean power output or total work between 
β-alanine and placebo groups during a 60 sec modified Wingate test performed by 26 
college football players [107]. 
 
Other exercise tasks of similar duration (<60 sec), performed by male college students, 
college wrestlers and football players and elite sprinters aged between 19 and 24 
years all remained unchanged after supplementation of 4 – 6·4 g·day-1 β-alanine over 
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4 to 10 weeks.  These tests include; upper arm curl test (~ 29 sec ) [79, 160], 183 m 
shuttle run (~ 39 sec) [107] and 274 m shuttle run [161], and 400 m sprint (~ 51 sec) 
[52].  
 
Effect of β-alanine supplementation on high intensity intermittent exercise (60 – 
240 s) 
Hill et al. [72] investigated the effect of β-alanine supplementation on twenty five 
physically active male students during a high intensity cycle test (CCT110%) that lasted 
between 120 and 240 sec.  The CCT110% was designed to induce a significant fall in 
intramuscular pH [18].  In the first four weeks, 13 participants ingested daily doses of 
4.0 g, 4,8 g, 5.6 g and 6.4 g of β-alanine (in weeks 1, 2, 3 and 4 respectively), whilst 
the remaining 12 participants took a matched placebo.  After four weeks, the 
participants who had supplemented with β-alanine increased their M-Carn levels, 
measured via muscle biopsy, by 60% and significantly increased the total work done 
(TWD) in the CCT110% by 13% (p < 0.015).  A further six weeks of β-alanine 
supplementation (6.4 g·day-1 yielded an additional 20% increase in M-Carn and a 16% 
increase in TWD compared to baseline values.  There was no change in any 
parameters in the control group.  Whilst muscle buffer capacity was not directly 
measured, the authors estimated the contribution of carnosine to muscle buffer 
capacity prior to supplementation was 8.2% and that this increased to 13.5% following 
10 weeks of supplementation [72]. 
 
This study was one of the first to show that β-alanine supplementation increases M-
Carn levels and improves high intensity exercise performance and that these changes 
were most likely related to the regulation of intramuscular pH [18].  These findings 
were later replicated by Sale et al. [162] who found a 14.6% increase in TWD on the 
CCT110% after four weeks of supplementation of 6.4 g·day-1 in ten active males.  
Exercise-induced changes in blood pH compared before and after the intervention 
period were used to assess potential changes in buffering capacity.  Whilst there was 
no significant difference in blood pH following supplementation between groups the 
authors suggested that the increase in performance was due to an attenuation of the 
reduction in intracellular pH during high-intensity exercise [162].   
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Evidence to support the theory that an increase in M-Carn will attenuate the fall in 
intracellular pH during high intensity exercise has been provided by Baguet et al.,  
[109].  Fourteen physically active male students, were equally divided into a 
supplementation or placebo group and before and after four weeks of β-alanine 
supplementation, completed a 6 min cycle test at a fixed intensity above the ventilatory 
threshold (VT) (50% of the difference between VT and V̇O2peak).  Capillary pH reduced 
from ~ 7.4 to ~ 7.2 in both groups, yet when the acidosis was expressed as the 
difference between baseline and post-exercise, not in absolute terms, it was less 
pronounced in the supplemented group [109].  A 19% reduction (p = 0.03) in exercise-
induced acidosis after high intensity cycling exercise, in the group supplemented with 
β-alanine, confirms that carnosine may act as a physiologically meaningful 
physiochemical buffer in human skeletal muscle [109].   
 
In contrast to the findings of Baguet et al. [109], no significant differences in blood pH, 
average power and TWD were observed in highly trained cyclists who completed a 
four minute performance time trial before and after 28 days of supplementation of β-
alanine (65 mg·kgBM-1 per day) [116]. However, using magnitude-based statistics, 
there was a 37% likelihood of an increase in average power following 
supplementation.  This small, non-significant improvement was consistent with 
previous research that had investigated the effect of β-alanine supplementation on 
high intensity exercise in highly trained participants. 
 
Whilst the majority of studies have shown positive effects of β-alanine supplementation 
during high intensity cycling exercise, the same has not been found in high intensity 
running tests despite the tests lasting similar duration (2 – 4 min), the ideal duration to 
elicit maximal H+ accumulation.  β-alanine supplementation (2 × 800 mg tabs, 3 × 
daily; n=26) versus placebo (PL, 2 x 800 mg maltodextrin tabs, 3 × daily; n = 24) had 
no effect on running tests completed at 90%, 100%, 110% of peak velocity in fifty 
recreationally active (1 – 5 hours·week-1) men and women [131]. 
 
Twenty-six recreationally trained males and twenty-four recreationally trained females 
were randomly divided into a placebo or β-alanine (4.8 g·day-1) group and underwent 
28 days of supplementation.  Maximal oxygen consumption and time to exhaustion at 
90%, 100%, and 110% of peak velocity tests were completed before and after 
 38 
 
supplementation and there were no treatment effects for any of the measures in males 
or females.  In some of the tests, the placebo group improved more than the β-alanine 
group and the authors suggested that participant motivation and changes in exercise 
patterns during the loading period have influenced the results.  No measures of M-
Carn or pH were reported in the study.   
 
Similar findings were reported for running sprints to exhaustion at 115% and 140% of 
V̇O2max following five weeks of supplementation of 4 – 6 g·day-1 of β-alanine [163].  
The participants were male wrestlers (n = 11), recreationally active strength trained 
males (n = 6) and rugby players (n = 4).  These results are consistent with previous 
research using trained participants [52, 100, 116, 132].  The authors suggest that the 
wrestlers in the study may have been restricting their carbohydrate intake in order to 
make weight for an upcoming competition and every wrestler (in both groups) 
produced less lactate in the post-testing than the pre-testing.  Again, no measures of 
M-Carn or pH were recorded in this study making it difficult to speculate whether or 
not M-Carn was increased and if this effected physiological buffering mechanisms.   
 
The majority of studies examining the effect of β-alanine supplementation on high 
intensity running performance have found no positive effect suggesting that the mode 
of exercise may contribute to the lack of findings. However, this is yet to be further 
investigated. 
 
Effect of β-alanine supplementation on exercise capacity 
When examining the influence of supplements on exercise it is important to define the 
difference between exercise capacity and exercise performance tests.  Exercise 
capacity tests are typically maximal tests and are used when physiological 
mechanisms are being investigated.  Exercise performance tests typically have a fixed 
end point and they provide a physiological simulation of sport-specific performance 
[164], however they can rely on intrinsic pacing strategies of participants which may 
affect performance [165].   
 
Baguet et al. [100], examined the effect of rowing training and 7 weeks of 5 g·day-1 of 
β-alanine on elite Belgian rowers during 2000 m rowing ergometer performance and 
found a non-significant improvement of 4.3 sec (p = 0.07) in the supplemented group.  
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Similarly, Australian competitive rowers (n = 7) who supplemented with β-alanine (80 
mg·kgBM-1.day-1 for 28 days) completed a 2000 m ergometer row 2.9 s faster than 
before supplementation. However, this result only approached significance (p = 0.055) 
and was not supported by moderate-large ES [166].  As p values were near 
significance in both studies, a larger sample size may have produced statistically 
significant results, however at present, there remains very limited evidence of β-
alanine supplementation improving competition rowing performance of well-trained 
rowers [166]. 
 
Despite a 47% and 37% post-supplementation increase in M-Carn in the soleus and 
gastrocnemius muscles of trained athletes, no significant difference was found when 
they completed a 400 m performance running tests [52].  A similar non-significant 
change was reported by Kern and Robinson [160] in trained college football players 
(n = 7) and wrestlers (n = 10) who completed a 300 yard shuttle run test following a 
period of supplementation (4 g·day-1 for 8 weeks).  
 
A non-laboratory controlled ‘real-world’ experiment showed that 10 weeks of β-alanine 
supplementation appears to have minimal effect on swimming performance in training 
and competition settings for elite/sub-elite swimmers.  Finally, 26 Vietnamese sports 
science students completed a 10 week resistance training program whilst consuming 
6.4 g·day-1 of β-alanine or a matched dose of a placebo.  There was no significant 
effect of β-alanine on whole body strength, isokinetic force production, muscular 
endurance [79].   
 
Despite the majority of performance tests showing no benefit of β-alanine 
supplementation, a positive effect was found in when 16 amateur boxers completed a 
boxing-specific performance test [135].  Before and after supplementation, the boxers 
completed a simulated contest consisting of 3 x 3 min rounds on a punching bag with 
a force transducer attached. Each round involved performing 2 min 50 sec 
standardized punching and the last 10 s involved maximal-output punching, during 
which time punch force and frequency were recorded.  During the 10 sec maximal-
output punching, changes in mean punch force and frequency and punch frequency 
were greater (p < 0.05) in the β-alanine group.  The authors concluded that β-alanine 
supplementation improved punching performance in amateur boxers and suggested 
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that this supplementation protocol may also prove ergogenic for other combat-related 
sports. 
 
Effect of β-alanine supplementation and training on exercise performance 
β-alanine supplementation has been shown to increase the training volume during 10 
weeks of resistance training, compared to a placebo [107].  In addition, the participants 
taking β-alanine reported lower subjective feelings of fatigue as the duration of 
supplementation increased.  The greater training volume could potentially provide a 
greater stimulus for muscle adaptation leading to improvements in performance after 
extended periods of training.  Whilst not statistically significant, the β-alanine group 
trained at higher workloads for longer during six weeks of high intensity cycle interval 
training [167].  Another study by the same group suggests that the antioxidant role of 
M-Carn, increased through β-alanine supplementation, may indirectly reduce oxidative 
stress by scavenging free radicals and maintain the stability of the cell [149].  They 
suggest that while this effect may not be large enough to influence performance, there 
could be benefits relating to recovery and training volume.  
 
There is currently a lack of well controlled studies that monitor the volume of training 
during a period of combined training and β-alanine supplementation.  It may be 
possible that β-alanine supplementation can increase the amount of work performed 
during high intensity training which over time may have a significant benefit on 
exercise capacity and performance.  
 
Effect of β-alanine supplementation combined with other supplements on 
exercise performance 
Several groups of researchers have combined β-alanine with other ergogenic aids to 
investigate possible additive effects.  Hoffman et al. [168] examined changes in 
strength (1RM bench press and squat), anaerobic performance (2 x 30 sec Wingate 
tests) and power (20 sec vertical jump) following creatine alone or creatine combined 
with β-alanine.  The direct influence of β-alanine alone was not possible as there was 
no β-alanine-only group.  However, participants who combined their supplements had 
a greater training volume, increased their lean mass and decreased their fat mass 
compared to the creatine-only and placebo groups.  The increased training volume 
however did not translate to any differences in any of the performance tests.  It does 
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not appear that the addition of β-alanine to creatine has an additive benefit on 
performance tests, however there was a positive benefit on the accruement of lean 
tissue and decreased body fat.  Similarly, no additional differences in neuromuscular 
fatigue (PWCFT) [169], anaerobic performance (CCT110%) (2007, unpublished thesis), 
peak power, mean power, total work and rate of fatigue during multiple Wingate tests 
[170] and V̇O2max, lactate and ventilatory threshold [170, 171] were found when β-
alanine and creatine were combined. 
 
Whilst M-Carn plays a role in the intracellular buffering of H+, extracellular buffering 
capacity is influenced by the bicarbonate ion.  During intense exercise the 
transmembrane transport of H+ increases as the increased extracellular concentration 
of bicarbonate increases the pH gradient between the intracellular and extracellular 
compartments.  Several studies have shown the efficacy of the supplementation of 
sodium bicarbonate to enhance high intensity cycle performance [172].  Sale et al. 
[162] were the first to test the hypothesis that the intracellular buffering of carnosine 
and extracellular buffering of sodium bicarbonate would be additive resulting in an 
increase in high intensity cycling performance.  They found a 6 sec improvement in 
time to exhaustion during the CCT110%, suggesting a ~70% probability of a meaningful 
positive difference, using magnitude-based inferences.   
 
Using elite cyclists, Bellinger et al. [116] found no difference in four minute cycle 
performance following the combined supplementation of β-alanine and sodium 
bicarbonate.  Fourteen highly trained cyclists were required to complete two high 
intensity interval training sessions per week.  The authors suggest that the lack of any 
significant effect may have been due to the highly developed buffering capacity of the 
trained athletes used in the study. 
 
Effect of β-alanine supplementation on other exercise parameters  
Strength and power 
β-alanine supplementation had no effect on 1 repetition maximum bench press, box 
squat and deadlift, or isokinetic force production when combined with 10 weeks of 
resistance training [79]. Similarly, Hoffman et al. [144] found no difference in 1 
repetition maximum squat and peak and mean power output when participants 
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completed four weeks of resistance training combined with 30 days of β-alanine 
supplementation.  
 
Neuromuscular fatigue 
Stout and colleagues completed a series of studies using the physical work capacity 
test at fatigue threshold.  This protocol utilises the relationship between 
electromyogrpahic amplitude and fatigue during submaximal ergometry to identify the 
power output that corresponds to the onset of neuromuscular fatigue  They observed 
that β–alanine was effective in reducing neuromuscular fatigue in men [169], women 
[152] and the elderly [173].  
 
Aerobic measures 
Evidence suggests that β-alanine supplementation has no effect on ‘aerobic’ 
parameters [109, 127, 174].  Submaximal endurance, measured by the onset of blood 
lactate accumulation (OBLA), was improved following 28 days of β-alanine 
supplementation [127]. β-alanine appears effective during brief (30 sec) supra-
maximal excessive immediately preceded by a fatiguing simulated cycle race of 110 
min [175]. Detailed discussion into the efficacy, or lack of efficacy, of β-alanine and 
the possible mechanisms related to these findings is beyond the scope of this review 
and the reader is directed to the reviews by Sale et al. [18] and Derave et al.[153]. 
 
Repeated-sprint ability 
Repeated-sprint ability (RSA) has been defined as the ability to recover from a short 
duration sprint (< 10 sec) and to maintain performance in subsequent sprints after a 
brief rest period (< 60 sec) [176].  An extensive review on RSA is beyond the scope of 
this document, however the reader is direct to the recent two-part comprehensive 
review of RSA which examines the factors contributing to fatigue (Part I) [177] and 
recommendations for training (Part II) [176].   
 
Fatigue during RSE can be caused by a variety of factors, ranging from the generation 
of an inadequate motor command in the motor cortex (i.e. neural factors) to the 
accumulation of metabolites within muscle fibres (i.e. muscular factors); there is no 
one single mechanism responsible for all manifestations of fatigue [177].  RSE 
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performance may be adversely affected by H+ accumulation in the muscle and blood.  
Correlations between sprint decrement and both muscle buffer capacity and changes 
in blood pH support this theory [154, 155, 157].  Similarly, an inverse relationship has 
been found between the fatigue index during ten repeated 10 sec sprints (30 sec rest) 
and the content of skeletal muscle monocarboxylate transporters (MCTs) (i.e. MCT1), 
which facilitate the intramuscular lactate and H+ removal process [177].   While 
intramuscular buffering capacity is known to be influenced by carnitine, other factors, 
such as free phosphate can strongly influence estimations.   Moreover, when buffering 
capacity is estimated from muscle homogenate, phosphate liberated from its bound 
forms may somewhat exaggerate buffering values. 
 
Training to improve RSA 
To improve RSA, effective training will increase either muscle buffer capacity or MCTs.  
While the intramuscular accumulation of H+ and/or lactate provides on important 
stimulus to improve muscle pH regulating systems [157], research suggests that too 
large an accumulation of H+ during training (>100% V̇O2max) may have a detrimental 
effect on these adaptations ([157, 178].  While an optimal training volume to improve 
muscle buffer capacity is yet to be established, it appears that interval training at (~80-
90% V̇O2max ), 2 – 3 times per week, for 3 – 5 weeks, can significantly increase muscle 
buffer capacity [179, 180]. 
 
Bishop and colleagues [176] report that research is yet to investigate the influence of 
repeated-sprint training on changes in MCT content.  However, intermittent-sprint 
training (15 x [6 sec sprint: 1 min jogging recovery]) and interval training (8 x [30 sec 
at 130% V̇O2max: 90 sec rest]) have been reported to be equally effective for increasing 
MCT1 content [181].  Significant changes in MCT content appear more likely when 
training is performed 2 – 3 times per week for 6 – 8 weeks [176].  
 
Girard et al. [177] and Bishop et al. [176] made two key recommendations from their 
reviews regarding training to improve RSA.  They suggest it is important to include (i) 
some training to improve single-sprint performance; and (ii) some high-intensity (80 – 
90% maximal oxygen consumption) interval training to best improve the ability to 
recover between sprints.  
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Sodium bicarbonate  
The ergogenic properties of sodium bicarbonate (NaHCO3) have been investigated 
since the 1930’s [182] and a number of review articles [172, 183] provide conflicting 
views regarding its efficacy.  A recent meta-analysis by Peart et al. [16], concluded 
that when participants used the recommended dosing strategies [184-186], the overall 
effect size for the influence on performance was moderate.  Bishop et al. [157] 
assessed the effects of NaHCO3 ingestion on muscle metabolism and power output 
during repeated short-duration (5 x 6 sec; 24 sec rest) cycle sprints.  NaHCO3 
improved performance but did not increase resting muscle pH or buffer capacity.  The 
authors found a significant increase in post-test muscle [La] in NaHCO3 and suggested 
that an increased anaerobic energy contribution is one mechanism by which NaHCO3 
ingestion improved RSA.  
 
A study from the same group examined the effects of chronic (3 times per week for 8 
wk.) ingestion of NaHCO3 before training (6 – 12 x 2 min at 140 – 170% LT) on buffer 
capacity, time to fatigue, V̇O2 peak, and lactate threshold (LT) [179].  They found that 
training intensity, rather than the accumulation of H+ during training, may be more 
important to improvements in muscle buffer capacity.  Also, the group ingesting 
NaHCO3 before each training session had larger improvements in the LT and 
endurance performance, possibly because of a reduced metabolic acidosis during 
training and a greater improvement in muscle oxidative capacity.   
 
It is possible that the chronic supplementation of β-alanine has a similar effect on 
performance to the chronic supplementation of NaHCO3.  Following chronic 
supplementation of β-alanine, the addition of an acute dose of NaHCO3 may further 
enhance buffer capacity and positively influence RSA performance.   
 
The prevalence, knowledge and attitudes relating to supplement use among 
athletes 
It has been consistently shown over the past few decades that a high number of 
athletes take dietary supplements [187-196].  The 1994 Dietary Supplement Health 
and Education Act defined a dietary supplement as an orally consumed product 
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intended to supplement one’s diet.  This includes vitamins, minerals, herbs or 
botanicals, amino acids, enzymes, organ tissues, glandulars, metabolites, extracts, or 
concentrates in the form of tablets, capsules, liquids, powders, bars, soft gels, or gel 
caps.  In addition, some researchers have also included, as supplements, coffee [197] 
and essence of chicken [193, 196].  Whilst the majority of dietary supplements are 
taken by the general public to improve their health, athletes typically take supplements 
to enhance their training capacity and/or improve performance.   
 
General supplement survey studies on adolescent athletes [198, 199], university 
based athletes [196, 197, 200-202], recreational athletes [203] and elite athletes [189, 
195, 204-208] have revealed that up to 98% of athletes use supplements, mainly to 
enhance sports performance.  Previous studies have reported that 62 – 80% of high-
performance athletes under 20 years of age [188, 190, 209] and 51 – 99% of all elite 
athletes use at least one dietary supplement [187, 188, 190, 192, 193, 195].   
 
Despite an abundance of information on the general supplement use of various athletic 
populations, little is known about specific supplements as only a few investigations 
have explored individual supplement use to such an extent.  The majority of studies 
presented earlier have reported high supplement use typically dominated by 
multivitamins and other health related supplements, which does not represent the 
ergogenic use of supplements amongst athletic populations.  Ayranci et al. [210] 
surveyed Turkish university students (n = 1,871) on non-vitamin non-mineral 
supplement usage and found 16.5% students used non-vitamin, non-mineral 
supplements.  Of those using supplements, between 60 – 80% used them to improve 
energy or vitality, enhance weight loss or enhance performance.  The participants 
were not elite or professional athletes, thus it is difficult to draw clear conclusions from 
this research in relation to professional athlete’s ergogenic aid use.   
 
A number of studies have investigated the use of a single supplement taken to improve 
exercise capacity and/or performance.  Creatine, an ergogenic aid similar to β-alanine, 
has been supplemented by athletes for at least two decades to enhance muscle 
creatine stores.  Creatine use in various cohorts and athletic populations has been 
investigated in a number of studies.  Creatine supplementation use varied relative to 
the age of the population studied and also the type of sport that respondents were 
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engaged in.   Generally, 6% of athletes aged 10 – 18 years, 8% of male high school 
athletes, 28 – 100% of college aged athletes and 29 – 57% of civilian and military 
health club members reported using creatine [211-215], however creatine use in 
professional athletes has not been reported.  Similarly, over 50% of college hockey 
players used stimulants including ephedra to improve performance despite 71.9% of 
the respondents being aware of potential adverse side effects including increased 
blood pressure, sleep disturbance and heart disorders [216].  
 
The available literature relating to supplementation use reveals that relatively little is 
known of supplementation habits of professional athletes.  The majority of athletes 
involved in studies have been from state or national sporting institutions [189, 190, 
195, 204, 208] or schools, colleges and universities [190, 196, 197, 200-202, 210, 
215].  Some studies have explored American football athletes supplementation habits 
[212, 213, 217], whilst Tscholl et al. [207] explored medication and supplement use in 
international football players at the 2002 and 2006 FIFA world cups.  However, there 
are no data currently available on the supplementation habits and beliefs of Australian 
professional athletes.  Professional footballers (rugby league, rugby union and 
Australian rules football) could potentially benefit from β-alanine supplementation due 
to the highly intermittent nature of their sports. However, little is known as to the extent 
these professional athletes utilise β-alanine, as well as their knowledge of the benefits 
of its use including the correct dosing strategies, time required to elicit improvements 
in carnosine levels and the safety of its use are yet to be examined. 
 
Nutrition knowledge 
Desbrow and Leveritt [218] explored caffeine use in a selection of triathletes at a world 
championship event.  Whilst 73% of the athletes sampled (n = 140) believed caffeine 
was beneficial to performance, more than half (53%) the sample could not correctly 
identify the amount of caffeine required to benefit performance.  A small sample (n = 
61) of high school American football players surveyed on their knowledge of and 
sources of information regarding protein use [217], revealed that of the 64% of athletes 
who used protein, users had greater misconceptions on its use than non-users.  
Similar to Desbrow and Leveritt [218] and Duellman, et al. [217], LaBotz and Smith 
[215] reported most creatine users could not identify specific dosages.  Early creatine 
studies have provided sport scientists and coaches with an understanding of athlete 
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habits and beliefs regarding creatine and ergogenic aid use.  This information provides 
evidence that education on ergogenic supplements is required for athletes regardless 
of the level of competition.   
 
Source of information 
It is evident that supplement use increases with the level of athlete [190, 196, 199, 
201, 204].  The majority of these studies, particularly surveys on college or elite 
athletes, explore the athlete’s source of information regarding supplement use.  
Education may be delivered by a variety of providers including coaches and athletic 
trainers, sport dietitians, nutritionists, sport scientists, and medical practitioners.  
Athletes also obtain information from a variety of other sources including school or 
tertiary-education programs, books, sport-specific magazines, the mass media, and, 
increasingly, the Internet [200, 201, 219].  Sixty-nine per cent of civilian and military 
health club users obtained their information on creatine from popular magazines 
compared to physicians (14%) or dietitians (10%).  Whilst college athletes who 
reported using creatine [214, 215] listed their strength and conditioning coach as their 
primary source of information.  It appears most athletes at the college or elite level 
receive information from either strength and conditioning coaches, available dietitians 
or sports trainers [196, 199-201, 208], whilst younger athletes seek advice from their 
coaches [198, 209] and recreational athletes typically source their information from the 
internet [196, 197, 202, 203].   
 
Current β-alanine use in athletes is yet to be examined; little is known about the 
prevalence of β-alanine use and purported side effects, use of β-alanine with other 
supplements, where athletes are sourcing their information on β-alanine use, and the 
level of knowledge of the ergogenic effects of β-alanine.  Typically when new 
supplements enter the marketplace the first users are professional and elite athletes.  
Therefore it would be prudent to collect information on this population, pertaining to 
the prevalence of use of β-alanine and to determine the level of knowledge and the 
sources of information on this supplement.  Finally, the level of side effects 
experienced by elite athletes is of interest.  
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Summary  
While the research generally suggests that high intensity exercise performance can 
be improved following chronic β-alanine supplementation, current evidence regarding 
the efficacy of β-alanine supplementation when combined with a training intervention 
is equivocal [3-5].  The current supplementation practices and level of knowledge 
relating to the benefits of supplementing with β-alanine among elite athletes is unclear. 
Given that greater adherence to a supplement correlates strongly with an individual’s 
knowledge of the therapy [6], poor knowledge of the benefits and correct dosages of 
β-alanine may influence adherence.  This is especially relevant to β-alanine 
supplementation, as multiple daily doses of β-alanine over several weeks are 
necessary to optimise increases in muscle carnosine levels over a period of time; non-
compliance is thus likely to reduce the potential of β-alanine supplementation to 
improve performance.  To date, factors that influence compliance to a β-alanine 
supplementation program and strategies that may minimise the side effects have not 
been investigated.  An improved understanding of these factors will inform 
recommendations for individualising β-alanine supplementation that in turn may 
improve its effectiveness in applied settings.  
 
 
 49 
 
CHAPTER 3: STUDY 1: EFFECT OF REPEAT SPRINT TRAINING, β-ALANINE 
AND SODIUM BICARBONATE ON REPEAT SPRINT ABILITY AND HIGH-
INTENSITY CYCLING CAPACITY 
 
Abstract 
The aim of this study was to investigate whether supplementation of β-alanine for 28 
days, in conjunction with repeated sprint and sprint interval training (SIT) and when 
combined with a pre-exercise dose of NaHCO3, could improve repeated-sprint ability 
and high intensity cycling capacity in healthy males. A randomised placebo-controlled 
four week training study was conducted with an additional cross-over component 
where NaHCO3 was ingested prior to the performance trials.  The NaHCO3 and 
placebo control cross-over component of the study occurred before and after 28 days 
of either β-alanine (6.4 g·day-1) (n = 14) or placebo (n = 13) supplementation combined 
with repeated sprint and SIT (3x/week).  In a random order, participants completed a 
repeated sprint (5 x 6 sec sprint) and a time to fatigue test (~110% maximum cycling 
power output - CCT110%) twice before and after training; once following NaHCO3 
ingestion and once following placebo ingestion.  The training program resulted in a 
‘likely’ improvement (4.8%) in total work during the 5 x 6 sec sprints in the placebo 
group while the β-alanine group had a slightly larger, ‘almost certain’, magnitude of 
improvement (7.7%); coingestion of β-alanine and NaHCO3 resulted in a ‘likely’ 
improvement (5.0%) in repeat sprint performance.  Following training, the biggest 
difference in repeat sprint performance was found in the 3rd (8.9%, ‘very likely’), 4th 
(11.6%, ‘almost certain’) and 5th (12.3%, ‘almost certain’) repetition in the β-alanine 
alone condition compared to the placebo or coingestion conditions.  During the 
CCT110% test prior to the intervention, the likelihood of a meaningful change following 
NaHCO3 was ‘almost certain’ – however, this change was not evident after the 
intervention. The likelihood of a meaningful change in time to exhaustion in the 
CCT110% test in any of the conditions was similar in all groups (‘almost certain’, ES = 
1.05, 1.17 and 1.17, placebo, β-alanine alone, coingestion, respectively). In summary, 
the current study found that β-alanine supplementation in conjunction with high 
intensity training improved repeat sprint ability but did not alter high intensity cycle 
capacity. Furthermore, acute NaHCO3 ingestion improved high intensity cycle capacity 
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(CCT110% ) before training but had no influence on performance after a period of SIT.  
It is possible that benefits of training may have outweighed the potential ergogenic 
effects of β-alanine and/or NaHCO3 (i.e., alone or in combination).   
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Introduction 
During repeated sprints and intermittent exercise performed at intensities exceeding 
the capacity of aerobic metabolism to resynthesize ATP [132, 220, 221], performance 
is significantly impaired due to increased acidity in the working cells [222, 223].  This 
has been largely attributed to the accumulation of hydrogen ions (H+) which can limit 
the capacity of the contractile proteins to function effectively [45, 224-226].  During 
very high intensity exercise, intramuscular H+ concentration may increase 10-fold, with 
muscle pH decreasing from ~7.1 to ~6.3 [54, 227].  Possible mechanisms of fatigue 
caused by intramuscular H+ accumulation include inhibition of glycolytic enzymes 
[228], impaired calcium handling [225] and cross-bridge cycling [226], impaired 
phosphocreatine recovery [229], and interference to the buffering processes [230].  
Independent of supplementation with β-alanine and/or NaHCO3, sprint and high-
intensity interval training can improve muscle buffer capacity and this increase has, in 
turn, been significantly associated with improvements in high intensity exercise and 
sprint performance [179, 180, 231, 232]. An individual may be able to delay fatigue 
and improve high intensity exercise performance by enhancing the capacity to buffer 
H+, through interventions such as high-intensity training and/or nutritional interventions 
[233-235].  Specific nutritional supplements which can influence buffering include β-
alanine which influences intracellular buffering, and sodium bicarbonate which buffers 
extracellular H+ in the blood [18].   
 
Carnosine (β-alanyl-L-histidine) is a cytoplasmic dipeptide found in relatively high 
concentrations in human skeletal muscles [10, 236] and has been strongly associated 
with an individual’s intramuscular buffer capacity [109, 175].  Indeed, the pKa of the 
imidazole ring of carnosine is 6.83 [237], making it an effective buffer over the 
physiological pH range [49, 237].  Carnosine is synthesised from histidine and β-
alanine with β-alanine being the rate-limiting substrate for carnosine synthesis in 
skeletal muscle [10, 88].  Muscle carnosine levels can increase by 30 – 80% following 
supplementation (3 – 6 g·day-1 for 4 weeks) of β-alanine [98].  Measures of exercise 
capacity are improved by an average of 2.8% following between 21 – 90 days of β-
alanine supplementation, with the greatest effect observed in tests lasting between 1 
– 4 minutes in duration [2].  The influence of β-alanine supplementation on repeated-
sprint ability (RSA) is less consistent [107, 132, 146, 238].   
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Increases in repeated-sprint performance in addition to improvements in single bouts 
of high intensity exercise have been shown to occur following an acute oral dose (0.3 
g·kgBM-1) of sodium bicarbonate (NaHCO3) consumed 60 – 90 minutes before 
exercise [157, 161, 239, 240] see Linderman and Gosselink [241] and McNaughton et 
al. [172] for recent reviews.  NaHCO3 acts as an extracellular buffer during exercise; 
acute ingestion of NaHCO3 increases the pH gradient between the intracellular 
(muscle) and extracellular (blood) spaces, promoting the transmembrane movement 
of H+ from the exercising muscle [172, 224, 239].   
 
A number of studies have examined the influence of co-supplementation of β-alanine 
and NaHCO3 on high intensity exercise and sprint performance; the rationale has been 
to enhance both intracellular muscle buffering (via carnosine) and extracellular blood 
buffering (via NaHCO3) to potentially produce a greater combined physiological 
benefit.  Results have been mixed, with additive benefits reported for upper-body 
intermittent performance [133] and small non-significant but likely increases in 
performance reported in cycle capacity [116, 162], 2000m rowing [242] plus 100 m 
and 200m swimming [120].  Other studies have reported no additive benefit for cycle 
capacity [4] and RSA during cycling and running [4, 146, 238].  However, these studies 
were limited by small sample sizes and did not include any structured training during 
the supplementation period.  Cochran et al. [5] recently combined β-alanine 
supplementation with six weeks of sprint interval training (SIT) and reported an 
increase in V̇O2 peak, repeated-sprint capacity, and 250 kJ time trial performance 
following training however, β-alanine supplementation conferred no additional benefits 
to those adaptations resulting from training without supplementation.  Repeat-sprint 
training was not included in this study, and the ergogenic influence of combined β-
alanine and NaHCO3 supplementation during repeat-sprint training is yet to be 
established. 
 
Research has shown that β-alanine and NaHCO3 supplementation can independently 
improve high intensity exercise performance and some studies have found that when 
combined, performance may be further improved.  The findings from those few studies 
that have combined β-alanine supplementation with sprint interval training have not 
shown any additive benefits compared to single interventions.  Research is yet to 
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examine the potential influence of β-alanine and NaHCO3 with repeat sprint and sprint 
interval training on performance.  The aim of this study was therefore to investigate 
whether supplementation of β-alanine for 28 days, in conjunction with repeated sprint 
and sprint interval training when combined with a pre-exercise dose of NaHCO3, could 
improve repeated-sprint ability and high intensity cycling capacity in healthy males. 
 
Methods 
Overview 
A randomised placebo-controlled four week training study was conducted with an 
additional cross-over component where NaHCO3 was ingested prior to performance 
tests.  The NaHCO3 and placebo control cross-over component of the study occurred 
before and after 28 days of either β-alanine or placebo supplementation combined 
with repeated sprint and SIT. NaHCO3 and placebo supplements were provided to 
participants in a double blind fashion (label by a specific participant and supplement 
code) by a laboratory assistant not directly involved in the investigation.  The 
laboratory assistant provided the supplement code to the primary investigator after all 
data collection was complete. A repeated-sprint ability test (5 x 6 sec sprint) and a time 
to fatigue test at ~110% maximum cycling power output (Wmax) was performed before 
and after the training period.  This repeated-sprint ability test was chosen as it has 
been shown to be a valid test for well trained team sport athletes and also because, 
NaHCO3 has been shown to facilitate improvements in both work done and power 
output during 5 x 6 sec all out sprints separated by 30 sec recovery [224]. Following 
baseline testing, participants were matched for Wmax and randomly allocated (using a 
random number generator software program) into one of two experimental groups.  In 
multiple doses across the day, one group ingested eight placebo capsules per day 
while the supplementation group ingested eight β-alanine capsules per day; the total 
daily dose of β-alanine for the supplementation group was 6.4 g·day-1.  Again β-alanine 
and placebo supplements were provided to participants in a double blind fashion (label 
by a specific participant and supplement code) by a laboratory assistant not directly 
involved in the investigation with the laboratory assistant provided the supplement 
code to the primary investigator after all data collection was complete. All participants 
trained three times a week for four weeks; training involved repeated 6 sec and 30 sec 
sprints.  Figure 3.1 provides an overview of the research design.  Participants 
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completed the repeated sprint tests and time to fatigue tests twice before and after 
training; once following NaHCO3 ingestion and once following a placebo ingestion, 
provided in a randomised order.  
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Figure 3.1 Research design 
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Participants 
Twenty eight recreationally active males volunteered to participate in the study and 
were assigned to one of the following two groups, matched on Wmax during preliminary 
testing: 1) β-alanine/training or 2) placebo/training.  To be accepted into the study, 
participants were required to meet the current Australian physical activity guidelines 
(>150 min·week−1), they needed to be consuming meat occasionally in their diets, and 
to have not taken any nutritional or dietary supplement in the previous three months 
or β-alanine for at least six months.  Participants were fully informed of any risks 
associated with the study before completing the Active Australia Self-Report Physical 
Activity Measure (Australian Institute of Health and Welfare.), and stage one and two 
of the Adult Pre-exercise Screening Tool (Exercise and Sport Science Australia).  They 
were excluded from the study if they reported more than two risk factors on the pre-
exercise screening.  Each was asked to maintain his usual levels of physical activity 
for the duration of the study and to avoid any significant change to their diet for the 
same period.  The study was approved by an Ethics Committee of The University of 
Queensland. 
 
Baseline assessment 
Figure 3.2 provides an overview of the baseline, familiarisation and pre-testing 
timeline. Participants were asked to avoid strenuous exercise in the 24 hours 
preceding baseline testing and to abstain from alcohol and caffeine whilst maintaining 
fluid intake and fast for 8 hours prior to testing.  During their first visit to the laboratory, 
each participant’s stretch stature (SE206, Seca, UK), and body mass (SE719, Seca, 
UK) were measured for determination of body mass index (BMI).  Dual energy X-ray 
absorptiometry (DXA) (Hologic QDR Discovery, MA , USA) was used to determine 
bone mineral-free lean mass (LM), fat mass (FM), and % body fat.  Participants voided 
their bladder prior to scanning and wore the same clothing for all scans and whilst 
positioning aids were not used, the hands and feet were secured throughout the scan. 
The same DXA operator performed all scans and was blinded to any treatment 
conditions.  The CV’s in our laboratory for LM, FM and % body fat are 0.3, 0.9 and 
0.9%, respectively.  All performance tests were completed on an electronic ergometer 
(Lode Excalibur Sport, Lode B.V., Groningen, Netherlands) and each participant’s 
position (saddle height, handle bar position etc.) on the cycle ergometer was 
established during these baseline sessions, and replicated for all subsequent trials.  
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Each participant’s maximal power output (Wmax) was determined using a graded 
cycling exercise test to exhaustion on the cycle ergometer using the protocols 
previously described by Sale et al. [162].  Exercise intensity was increased by 6 W 
every 15 sec (ramp rate of 24 W·min-1) from a starting power output of 100 W.  
Participants maintained a pedal cadence of 90 rpm throughout exercise until volitional 
exhaustion.  Wmax was defined as the maximum power output averaged over the final 
two stages.  
 
 
Figure 3.2 Baseline assessment, familiarisation and pre-testing timeline. 
 
Familiarisation 
Forty-eight hours following baseline assessment, participants returned for the first of 
two familiarisation sessions, each separated by 48 hours (Figure 3.3). Based on 
previous recommendations [243], all participants performed two sets of five supra-
maximal 6 sec sprints on the same ergometer.  The repeated sprints were preceded 
by a standardised warm-up that involved 5 min cycling at 80 W, followed by a passive 
rest period of 90 sec and one near-maximal practice sprint of 2 – 3 sec.  Following the 
practice sprint, and 180 sec of passive rest, participants produced one 6 sec maximal 
sprint with work and power outputs recorded for benchmarking.  As recommended by 
Fitzsimons et al. [244], to prevent pacing during the repeat sprint test, the work 
produced during the first sprint of the 5 x 6 sec test had to equal or exceed 95% of the 
work completed during the benchmark sprint.  If this was not achieved, participants 
were required to rest for 5 min and repeat the 5 x 6 sec sprint test. This occurred three 
times during pre-testing and once in post-testing.  After the initial warm up, participants 
rested for 5 min before the start of the first sprint.  Repeat sprint ability (RSA) tests 
were completed on an electromagnetically braked cycle ergometer (Lode, Excalibur 
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sport; Groningen, The Netherlands) using a protocol similar to that of Baguet et al 
[245].  Each of the five all-out 6 sec sprints was separated by 24 sec of low-intensity 
cycling.  About 5 sec before the start of each sprint participants were asked to 
accelerate until the display showed ~80 RPM. Participants were required to complete 
the test in a seated position and strong verbal encouragement was provided 
throughout; the participant’s feet were securely attached to the pedals using toe clips 
and straps.  The cycle ergometer was used in the linear mode, with the linear factor 
set at a torque factor of 0.8 Nm·kgBM-1.  Peak power output (W), mean power output 
(W), mean power per kilogram of body mass (W·kgBM-1) and total work (J) were 
recorded for each sprint.   
 
A test-retest study was conducted to determine the reliability of the repeated sprint 
test.  Twelve participants (age 22 ± 4 yrs, height 1.74 ± 0.06 m, body mass 78.5 ± 6.2 
kg) completed two sets of 5 × 6 sec sprints on two occasions separated by at least 48 
hours; the two sets were performed 45 min apart during which time the participants 
rested.  All participants completed the test after abstaining from caffeine or alcohol for 
the previous 24 hrs and following a 12 hour fast. There was no significant difference 
in total work (J) (p = 0.27) and mean power (W) (p = 0.36) between data sets.  The 
coefficient of variation between sets 1 and 2 was 2.16% for total work and 2.74% for 
mean power.  The coefficient of variation (CV) between trials 1 and 2 was 3.89% for 
total work and 4.42% for mean power output. Whilst these result provide a significant 
level of reliability, ideally 30 – 40 participants provide a tighter measure of reliability 
[246].   
 
Following the final sprint, participants warmed down for 10 min at 80 – 100 W and 
rested for 20 min.  They then completed a cycle test to fatigue at 110% of the 
previously determined Wmax (CCT110%).  Similar to the protocol used by Saunders et al 
[247], participants completed a gradual warm up for the first 30 sec.  Power output 
was then incrementally increased from 80% Wmax for the first 15 sec to 95% Wmax for 
the second 15 sec and 110% Wmax until the completion of the tested.   
 
Participants could view their cadence during exercise on the monitor of the ergometer 
and were encouraged to maintain a steady cadence throughout (~80 to 100 rev·min-
1); this cadence was repeated in all subsequent bouts.  Apart from cadence, 
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participants were blinded from all performance results.  The test was concluded when 
the participant’s cycling cadence dropped 20 rev·min-1 below their optimal self-
selected cycling cadence.  Time to exhaustion (TTE, sec) was recorded as the 
outcome measures for all tests. Relative and absolute reliability for TTE during the 
CCT110% have narrow agreement ratios and ICCs just below and above 0.9 and a CV 
of 4.43% [247]. 
 
 
Figure 3.3 Familiarisation timeline 
 
Pre- and post-testing 
Pre-testing occurred 72 hours following the second familiarisation trial.  Again, 
participants were asked to avoid strenuous exercise in the 24 hours preceding testing 
and to abstain from alcohol and caffeine. They each completed a 24 hour food record 
and were requested to follow the same diet for 24 hours prior to each subsequent trial.  
The diet records were evaluated using the FoodWorks dietary assessment software 
program (Xyris Software, Qld, Australia) to determine average daily energy (kJ) and 
average daily fat (g), carbohydrate (g), and protein (g) intake.  
 
Blood analysis 
Blood (5 ml) was sampled by a qualified phlebotomist from an antecubital vein; blood 
gases, pH, and lactate (mg·dL), were measured using an automatic blood gas and 
electrolyte analyzer (GEM Premier 3000, Instrumentation Laboratory Diagnostics, 
Italy).  In order to avoid blood clotting, heparinised lithium capillaries were used (GEM 
Premier 3000, Instrumentation Laboratory Diagnostics S.A. de C.V. Mexico).  In 
addition, bicarbonate and base excess was calculated; bicarbonate was calculated 
from PCO2 and pH values according to the Henderson-Hasselbalch equation and base 
excess was calculated according to ((1 – 0.014[Hb]) x ([HCO3 -] – 24 + (1.43[Hb] + 
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7.7) (pH – 7.4))).  Blood was sampled on five occasions: at rest, pre- and post- repeat 
sprint test and pre- and post- the CCT110% test.   
 
Upon arrival at the laboratory, venous blood was sampled. Participants were then 
administered either NaHCO3 or a placebo with a standardised breakfast before resting 
for 90 min.  NaHCO3 was supplemented at a dose of 0.3 g·kgBM-1 in white gelatine 
capsules; a calcium sulphate placebo was administered in capsules identical in 
appearance for the placebo trial.  An equal number of NaHCO3 or placebo capsules 
were taken with 7 ml·kgBM-1 of water at 15 minute intervals for 30 minutes.  The 
NaHCO3 or placebo capsules were ingested with a standardised breakfast of 1.5 g 
carbohydrate per kilogram of body mass (which equated to between 3 – 5 slices of 
toast with jam) [184].  Participants then completed a set of 5 x 6 sec cycle sprints 
followed by a CCT110% test 15 min after the completion of the sprints.  Testing was 
repeated 48 hours later with the alternative supplement protocol.    
 
For the following four weeks, participants were then supplemented with either 6.4 g·d-
1 sustained release β-alanine tablets (High Intensity Sustained Release Beta Alanine, 
PowerBar, Nestlé, Switzerland) or an equivalent number of placebo tablets (6.4 g·d-1 
maltodextrin).  β-alanine tablets were tested by the manufacturer prior to the study to 
ensure no contamination with steroids or stimulants and that they conformed to the 
label claim for β-alanine content.  The β-alanine and placebo dosing regimens required 
participants to consume two 800 mg tablets, four times per day at 3 – 4 hour intervals.  
Participants were required to verbally verify their supplementation compliance and 
compliance was recorded.  Supplements were distributed to all participants on a 
weekly basis.  At the completion of the study, participants were asked to report the 
substances they believed they were take throughout the four week training period 
(placebo or β-alanine) and during pre- and post- testing (placebo or NaHCO3).   
 
Training 
Participants trained three times a week, with a minimum of 48 hours separating each 
training session; training involved repeated 6 sec and 30 sec sprints.  Details of the 
training sessions are shown in Table 3.1.  All training was completed using a Wattbike 
Pro (British Cycling, Nottingham, England) and the Air Brake resistance was set on 
level 7.  Where possible, participants completed each training session on the same 
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bike.  All 6 sec sprints were completed in a standing position and began with pedals 
in a level position.  During the 30 sec sprints, participants were permitted to sit or 
stand.  Training sessions were supervised by the lead investigator and were 
completed in small groups.  Peak and average power output and heart rate were 
recorded after each sprint and participants’ best performance scores for each set were 
visually displayed to encourage effort.  All participants completed a total of twelve 
training sessions. 
 
Table 3.1 Four week training requirements.  
Week Repeated Sprint Sprint Intervals 
1 3 x (5 x 6 sec W: 24 sec R) 
4:30 min between sets 
3 x 30 sec 
4:30 min between sets 
2 3 x (5 x 6 sec W: 24 sec R) 
4:30 min between sets 
4 x 30 sec 
4:30 min between sets 
3 3 x (5 x 6 sec W: 24 sec R) 
4:30 min between sets 
5 x 30 sec 
4:30 min between sets 
4 3 x (5 x 6 sec W: 24 sec R) 
4:30 min between sets 
6 x 30 sec 
4:30 min between sets 
W = work, R = passive rest 
 
Statistical analysis 
The Gaussian distribution of data was verified by the Shapiro-Wilk test and when data 
were normally distributed they are presented as mean ± standard deviation (SD).  
Before the supplementation period, a comparison between groups of participant’s 
body composition characteristics and Wmax was performed using an independent-
samples t-test.  
 
To detect changes in repeat sprint performance, TTE following training, β-alanine 
supplementation or β-alanine and sodium bicarbonate supplementation the data were 
interpreted using Cohen’s d effect sizes (ES).  The ES with a 90% CI was determined 
using a spreadsheet available at www.sportsci.org/resource/stats with the following 
threshold values used: ≤ 0.49: small; 0.5 – 7.9: moderate; ≥ 0.8: large. Using the 
method (and spreadsheet) described by Hopkins [248], further analysis was 
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conducted applying the Cohen’s ES principle to estimate the probabilities of whether 
there was a practically meaningful effect using the smallest worthwhile change (SWC) 
(0.2 multiplied by the between-participant SD of pre-training value), as follows:  
 
Threshold values for practically meaningful (% +/-) = [(SD x 0.2) ÷ M] x 100; 
 
where SD is the pooled SD, and M is the mean of the pre-training values.  For repeat 
sprint measures the SWC was calculated based on the SD and M of the first sprint for 
each variable.  The constant 0.2 represent the Cohen’s ES principle. 
 
Each participant’s change score was computed as a percent of the pre-training or pre-
supplementation value and log transformed to reduce any bias from non-uniformity of 
error.  
 
The quantitative chances of benefit were estimated through magnitude-based 
inferences and a qualitative descriptor was applied to the threshold inferences: <1%, 
almost certainly not; 1–5%, very unlikely; 5–25%, unlikely; 25–75%, possibly; 75–95%, 
likely 95–99%, very likely; >99%, almost certain. Where the chance of benefit or harm 
was calculated to be >5%, the true effect was deemed unclear [248]. 
 
Blood data were analysed using a two-way ANOVA and Tukey tests were used for 
post hoc analyses.  Body composition data were analysed using two-way ANOVA for 
changes over time.  Analyses were completed using SPSS package, version 22 
software for Windows. Significance level was set at p < 0.05. 
 
Results 
All data were normally distributed. One participant withdrew due to personal 
circumstances unrelated to the current study.  There were no differences in Wmax, age, 
height, body mass, BMI, bone free mass, fat mass and percent body fat between the 
two groups  (n = 27) (Table 3.1). 
 
Table 3.2 Physical characteristics (mean ± SD) of participants. 
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 Placebo  
(n = 13) 
β-alanine  
(n = 14) 
p value 
Age (yrs) 24.7 ± 4.2 22.9 ± 3.0 0.19 
Height (cm) 178.9 ± 5.4 178.3 ± 6.6 0.79 
Body mass (kg) 84.7 ± 11.1 75.4 ± 13.1 0.06 
BMI (kg m2) 26.5 ± 4.0 23.8 ± 3.5 0.08 
Bone-free lean mass 
(kg) 
60.7 ± 5.3 56.9 ± 7.7 0.15 
Fat mass (kg) 15.0 ± 6.2 19.8 ± 8.4 0.10 
Body fat (%) 23.2 ± 6.7 19.5 ± 4.7 0.11 
Wmax 329 ± 51 326 ± 37 0.84 
BMI – body mass index 
 
Repeat sprint ability test (RSA) 
During the RSA test, no differences in total or mean power were observed between 
the calcium sulphate (placebo) and NaHCO3 conditions either before or after the β-
alanine supplementation period (Figure 3.4).  The training program resulted in a ‘likely’  
improvement (4.8%) in total work during the 5 x 6 s sprints in the placebo group while 
the β-alanine group (BA) had a slightly larger ‘almost certain’ magnitude of 
improvement (7.7%) and coingestion of β-alanine and NaHCO3 (BASB) resulted in a 
‘likely’  improvement (5.0%) (Figures 3.5 & 3.6).  When examining the total work 
completed in each individual repetition (Figure 3.7) the changes following the training 
and supplementation period in the first repetition were trivial in the placebo, BA and 
BASB groups.  Whilst effect sizes were small (d = 0.13 – 0.39), as the set progressed, 
the total work completed in each subsequent repetition improved 5.1%, 6.5% (‘likely’); 
8.5%, 9.2% (‘very likely’) in the 2nd, 3rd, 4th  and 5th repetition respectively, in the 
placebo group. A similar pattern was present in the BA group following training with 
effect sizes small (d = 0.12) to moderate (d = 0.52) and the percent change and 
likelihood of change becoming greater in the 3rd (8.9%, ‘very likely’), 4th (11.6%, ‘almost 
certain’) and 5th (12.3%, ‘almost certain’) repetition.  Following BASB effect sizes were 
small (d = 0.13 – 0.34) with likelihood of change ranging from ‘trivial’ to ‘very likely’ 
between the 1st and 5th repetition.  A similar pattern was evident for measures of mean 
power relative to body mass, however the likelihood of a meaningful change was 
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greater during the 1st repetition (‘likely’), 2nd repetition (‘almost certain’) and 3rd 
repetition (‘very likely’), (ES, d = 0.25 – 0.61) in the BA group, with an ‘almost certain’ 
change in mean power relative to body mass during the 4th and 5th repetitions in both 
the BA (ES, d = 0.74 and 0.87) and BASB (ES, d = 0.63 and 0.55) group (Table 3.3).  
 
 
Figure 3.4 Mean total work ± SD for all repetitions combined following acute 
supplementation of sodium bicarbonate (SB) or calcium sulphate (CS).  
Whole group n = 27, Placebo n = 13, β-alanine n = 14.  
 
 
Figure 3.5 Mean total work ± SD for all RSA repetitions combined following training 
and supplementation. BA = β-alanine BASB = β-alanine and sodium bicarbonate.  
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blikely chances of improvement, dalmost certain chances of improvement.  
 
 
 
Figure 3.6. Change in RSA (± SD) total work done following training and 
supplementation. BA = β-alanine BASB = β-alanine and sodium bicarbonate.  
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Figure 3.7 Mean total work ± SD for each repetition following A, training and placebo 
supplementation; B, training and β-alanine supplementation; C. training and β-alanine 
and sodium bicarbonate supplementation.  
*Moderate (d = 0.59 – 0.79) effect size for difference between pre-test and post-test, 
blikely chances of improvement, cvery likely chances of improvement, dalmost certain 
chances of improvement. 
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Table 3.3 Mean power in watts per kilogram body mass (W·kgBM-1) ± SD for each 
repetition of the repeat sprint ability test for the placebo (n = 13), β-alanine 
supplementation (n = 14), (BA) and β-alanine and sodium bicarbonate (n = 13) 
conditions pre-supplementation and post-supplementation.  
ES = effect size. 
 
 
Placebo BA BASB
Repetition 1
Presupplementation (W·kgBM-1) 11.7 ± 1.7 13.0 ± 1.4 13.0 ± 1.4
Postsupplementation (W·kgBM-1) 11.8 ± 2.1 13.0 ± 1.4 13.3 ± 1.4
ES Cohen's d 0.07 0.25 0.21
Mean change (%) ± 90% confidence limits 0.4 ± 0.26 3.3 ± 0.41 2.8 ± 0.25
% chance - Benefical/Trivial/Harmful 60/13/27 83/5/12 78/6/16
Description Unclear Likely Unclear
Repetition 2
Presupplementation (W·kgBM-1) 10.7 ± 2.1 11.9 ± 1.4 11.9 ± 1.4
Postsupplementation (W·kgBM-1) 11.1 ± 1.7 12.6 ± 1.3 12.6 ± 1.3
ES Cohen's d 0.20 0.54 0.15
Mean change (%) ± 90% confidence limits 4.8 ± 0.18 7.0 ± 0.35 2.5 ± 0.25
% chance - Benefical/Trivial/Harmful 94/4/2 99/0/1 71/9/20
Description Likely Almost certain Unclear
Repetition 3
Presupplementation (W·kgBM-1) 9.7 ± 2.4 10.7 ± 1.4 10.7 ± 1.4
Postsupplementation (W·kgBM-1) 10.2 ± 1.8 11.6 ± 1.4 11.6 ± 1.4
ES Cohen's d 0.23 0.61 0.34
Mean change (%) ± 90% confidence limits 7.5 ± 0.24 9.1 ± 0.42 5.7 ± 0.39
% chance - Benefical/Trivial/Harmful 90/5/5 98/1/1 90/4/6
Description Likely Very likely Likely
Repetition 4
Presupplementation (W·kgBM-1) 9.1 ± 2.2 9.9 ± 1.4 9.9 ± 1.4
Postsupplementation (W·kgBM-1) 9.6 ± 1.6 11.0 ± 1.4 11.0 ± 1.4
ES Cohen's d 0.28 0.74 0.63
Mean change (%) ± 90% confidence limits 8.5 ± 0.27 12.0 ± 0.37 10.3 ± 0.41
% chance - Benefical/Trivial/Harmful 93/4/3 100/0/0 99/1/1
Description Likely Almost certain Almost certain
Repetition 5
Presupplementation (W·kg BW-1) 9.0 ± 2.4 9.4 ± 1.3 9.4 ± 1.3
Postsupplementation (W·kg BW-1) 9.6 ± 1.9 10.5 ± 1.2 10.5 ± 1.2
ES Cohen's d 0.26 0.87 0.55
Mean change (%) ± 90% confidence limits 9.4 ± 0.23 12.3 ± 0.34 8.3 ± 0.34
% chance - Benefical/Trivial/Harmful 95/3/2 100/0/0 99/1/0
Description Very Likely Almost certain Almost certain
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Cycling capacity test (CCT110%) 
During the CCT110% test prior to the intervention, the likelihood of a meaningful change 
following NaHCO3 was ‘almost certain’ - however this change was not evident after the 
intervention (Figure 3.8).  The likelihood of a meaningful change in TTE following 
training only (placebo), BA and BASB supplementation were all ‘almost certain’ with 
strong effect sizes of 1.05, 1.17 and 1.17, respectively (Figure 3.9).  Mean TTE 
following intervention increased by a range of 33.8 – 39.5 sec (Figure 3.10).  
 
 
 
Figure 3.8 Changes in TTE following acute supplementation of sodium bicarbonate 
(SB) or calcium sulphate (CS) supplementation. 
 Whole group n = 27, Placebo n = 13, β-alanine n = 14. dalmost certain chances of 
improvement. 
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Figure 3.9 Mean TTE ± SD following training and supplementation.  
BA= β-alanine, BASB= β-alanine and sodium bicarbonate.  
**Strong (d ≥ 0.8) effect size for difference between pre-test and post-test, dalmost 
certain chances of improvement. 
 
 
Figure 3.10 Time and percent changes in TTE following training and supplementation.  
BA= β-alanine, BASB= β-alanine and sodium bicarbonate.  
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Blood analyses 
Baseline blood pH, lactate, bicarbonate and bases excess were similar between all 
trials (Table 3.4).  There were significant increases in blood pH, HCO3− and base 
excess from baseline in all trials that involved NaHCO3 supplementation (Table 3.4).  
The placebo conditions showed no changes in pH, HCO3− and base excess in any of 
the trials.  Blood pH, bicarbonate, and base excess were significantly reduced from 
baseline immediately after both RSA and CCT110% in all trials (p < 0.05) and when 
NaHCO3  was ingested (BA and BASB) blood pH, bicarbonate, and base excess were 
significantly higher (p < 0.05) than in the calcium sulphate trials. Blood lactate was 
significantly increased (p < 0.05) from baseline immediately after both RSA and 
CCT110% tests.  After the intervention there was no significant change in post-RSA 
blood lactate in any of the interventions.  A significant increase in lactate was observed 
following the training intervention in the calcium sulphate condition compared to pre-
testing while there was no difference in pre and post-testing lactate response in the 
BA (p = 0.40) and BASB groups (p = 0.20). 
 
 71 
 
Table 3.4 pH, lactate, bicarbonate, and base excess (mean ± SD) at baseline, pre and post repeat sprint ability (RSA) test, pre and 
post time to fatigue (CCT110%) test before training (n = 27) and after training in the placebo (n = 13) and β-alanine (n = 13) groups, 
after supplementation with calcium sulphate (CS), and after supplementation with sodium bicarbonate (SB).   
 
CS SB p value CS SB p value CS SB p value
pH
Baseline 7.36 ± 0.02 7.36 ± 0.03 0.266 7.35 ± 0.04 7.36 ± 0.03 0.591 7.35 ± 0.02 7.34 ± 0.03 0.288
Pre RSA 7.35 ± 0.02 7.39 ± 0.03 <0.05 7.35 ± 0.02 7.40 ± 0.02 <0.05 7.32 ± 0.04 7.39 ± 0.03 <0.05
Post RSA 7.19 ± 0.04 7.24 ± 0.05 <0.05 7.19 ± 0.07 7.28 ± 0.06 <0.05 7.14 ± 0.06 7.21 ± 0.07 <0.05
Pre CCT110% 7.31 ± 0.03 7.39 ± 0.03 <0.05 7.34 ± 0.03 7.41 ± 0.05 <0.05 7.29 ± 0.05 7.37 ± 0.05 <0.05
Post CCT110% 7.21 ± 0.06 7.26 ± 0.07 <0.05 7.19 ± 0.08 7.28 ± 0.08 <0.05 7.17 ± 0.06 7.22 ± 0.05 <0.05
Lactate (mmol·L-1)
Baseline 0.8 ± 0.4 1.0 ± 0.9 0.202 0.6 ± 0.4 0.7 ± 0.3 0.45 0.9 ± 0.3 0.9 ± 0.8 0.935
Pre RSA 1.2 ± 0.3 1.3 ± 0.4 0.070 1.1 ± 0.5 1.1 ± 0.3 0.938 1.5 ± 0.1 1.5 ± 0.5 0.957
Post RSA 9.3 ± 2.8 9.8 ± 2.5 0.370 9.2 ± 2.2 9.4 ± 2.6 0.796 11.0 ± 2.0 10.4 ± 2.7 0.511
Pre CCT110% 7.7 ± 2.2 8.4 ± 2.1 0.109 6.0 ± 1.8 6.2 ± 1.9 0.507 8.4 ± 2.6 8.5 ± 2.9 0.810
Post CCT110% 10.7 ± 2.4 12.1 ± 2.8 <0.05 11.3 ± 3.0 12.1 ± 3.0 0.088 12.7 ± 2.8 13.2 ± 3.0 0.544
Bicarbonate (mmol·L-1)
Baseline 26.52 ± 0.95 26.40 ± 1.01 0.501 26.74 ± 1.19 26.38 ± 1.15 0.229 26.99 ± 1.21 26.67 ± 1.64 0.445
Pre RSA 26.84 ± 0.99 31.07 ± 1.62 <0.05 27.78 ± 1.04 32.13 ± 1.35 <0.05 26.99 ± 1.69 31.30 ± 1.63 <0.05
Post RSA 18.34 ± 2.31 21.93 ± 2.28 <0.05 19.36 ± 1.96 24.59 ± 2.96 <0.05 17.34 ± 2.52 21.60 ± 3.03 <0.05
Pre CCT110% 20.76 ± 2.37 25.04 ± 2.23 <0.05 23.04 ± 2.25 27.33 ± 3.33 <0.05 20.24 ± 3.26 24.47 ± 3.28 <0.05
Post CCT110% 17.14 ± 2.34 19.99 ± 3.29 <0.05 17.59 ± 3.14 21.69 ± 3.43 <0.05 15.41 ± 2.89 18.66 ± 3.16 <0.05
Base Excess (mmol·L-1)
Baseline 3.87 ± 1.80 4.09 ± 1.66 0.539 4.70 ± 1.31 4.13 ± 1.46 0.313 5.09 ± 1.89 4.71 ± 2.53 0.540
Pre RSA 4.91 ± 1.50 10.31 ± 2.19 <0.05 5.54 ± 1.54 11.77 ± 2.03 <0.05 5.32 ± 1.54 10.60 ± 2.21 <0.05
Post RSA -5.63 ± 3.80 -0.86 ± 3.39 <0.05 -4.10 ± 2.90 2.18 ± 3.85 <0.05 -6.48 ± 3.28 -1.04 ± 3.79 <0.05
Pre CCT110% -3.67 ± 3.51 1.66 ± 2.99 <0.05 -0.92 ± 3.32 4.55 ± 4.44 <0.05 -4.17 ± 4.22 0.64 ± 4.43 <0.05
Post CCT110% -7.41 ± 3.35 -3.90 ± 4.67 <0.05 -6.84 ± 4.41 -2.19 ± 4.89 <0.05 -9.68 ± 4.39 -5.86± 4.81 <0.05
Pre-Training Post-Training 
Placebo β -alanine
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Body composition 
There was no significant difference between groups in body mass, bone free lean 
mass or fat mass, p = 0.956, p = 0.678, p = 0.134 for time or interaction p = 0.926, p 
= 0.086, p = 0.138 respectively.  No significant differences were observed for percent 
body fat over time p = 0.058, there was a significant interaction p = 0.048 with an 
approximate 0.7% decrease in percent body fat following β-alanine supplementation. 
 
Diet 
There was no significant difference between the 24 hr dietary intake before each of 
the performance trials in total energy intake (range 10,365 ± 1,990 kJ to 10,399 ± 
2,169 kJ).  The composition of dietary intake during the course of the intervention was 
the same for all groups and averaged 53 ± 8% carbohydrate, 27 ± 3% protein, and 20 
± 5% fat.  
 
Discussion 
The aim of this study was to investigate whether supplementation of β-alanine, in 
conjunction with repeated sprint and sprint interval training combined with pre-exercise 
NaHCO3 supplementation could improve repeated-sprint ability and high intensity 
cycling capacity. The main finding was that β-alanine supplementation during a 4-week 
repeat sprint and SIT program enhanced repeat sprint performance but not time to 
fatigue at 110% Wmax (CCT110%). Specifically, improvements were seen in the later 
repetitions of the RSA test, with the greatest improvement in performance in the 4th 
and 5th repetition following β-alanine supplementation. Sodium bicarbonate 
supplementation (alone) resulted in improved CCT110% performance prior to training, 
however it did not influence performance after the training intervention.  
 
Efficacy of NaHCO3 supplementation 
In both the pre-training and post-training repeated sprint and CCT110% testing, blood 
bicarbonate, pH and base excess significantly increased 90 minutes after NaHCO3 
ingestion. There was a significant elevation in blood bicarbonate (4.67 – 5.75 mmol·L-
1) from baseline, which is in line with the mean increase of 5.30 mmol·L-1 previously 
reported in a meta-analysis using the same 0.3 g·kgBM-1 dose [249] and greater than 
the average increase (3.9 mmol·L-1) reported in a more recent meta-analysis by Carr 
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et al. [17]. Similarly, there was an increase in blood pH and base excess following 
acute NaHCO3 supplementation, hence circulatory alkalosis had occurred and this is 
in agreement with previous studies that used similar dosing protocols [224, 250-253].  
 
RSA – NaHCO3 supplementation 
Despite circulatory alkalosis having been achieved following NaHCO3 
supplementation, there was no improvement in any of the performance measures 
during the RSA test after NaHCO3 supplementation alone either before or after 
training.  Danaher et al. [4] also reported no influence on performance following 
NaHCO3 supplementation in men using a similar dosage and testing protocol to those 
used in the present study.  Despite a significant increase in pre-exercise blood 
bicarbonate following supplementation in their study, the authors stated that metabolic 
alkalosis was not achieved due to a lack of change in blood pH following NaHCO3 
supplementation [4].  They did not elucidate why there was no change, as several 
investigations using the same protocol have previously shown changes in pH after the 
ingestion of similar doses of NaHCO3 [224, 252, 253].  Using a similar dose of NaHCO3 
and a similar testing protocol (5 x 6 sec cycle sprint starting every 30 sec) to the 
present study, Bishop et al. [224] reported an increase in  total work and peak power 
output during the last three sprints (compared to a placebo) in active female hockey 
players.  The authors stated that these contrasting results may be due to a participant 
effect (e.g., fitness levels or gender); trained individuals may be better able to 
consistently take advantage of an increased extracellular buffering capacity compared 
to untrained participants [254].  Finally, recent research has shown that the time-to-
peak pH (64.41 ± 18.78 min) was variable with a range of 10–85 min and a coefficient 
of variation of 29.16%. Therefore, when using NaHCO3 as an ergogenic aid in future, 
the time-to-peak pH of participants should be determined to best utilize the added 
buffering capacity this substance allows [255]. 
 
That NaHCO3 treatment did not influence RSA performance either pre- or post-training 
suggests that either a potential improvement in extracellular buffering capacity was 
insufficient to influence performance, or that decreases in pH are not the predominant 
factor limiting repeat sprint ability.  A variety of mechanisms including neural factors, 
the generation of an inadequate motor command in the motor cortex, muscular factors 
and/or, the accumulation of metabolites within muscle fibres are all believed to 
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contribute to fatigue during repeat sprint exercise [177]. Several authors have 
postulated that a significant limitation to repeat sprint exercise performance may be 
phosphocreatine availability [256, 257].  Phosphocreatine stores can be reduced by 
35–55% of resting levels after an all-out 6 sec sprint [258, 259] and up to 5 minutes of 
recovery may then be needed for level to return to pre-exercise levels [257, 260].  The 
24 sec recovery period used in the present study would not have been sufficient for 
complete resynthesis of phosphocreatine levels before the onset of the subsequent 
repetition [258, 261].  The lower levels of pre-exercise phosphocreatine in subsequent 
sprints would have resulted in lower power outputs, particularly peak power outputs 
[256, 259].  Therefore, it is reasonable to speculate that incomplete phosphocreatine 
resynthesis between sprint bouts may have been a greater cause of fatigue than 
acidosis and any potential ergogenic effects of NaHCO3 as a physiochemical buffer 
may not have been evident. 
 
RSA – Training and β-alanine supplementation 
In the current investigation there may have been some improvement in performance 
in response to the training intervention, as there was a 4.8% improvement in the 
placebo group in total work during the 5 x 6 sec sprints following the training program.  
Whilst muscle buffer capacity was not measured directly in this study, female 
recreational team sport athletes have been shown to improve their muscle buffer 
capacity by 25% after completing high-intensity cycle interval training (6 – 10 x 2 min 
at 120 – 140% lactate threshold with 1 min rest) for 5 weeks, 3 days per week.  During 
training, the repeated high-intensity sprints were interspersed with short rest periods, 
causing lactate and H+ production to exceed removal or utilisation, which most likely 
resulted in an increased accumulation of H+ and a decrease in intracellular pH [262].  
Following four weeks of cycle sprint training (3 sets of 5×10 sec all-out repeated sprints 
with 5 min recovery), Faiss et al. [263] showed that moderately trained males had 
improved activity of lactate dehydrogenase, suggesting an increased capacity for pH 
regulation [264].  Therefore in the present study, the second and third sets of repeated 
sprints would have been performed with a considerable stress on the mechanisms 
involved in intracellular pH regulation [227].  This accumulation of H+ throughout the 
training program has been suggested to be an important stimulus to increase muscle 
buffer capacity [265]; increases of 16 – 25% in muscle buffer capacity have been 
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previously reported [179, 180, 266] following periods of sprint and high intensity 
intermitted training (HIIT).  
 
The ‘almost certain likely’ benefit (99%) of β-alanine ingestion on repeat sprint 
performance is a unique finding; previous researchers have reported little ergogenic 
effect of β-alanine on RSA.  Using an almost identical testing and dosage protocol to 
that used in the present study, Danaher et al. [4] reported no change in RSA 
performance after six weeks of β-alanine supplementation (4.8 g·day−1 for 4 weeks, 
6.4 g·day−1 for final 2 weeks).  However, participants did not train during the 
supplementation period.  Additionally, Danaher et al. [4] used a crossover design that 
included a six week washout period which may not have been sufficient to decrease 
muscle carnosine levels to baseline [101] and that consequently may have 
confounded their results.  In contrast to the present findings, Sweeney et al. [132] 
reported no significant improvements in repeated non-motorised treadmill running 
performance (2 sets of 5 x 5 sec sprints with 45 sec rest between sprints) using a 
similar total dose of β-alanine in active males.  However, participants in each group 
did not perform the same type, intensity or volume of training as that used in the 
present study; their participants completed recreational strength training 3 – 4 times 
per week or an off-season football program that included 3 – 4 days of resistance 
training and 2 days of sprint training. It is possible that the differences in training may 
have influenced repeat-sprint performance following the supplementation period.  
Also, the limited ergogenic effect reported by the authors may have been due to the 
longer rest periods between exercise bouts used in their study, allowing participants 
to be better recover prior to subsequent sprints.  Danaher et al. [4] and Sweeney et al. 
[132] had small participant numbers (n = 8 and n = 9 respectively) and used traditional 
statistical methods which may not have been sufficiently sensitive to detect changes 
resulting from the intervention.  Ducker et al. [238] used magnitude based inferences 
similar to the current study and found that RSA marginally improved (‘likely benefit’) in 
the later sprints of the second and third set of 6 x 20m sprints with 25 sec recovery in 
the six participants who had supplemented with 80 mg·kgBM-1·day-1 β-alanine for 28 
days.  Greater improvement in the later repetitions was also seen in the present study 
with the greatest improvement seen in the 4th and 5th repetition following β-alanine 
supplementation.  The apparent effect of β-alanine supplementation seen in the latter 
sprints suggests that supplementation may have increased muscle carnosine levels 
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which in turn augmented intracellular buffering capacity during RSA and possibly 
allowed participants to complete more work throughout the four week training period. 
In practice, team and field sport athletes who perform repeat sprints in training may 
benefit from β-alanine supplementation.  
 
RSA – Training and combined β-alanine and NaHCO3 supplementation 
Consistent with the findings of Danaher et al. [4], NaHCO3 supplementation in the 
present study did not confer any additional performance benefit to that associated with 
β-alanine supplementation.  Similar to the present findings, Ducker et al. [238] reported 
that ingesting β-alanine (~ 6 g·day-1) and NaHCO3 (0.3 g·kgBM-1) resulted in no further 
improvement in repeated sprint running performance in team-sport athletes than with 
β-alanine or NaHCO3 alone.  A minimal additive effect of β-alanine and NaHCO3 was 
also reported by Bellinger et al. [116] which was associated with similar improvements 
in high-intensity cycling performance compared with acute NaHCO3 supplementation 
alone in trained cyclists. In contrast, a small non-significant performance benefit (4%) 
with magnitude-based inferences suggesting a ~70% probability of a meaningful 
positive difference, during a supramaximal cycle capacity test lasting 2 – 3 minutes, 
has previously been reported from combined supplementation [162].  These 
contrasting results provide further evidence of the efficacy of extracellular buffering 
agents which appear to be much more variable than that of β-alanine alone [267], with 
a number of further compounding factors contributing to this inconsistency including 
protocol length and training status of the participants. 
 
CCT110% – NaHCO3 supplementation 
In contrast to the present repeated sprint results, NaHCO3 supplementation resulted 
in a 9% improvement in CCT110% TTE prior to training (99% - almost certain benefit).   
However, this effect was not evident after the training period.  The majority of studies 
examining the effects of NaHCO3 supplementation have tested its effect after an acute 
dose prior to a bout of exercise (see Carr et al., [17] for review), however the effect of 
an acute dose of NaHCO3 supplementation following a period of SIT has not been 
reported.  Interval training has only been investigated in conjunction with the chronic 
NaHCO3 supplementation.  Team-sport athletes improved their endurance capacity 
and lactic threshold after a period of 8 weeks of HIIT when they consumed NaHCO3 
before each of three weekly sessions [234].  Percival et al. [268] recently showed that 
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NaHCO3 supplementation prior to an acute session of HIIT augmented skeletal muscle 
glycogenolysis during exercise and enhanced the expression of PGC-1α mRNA during 
recovery which is in line with the mechanisms mediating the enhanced adaptations 
previously observed with chronic NaHCO3 ingestion during training by Edge et al. 
[234].  However, when a similar chronic dose of NaHCO3 was ingested by elite-level 
rowers during a 4 week block of HIIT, both supplement and placebo groups improved 
their 2,000-m rowing performance without a difference between groups [269].  The 
authors hypothesised that the lack of change may have been due to the already well-
adapted ‘lactic threshold’ and mitochondrial oxidative capacity of the elite athletes.  
Specifically, the long-term consequences of repeated exercise-induced metabolic 
acidosis may not include as much of a detrimental effect on the mitochondrial functions 
in highly trained athletes than for their less-trained counterparts [269].  It is possible in 
the current investigation that the SIT had similar effects on mitochondrial function 
which may explain the lack of performance improvement when NaHCO3 was 
supplemented following the four weeks of SIT.   
 
Improvements in muscle buffer capacity have been reported following periods of HIIT 
[180, 250, 266, 270].  In the present study the training would most likely have resulted 
in an increase in intramuscular buffering capacity in both groups independent of 
supplementation.  Similar to others that have employed intense training with 
recreationally active participants [179, 271] there were large improvements following 
the training period, (40% improvement in CCT110% TTE, 99% – almost certain benefit) 
whilst the acute supplementation of NaHCO3 following training resulted in no additional 
benefit.  The potential improvement in muscle buffer capacity following SIT training 
may have simply ‘outweighed’ the acute ergogenic effect of NaHCO3 on extracellular 
buffering. 
 
The present results relating to CCT110% performance should however be interpreted 
with caution; Froio de Araujo Dias et al (2015) recently reported inconsistencies in 
mean and individual test results when the CCT110% was repeated on four separate 
occasions following the same NaHCO3 dosing protocol (0.3 g·kgBM-1).  CCT110% only 
improved in one out of four trials and five individuals were consistent non-responders 
with no improvement in any of the NaHCO3 supplementation trials. In the current 
investigation, only two participants were non-responders on both occasions.   
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CCT110% – Training and β-alanine supplementation 
Following training there was a 39.7% (almost certain) improvement in TTE in the 
CCT110% in the placebo group whilst the β-alanine group also had an almost certain 
improvement in TTE, (30.9%).  The changes in TTE are less than those previously 
reported following periods of SIT training, however the differences may be related to 
variations in testing protocols.  Recently, improvements of 48 – 54% in cycle capacity 
at the minimal power output that elicited a V̇O2max reading (Pmax) were reported 
following either 3 – 5 ‘all-out’ 30 sec cycling bouts or 6 – 10 cycling bouts at 125% 
Pmax over a similar four week training period [272].  A shorter, 2 week 30 sec all-out 
SIT program has also been shown to improve cycle time to exhaustion at 80% V̇O2max 
in untrained participants by 100% [273].  The improvement in performance observed 
in the current investigation is more than double the improvement in TTE of 14%, 15% 
and 13% reported in the identical continuous HIE cycling CCT110% protocol used 
previously by Danaher et al. [4], Sale et al. [162] and Hill et al. [72] after 6, 4 and 4 
weeks of β-alanine supplementation respectively.  However, our findings are the first 
to show that β-alanine supplementation did not improve TTE in the CCT110%.  The 
present findings are consistent with those from other investigations that report no 
change in cycling performance including; time to complete 250 kJ of work, repeated 
sprint (i.e., 4 x 30 sec “all-out” cycling efforts, 4-min rest) [5] and workload at the 
ventilatory threshold [174], when β-alanine supplementation is combined with training.  
Cochran et al. [5] required participants to complete a similar training intervention to 
that used in the present investigation (3 weekly sessions of 4 – 6 30 sec bouts of 
maximal cycling) and found no difference in treatment groups in 250 kJ time trial that 
averaged approximately 18 – 20 min or repeated sprint performance.  They also stated 
that increases in M-Carn (33-52%) did not improve training capacity which has also 
been shown by others [3, 167].  The authors suggested that the length of the exercise 
test may have influenced the lack of effect of β-alanine supplementation. A recent 
meta-analysis reported the ergogenic effect of β-alanine supplementation for exercise 
lasting 0.5 – 10 min with greater effect sizes for exercise capacity (0.4998 (95% CI 
0.246 to 0.753)) versus performance (0.1078 (95% CI −0.201 to 0.416)) [1, 2].  
However, many of the studies with tests lasting <60 sec did not prescribe training in 
addition to the β-alanine supplementation.  The current study along with previous 
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studies that combined β-alanine supplementation with interval training ranging from 
30 – 240 sec did not find any increase in training workload or exercise performance 
[3, 5, 167, 174].  This suggests that multiple sprint and sprint interval training may 
dampen or negate the ergogenic effect of β-alanine supplementation regardless of 
interval training length.  
 
Another possible explanation for there being no change between supplementation 
groups in the present study may be that the current SIT program would likely have 
produced increased skeletal muscle buffering capacity in both groups [146].  The 
capacity to buffer H+ ions has been associated with sprint-type activity where H+ ion 
production and accumulation is excessive [180].  A number of longitudinal sprint 
training studies, involving 6 to 30 sec all out sprint bouts, have found an increased 
muscle buffer capacity after supramaximal sprint training [231, 266, 274, 275].  
However, in the only study to measure buffering capacity following β-alanine 
supplementation, Gross et al. [3] reported no interaction effect on buffering capacity 
despite a 7.9% increase in muscle buffer capacity in the pooled cohort following 9 
sessions of HIIT.  It appears that repeat sprint training may be the most important 
stimulus to improve the intracellular buffers [179]. 
 
CCT110% – Training and combined β-alanine and NaHCO3 supplementation 
Similar to the combined effect of β-alanine and NaHCO3 supplementation on repeated 
sprint ability, co-ingestion did not improve performance parameters during the 
CCT110% relative to the placebo condition.  These results are consistent with as the 
findings of Danaher et al. [4] and Sale et al. [162], who reported non-significant 
increases of 2% and 4.1% respectively in TTE attained from co-ingestion compared 
to β-alanine alone. Similarly, there seemed to be minimal additive effect (0.2%) of 
combined β-alanine and NaHCO3 supplementation in trained cyclists during a 4 min 
cycling performance test [116].  The present results suggest that β-alanine 
supplementation, either alone, or in combination with NaHCO3, following a period of 
SIT may have a limited ergogenic effect on high intensity cycle capacity.  The 
improvement in the RSA protocol and not CCT110% performance may be related to 
differences in the intensity of exercise which may influence other performance factors 
such as neuromuscular adaptation which may have had different impacts on 
performance.  
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Lactate accumulation 
Post-exercise blood lactate concentrations were elevated after NaHCO3 ingestion, 
compared to placebo, following the CCT110%, prior to the training intervention.  A similar 
finding was observed after the training regimen in the placebo but not the β-alanine 
group.  These results are consistent with the findings of others following NaHCO3 
ingestion [172].  However, compared to placebo, there were no differences in plasma 
lactate when β-alanine was supplemented alone or in combination with NaHCO3 
following either the RSA or CCT110% tests.  These results conform to the majority of 
previous studies that have shown no effect of β-alanine on peak lactate accumulation 
[52, 109, 146, 160, 162, 163, 175], however some studies have suggested otherwise 
[133, 276]. 
 
Limitations 
A limitation of the current study was that neither M-Carn content nor muscle buffer 
capacity was measured to quantify potential changes in response to β-alanine 
supplementation.  The present supplementation protocol of 6.4 g·day-1 for four weeks 
was similar to that used by others who reported significant increases in CCT110% 
performance [4, 72, 162].  Others have used a supplementation period prior to a 
training intervention to ensure elevated M-Carn levels at the commencement of 
training.  It was felt that this was not necessary in the present study, as significant 
increases in M-Carn content have been reported after consumption of a total of just 
22.4 g of β-alanine which was achieved in just over three days in the current 
investigation.  However, a pre-supplementation period would have ensured likely 
higher ‘starting’ M-Carn levels.  Training workload was not recorded, however several 
investigations have shown no increase in training capacity after significant increases 
in M-Carn following β-alanine ingestion [3, 5, 167].  
 
Conclusion 
In summary, the current study found that β-alanine supplementation in conjunction 
with a structured training program improved RSA but did not alter high intensity cycle 
capacity.  Furthermore acute NaHCO3 ingestion improved high intensity cycle capacity 
before training but had no influence on performance after a period of SIT.  It is possible 
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that intramuscular buffer capacity increased as a result of training and that this may 
have outweighed the potential ergogenic effects of β-alanine and/or NaHCO3 (i.e., 
alone or in combination).  For practitioners working with athletes who participate in 
high intensity exercise, SIT (rather than supplementation with NaHCO3 and/or β-
alanine) will be the most effective means of eliciting improvements in performance. 
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CHAPTER 4: STUDY 2 - PREVALENCE, KNOWLEDGE AND ATTITUDES 
RELATING TO β-ALANINE USE AMONG PROFESSIONAL FOOTBALLERS 
 
Abstract 
The aim of this study was to investigate β-alanine supplementation use and level of 
knowledge amongst professional footballers.  A cross-sectional survey of Australian 
professional football players was performed.  Questionnaires assessing β-alanine 
supplementation behaviours, level of knowledge and sources of information were 
completed by professional rugby union (RU) (n = 87), rugby league (RL) (n = 180) and 
Australian Rules Football (ARF) (n = 303) players.  Approximately 61% of athletes 
reported β-alanine use, however use by ARF football players (44%) was lower than 
that of RU (80%) and RL players (80%).  The majority of respondents were not using 
β-alanine in accordance with recommendations.  Only 35% of the participants were 
able to correctly identify the potential benefits of β-alanine supplementation.  The main 
information sources that influenced players’ decision to use β-alanine were strength 
and conditioning coach (71%) and dietitian (52%).  Forty-eight per cent of athletes 
never read labels prior to supplementing and only 11% completed their own research 
on β-alanine. Compared to RL and ARF players, RU players had both a greater 
knowledge of β-alanine supplementation and better supplementation practices.  
Despite over half the surveyed professional footballers using β-alanine, the majority of 
athletes used β-alanine in a manner inconsistent with recommendations.  A better 
understanding of the environment and culture within professional football codes is 
required before supplement use becomes consistent with evidence based supplement 
recommendations. 
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Introduction 
Supplementation with β-alanine can increase muscle carnosine levels, intramuscular 
buffering capacity, improve high intensity and intermittent exercise [2] and is legal 
under the WADA code [277].  However, little is known of the supplementation 
behaviours of professional athletes, their beliefs and perceptions of β-alanine’s use 
and the sources of information utilised to inform decisions about supplement use.  
Studies on elite athletes [189, 208, 278] have revealed that up to 98% of athletes use 
supplements, mainly to enhance sports performance.  The majority of participants 
involved in many of these studies have been from state or national sporting institutions 
[189, 190, 208], however one investigation explored supplementation habits of 
professional football players and found that approximately 57% of professional football 
players used supplements in the 2002 and 2006 FIFA World Cups [207].  Relatively 
few studies have investigated the use of a single supplement taken to improve 
exercise capacity and/or performance [213, 215, 217].  However, a large range (28 – 
100%) of athletes have reported using creatine, [213, 215] and over 50% of hockey 
players have reported using stimulants including ephedra to improve performance 
[216].  
 
A wide range of sports supplements are available to professional athletes, often as a 
result of sponsorship arrangements.  Despite this, little is known as to the extent these 
professional athletes utilise the products available to them.  Similarly, knowledge of a 
supplement’s benefits including the recommended dosing strategies, time required to 
elicit improvements and potential side effects and the safety of their use is generally 
not known.  Previous research has shown that athletes report incorrect information 
about the supplements they use [189, 195] and they list themselves, fellow athletes 
and their coaches as the influential figures in determining their supplement use [189, 
195, 209]. 
 
Finch and Donaldson [279] stated that when injury prevention randomised control trial 
(RCTs) findings are implemented into real-world sports settings, rather than just 
contrived laboratory settings, they are not effective because they are not used by the 
target group in the way that was intended.  If the same is true for RCTs examining the 
efficacy of supplements and the dissemination of their findings it may be that athletes 
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are not adhering to recommended dosages and protocols and therefore not gaining 
maximum ergogenic benefit.  Several studies examining athlete’s supplement 
practices have tried to address whether the findings of supplement related RCTs are 
being adopted. 
 
The aim of this study was to investigate the prevalence of β-alanine supplementation 
amongst professional rugby and AFL players and to evaluate the knowledge and 
attitudes of these athletes using β-alanine with a view to informing best practice 
amongst professional sporting staff for their athletes in relation to their current habits 
and level of education. 
 
Methods 
Professional athletes from teams in the Australian Football League (ARF), National 
Rugby League (RL) and Super Rugby (RU) football competitions in Australia were 
surveyed regarding β-alanine use.  After providing written consent, athletes completed 
the questionnaire in the presence of their coaches, team support staff and teammates. 
The study was approved by an ethics committee of the University of Queensland. 
 
The questionnaire administered was based on previous dietary/supplementation 
questionnaires used to determine supplementation usage and knowledge [193, 218] 
and was designed to gather information on participant demographics, knowledge, use, 
side effects and sources of information regarding β-alanine.  The face validity of the 
survey’s early content was tested through a pilot study on multiple dietitians and 
following this work questions relating to β-alanine knowledge and use were modified.  
The survey was also piloted on 20 semi-elite athletes for construct validity and was 
determined to be satisfactory in eliciting the required responses relating to knowledge, 
use, side effects and sources of information regarding β-alanine. 
 
The questionnaire consisted of 38 questions in total. Participants were asked to 
provide demographic information including: date of birth, body mass, sport, type of 
training for their sport, current level of competition and number of years participation 
at that level, along with the number of hours for training and competing each week.  
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Knowledge of β-alanine was assessed by asking all participants to self-report their 
knowledge of β-alanine, the time required for benefits to occur, the dosage required, 
if there was a doping risk and what aspects of performance would be enhanced 
through β-alanine supplementation.  
 
Participants were asked to provide information (tick appropriate category) regarding 
their β-alanine supplementation behaviour, possible performance benefits, the product 
and exact dose, dosages per day and week (based on The International Society of 
Sports Nutrition Position Stand), along with where and how their β-alanine was 
obtained. Information regarding the side effects associated with their β-alanine 
supplementation was also obtained.  Finally, participants were asked to report the 
sources they consulted for information regarding β-alanine. 
 
Data were analysed using SPSS (version 21.0).  Descriptive statistics including mean 
± SD and frequencies were used for the demographic data and frequencies were 
calculated for all categorical data.  Cross tabulation and chi-square tests examined 
differences in supplement use and knowledge between the three football codes and 
when chi-square analysis was performed, categories were collapsed to ensure that 
fewer than 20% of cells remained below minimum counts.  Statistical significance was 
reported at a p value of ≤ 0.05. 
 
Results 
Thirty-seven professional teams amongst the three football codes were invited to 
participate; 7 teams declined, while 24 teams returned surveys. A total of 570 surveys 
were returned from 785 surveys sent (72.6% response).  Responses per code were: 
RU (n = 87), RL (n = 180) and ARF (n = 303).  
 
Demographic information for age, body mass, training volume for RU, RL and ARF 
were 25.2 ± 4.1 years; 102.6 ± 11.6 kg; 12.9 ± 5.3 hr·week-1; 23.6 ± 5.4 years; 95.3 ± 
16.8 kg; 14.2 ± 6.5 hr·week-1 and 22.0 ± 5.5 years; 87.1 ± 9.5kg; 18.0 ± 10.0 hr·week-
1 respectively.  Fifty-six per cent of participants had been playing professional football 
for greater than 3 years, 27% had 2 – 3 years experience and the remaining 17% had 
been playing for one year or less.   
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The results of the questionnaire showed that 347 out of 570 footballers (61%) reported 
they had used β-alanine with the strongest association (χ2 = 80.527, p < 0.001) for 
usage among the rugby codes, 80% for both RU and RL and 44% from ARF.  Non-
users reported lack of knowledge as the primary reason (61%) behind not 
supplementing with β-alanine, whilst 13% of non-users felt they were already healthy 
enough and didn’t need a supplement and 12% of ARF athletes reported it was not 
part of their club’s supplement program.  
 
Fifteen per cent of all participants were supplementing with the recommended dosage 
of > 6 g.day-1 whilst 50% were consuming less than half the recommended daily dose.  
RU players were the most likely to be consuming the recommended does (χ2 = 14.697, 
p = 0.005) and reported the highest percentage (25%) of recommend use. 99% of 
participants received their β-alanine from their club through their club’s sponsor with 
the remaining 1% from either a supplement store or a friend. β-alanine supplement 
use during training phases of the season was; off-season 37%, pre-season 80% and 
in-season 74% including 9% of players who reported supplementing immediately prior 
to matches.  Thirty per cent of users were supplementing 1 – 3 times per week, 21% 
4 – 6 times per week and 12% greater than six times per week. 
 
The athlete’s self-reported level of knowledge of β-alanine is shown in Figure 4.1. RU 
players were more likely to have a greater level of knowledge (χ2 = 30.203, p < 0.001) 
and were also more likely to understand the timeframe for performance benefits to 
occur following the start of supplementation (χ2 = 112.357, p < 0.001) (Figure 4.2) than 
RL and ARF players.  The athlete’s perceptions of the benefits from supplementing 
with β-alanine and the reasons for supplementation by participants who had used β-
alanine are presented in Table 4.1 (N.B. participants could report multiple benefits).  
Only 35% of the participants were able to correctly identify the potential benefits of β-
alanine supplementation; including increased high intensity exercise and reduced 
fatigue.  Also, a large portion of athletes incorrectly associated β-alanine 
supplementation with gains in endurance (20%) or increases in strength and muscle 
mass (16%).  There was no difference between codes in perceived benefits (χ2 = 
12.358, p = 0.417) or actual reason for use (χ2 = 11.590, p = 0.479).  
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The results showed that 315 out of 570 footballers (55%) were unsure of the 
recommended dose for performance benefit, including 68% of all ARF players.  The 
recommended dose was identified by only 9% of participants and RU players were 
more likely (24%) (χ2 = 21.737, p < 0.001) than RL or ARF players to identify the 
recommended does.  RL players were more likely to underestimate the required dose 
(χ2 = 21.737, p < 0.001).  Eighty-nine per cent of the total sample believed there was 
no doping risk.  There was a difference between codes regarding doping risk with RU 
(99%) most likely group to answer correctly (χ2 = 11.089, p = 0.004) compared to RL 
(88%) and ARF (86%). 
 
The main individual(s) or information sources that influenced players’ decision to use 
β-alanine were strength and conditioning coach (71%), dietitian (52%), trainer (23%), 
team mate (16%) and sport scientist (16%).  There was a difference between codes 
(χ2 = 53.819, p < 0.001) in who they sourced information from with RU players more 
likely to consult a dietitian.  Forty-eight per cent of respondents never read the labels 
before taking the supplement and this did not differ irrespective of code (χ2 = 12.358, 
p = 0.417).  Finally, only 11% of users sought information regarding the side effects of 
β-alanine.  
 
Numerous side effects with varying intensity were reported, with the greatest being 
pins and needles/tingling (64%) followed by tickling/itching (51%) then flush/shiver 
(21%) and skin irritation (20%).  Side effects were felt mostly on the arms (41%) and 
face (40%).  Only 3% of non-users reported side effects as the reason for not 
supplementing with β-alanine. 
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Table 4.1 Perceived performance benefits of β-alanine supplementation (n = 570) and reasons and desired benefits for taking β-
alanine (n = 341). 
 
ARF, Australian Rules Football; RL, Rugby League; RU, Rugby Union. 
  
Perceived benefit  
Reason for use 
TOTAL 
n = 570 
n = 341 
RU 
n = 87 
n = 69 
RL 
n = 180 
n = 142 
ARF 
n = 303 
n = 130 
Improve Endurance Perceived benefit 49.1% 63.2% 53.3% 42.6% 
 Reason for use 57.5% 60.9% 62.0% 50.8% 
Improve Sprint Perceived benefit 20.7% 16.1% 20.6% 22.1% 
 Reason for use 21.7% 15.9% 21.1% 25.4% 
Improve High Intensity Exercise Perceived benefit 38.2% 49.4% 34.4% 37.3% 
 Reason for use 38.7% 53.6% 31.7% 38.5% 
Improve Sport Performance Perceived benefit 26.8% 28.7% 29.4% 24.8% 
 Reason for use 35.2% 36.2% 40.1% 29.2% 
Improve Strength and Build Muscle Perceived benefit 39.3% 41.2% 55.0% 35.6% 
 Reason for use 47.5% 55.0% 46.5% 44.6% 
Reduced Fatigue Perceived benefit  46.0% 60.9% 44.4% 42.6% 
 Reason for use 52.8% 59.4% 51.4% 50.8% 
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Figure 4.1 Participant self-reported knowledge of β-alanine. 
 
 
Figure 4.2 Knowledge on the time before a performance benefit of β-alanine occurs -
participants were asked how long performance benefits were likely to occur following 
the start of supplementation. 
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Discussion 
β-alanine is a relatively new supplement that has been shown to improve exercise 
capacity and performance [2], however the rate of its use in professional sport is 
currently unknown.  The results suggest that over half the surveyed professional 
footballers are supplementing with β-alanine.  Despite many athletes reporting the use 
of information from either strength and conditioning coaches or dietitians, the majority 
of athletes used β-alanine in a manner inconsistent with recommendations.  
 
Sixty-one per cent of the athletes sampled reported they had used β-alanine in the 
current study, this was greater than previous single supplement studies of athletes.  
Twenty-eight per cent of 806 division I National Collegiate Athletic Association 
university athletes reported using creatine [215] while ephedra use in 139 male college 
hockey players was reported to be 50% [216].  Findings from junior, school, university 
& elite athlete surveys [199, 201, 204] show that supplement use tends to increase 
with the level (playing ability) of the athlete.  The current sample of professional 
athletes had a higher usage rate than that of other non-vitamin/mineral ergogenic aid 
studies [210].  This may be due to the increased level of competition and/or increased 
access to ergogenic aids through club supplement sponsorships.   
 
β-alanine usage in the rugby codes was almost double the ARF usage and it is difficult 
to speculate why this is the case as this is the first investigation to examine supplement 
use in this population.  However, 61% of non-users from ARF stated they did not use 
β-alanine as they had no knowledge of the supplement.  The recommended daily dose 
is 6.4 g·day-1 [153], yet only 15% of all users were consuming this amount and half of 
users were supplementing with less than 3.2 g·day-1.  In addition to this only 12% of 
users were taking β-alanine more than six times per week which was in line with the 
recommend dosage.  This is in contrast to Juhn et al. [214] who reported 75% of 
creatine users were taking more than the recommended dose.  A possible reason for 
the participants not consuming the recommended dose may be that they were not 
receiving the correct advice from their team support staff.  Alternatively, they may not 
have been adhering to the total recommended dosage of four daily doses of 1.6 g·day-
1.  In studies involving medications, there is an inverse relationship between number 
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of doses per day and rate of compliance and four doses of β-alanine may not have 
been adhered to [115]. 
 
Over half of the total number of respondents rated their knowledge of β-alanine as nil 
to limited (Figure 4.1) and the majority of respondents were unsure of how long 
benefits would take to occur following the onset of supplementation (Figure 4.2).  It 
appears that evidence from β-alanine RCTs is not being clearly disseminated to 
athletes by the team dietitians and strength and conditioning coaches.  Alternatively, 
if the information is being passed on to players they may not be completely 
understanding all the recommendations or adhering to the guidelines provided.  
 
The majority of footballers reported that strength and conditioning coaches and 
dietitians as their main source of information for β-alanine use.  This finding is similar 
to previous general supplement studies with the majority of college or elite athletes 
also sourcing information from strength and conditioning coaches, sports trainers 
and/or available dietitians [196, 199, 208].  Around 7% of the entire group sourced 
their β-alanine information from their coach.  This was lower than in previous studies 
by Scofield & Unruh [198] and Nieper,[209] who found the majority of athletes obtained 
their supplement information from their coach.  Both these studies examined 
supplementation use amongst junior and developing athletes, where in most instances 
coaches are the main source of information and there are fewer support staff.  This 
result highlights the importance of the role team dietitians and strength and 
conditioning coaches have in educating professional athletes. 
 
Approximately a third of participants were incorrect in believing that the correct time 
frame was between 15 minutes to 1 week.  Overall one quarter of participants, 
including almost half of the RL players, believed benefits could result within 15 – 30 
minutes of ingestion.  Additionally, 9% of all athletes reported using β-alanine before 
matches for a performance benefit.  These findings suggest that a large number of 
footballers perceived the benefits of β-alanine as being immediate rather than long 
term. It may be that players perceptions and behaviours are being influenced by the 
placebo effect, a positive outcome resulting from the belief that a treatment is 
beneficial [280].  The placebo effect is acknowledged as a factor in sports medicine, 
with effects of varying magnitudes reported across several sports [281]. 
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Approximately one quarter of RU athletes were able to identify the recommended daily 
dose and 41% were able to identify the time that potential benefits of β-alanine 
supplementation were likely to occur.  Around 14% and 12% of ARF and RL players 
respectively, incorrectly identified that β-alanine supplementation would return a 
positive drug test result yet only 1% of RU players thought this.  Therefore it appears 
that RU players may be the football cohort who had better knowledge with regard to 
β-alanine use in sport. It may be that the level of education provided to the RU players 
is better than the other codes or that the RU players are understanding and following 
the information provided better than the RL and ARF players. 
 
Although 60% of the total sample identified as having used β-alanine, the majority had 
misconceptions on the appropriate time, dose requirements or performance benefits.  
Similarly, Dasscombe et al. [189] found that the majority of elite Australian athletes 
had limited knowledge of the supplements they were taking.  In addition, Duellman et 
al. [217] and Desbrow and Leveritt [218] also showed athletes had comparable rates 
of misconceptions regarding individual supplement use.  It appears that knowledge of 
supplements across a range of sports and athletes is inadequate and greater 
education is required to ensure maximum performance benefits are being achieved 
and side effects and doping risks are minimised. 
 
Previous β-alanine supplementation studies have revealed symptoms of β-alanine use 
can include flushing, prickling of the skin and paraesthesia [97].  This study provides 
new information regarding the side effects of β-alanine supplementation in an athletic 
population.  Few studies have reported the side effects despite a large number of 
supplementation studies using β-alanine.  Up to 64% of β-alanine users in the current 
investigation were affected by side effects.  These symptoms have been shown to last 
up to 60 minutes and are believed to result from primary sensory neurons responsive 
to β-alanine on the skin from initial activation in the central nervous system [141].  It is 
possible that that these acute side effects may have influenced the participant’s 
“perceived benefit”, believing that the acute side effects reflected the efficacy of the 
supplement.  This is in line with the finding that one quarter of participants believed 
benefits from β-alanine occurred in 15 – 30min.  The current investigation revealed as 
many as 51% and 63% of β-alanine users reported experiencing symptoms of tickling 
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skin and pins and needles respectively.  Approximately 40% of participants 
experienced these symptoms on their arms or around their face. Other common sites 
of symptoms included ears, shoulders, chests and scalp.  Similarly, Decombaz et al. 
[97] reported symptoms on the arms and trunk with the majority of their participants.  
 
Conclusion 
The present investigation found that a large number of professional athletes are using 
β-alanine, yet many are unsure of the exact benefits or the correct dose to obtain the 
potential benefits.  Of those who did supplement with β-alanine, the majority were not 
supplementing enough to gain the benefits associated with improved performance.  
When comparing the supplementation habits among football codes in Australia, RU 
players have a greater knowledge of β-alanine supplementation and this appear to 
result in practices that are more consistent with recommendations.  The relatively 
limited knowledge of β-alanine amongst this population suggests either the 
supplement education programs organised by their clubs have limited effectiveness 
and/or the professional support staff are experiencing barriers in the translation of 
evidence based recommendations.  
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CHAPTER 5. STUDY 3: COMPLIANCE OVER 28 DAYS OF β-ALANINE 
SUPPLEMENTATION  
 
Abstract 
In β-alanine research trials, compliance rates of β-alanine supplementation are much 
greater than the rates reported in pharmacological research.  These β-alanine 
compliance rates were generally assessed using subjective indirect methods, such as 
verbal recall and pill counts which tend to be less accurate than objective direct 
methods.  Therefore the aim of this study was to examine compliance to 28 days of β-
alanine or placebo supplementation during a rugby league pre-season training period. 
Seventeen semi-professional rugby league players (mean ± SD age: 24.3 ± 3.3 yrs; 
body mass 92.8 ± 10.6 kg; height 182.7 ± 6.5 cm) were each randomly assigned to 
either a treatment (n = 9; β-alanine) or control (n = 8; placebo) group. The 
supplementation regimen required participants to consume two 800 mg tablets, four 
times per day at 3 – 4 hour intervals for four weeks.  Compliance to the 
supplementation protocol was assessed through weekly tablet counts.  Adherence 
was measured using a questionnaire adapted from the Morisky Medication Adherence 
Scale (MMAS-8).  Compliance over the 28 day period was 59% (± 24%) which was 
less than the mean β-alanine compliance rate previously reported (96%) (χ2 = 39.254, 
p < 0.0001).  Total compliance, measured via tablet count, was highest during the first 
week of supplementation (80.4 ± 21.3 %) and steadily declined with compliance rates 
of 63.2 ± 27.1 %, 51.4 ± 40.3 % and 39.4 ± 40.9 % during weeks 2, 3 and 4 
respectively.  Self-report adherence to the entire four weeks of the supplementation 
protocol rated by the MMAS-8 revealed that 12 players (71%) reported low levels of 
adherence, 5 players (29%) reported medium levels of adherence whilst no players 
reported high adherence.  The current study showed that compliance rates over a 28 
day β-alanine supplementation period were lower than previously reported; there is a 
need for a better understanding of determinants of β-alanine (non-) compliance in 
athletes. 
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Introduction 
In a recent position statement, the International Society of Sports Nutrition [282] 
concluded that daily supplementation of 4 to 6 g of β-alanine for at least 2 to 4 weeks, 
can show improvements in exercise duration lasting 1 to 4 min.  To minimise 
paraesthesia that can result from β-alanine supplementation, it is recommended to 
consume smaller doses of β-alanine (1.6 g) several times throughout the day [282].  
Whilst the evidence supporting the efficacy of β-alanine is growing, there is little 
research examining whether athletes, who supplement with β-alanine, comply with the 
recommended doses.  It is clear that a significant number of professional athletes are 
not using the recommended dose of β-alanine to gain the potential benefits associated 
with improved performance (Chapter 3).  When describing the application of β-alanine 
in sports practise, Stellingwerf [283] stated that athletes need to know the specific 
efficacious dosing protocol, and highlighted that “compliance is key”. 
 
Compliance is the degree to which patients' treatment-related behaviours are 
consistent with instructions or recommendations provided by health professionals 
[284].  Measurement of compliance in a diverse range of therapeutic fields has shown 
patterns of non-compliance across drug classes, diseases, prognoses and symptoms 
[285, 286].  Compliance in pharmacotherapy can range from 5 % to 90 %, and one of 
the most common factors for non-compliance is multiple daily doses, with over 30% of 
patients routinely skipping doses, regardless of their disease, prognosis or symptoms 
[287, 288].  Further to this,  Eisen et al. [289] and Claxton et al. [115] concluded that 
compliance is inversely related to the number of doses per day.  As multiple daily 
doses of β-alanine are necessary to achieve an increase in muscle carnosine (M-Carn) 
levels, non-compliance may reduce the potential of β-alanine supplementation to 
improve performance. 
 
In β-alanine research trials, the mean combined (β-alanine and placebo) compliance 
rate for 341 participants across 16 studies was 96.4 % (range 87 – 100 %) with similar 
rates in β-alanine (n = 174, 96.0 %) and placebo (n = 167, 96.9 %) groups (Table 2.2).  
These compliance rates were generally measured using subjective indirect methods, 
such as verbal recall and pill counts which tend to be less valid than objective direct 
methods such as electronic monitoring [285, 290].  This may explain the much greater 
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compliance rates of β-alanine supplementation compared to rates reported in 
pharmacological research. 
 
Similarly, these compliance rates were recorded as part of clinical randomised control 
trials and it is unknown if the compliance rates would be the same in an applied sport 
setting.  Also, compliance rates in β-alanine research trials are not always stated and 
when reported, there is variation in how they are measured.  A recent systematic 
review of compliance with sport injury prevention interventions noted that if there is no, 
or incomplete, information available on the extent to which participants have complied 
with the intervention, it will remain unclear as to whether the intervention has been 
truly efficacious or not [291].  Similar to pharmacotherapy compliance, sport injury 
prevention trials have found low levels of compliance [291]; it is therefore important to 
examine whether similar patterns exist in supplementation compliance in an applied 
sport setting.  The aim of this study was to examine compliance of semi-professional 
rugby league players to 28 days of β-alanine or placebo supplementation during a pre-
season training period. 
 
Methods 
Participants 
Seventeen semi-professional rugby league players (mean ± SD age: 24.3 ± 3.3 yrs; 
body mass 92.8 ± 10.6 kg; height 182.7 ± 6.5 cm) volunteered to participate in the 
study.  Each was randomly assigned to either a treatment (n = 9; β-alanine) or control 
(n = 8; placebo) group.  Thirteen of the seventeen participants reported previously 
using β-alanine.  All had completed four weeks of pre-season training involving three 
sessions per week each of conditioning based activity (45 min), strength training (45 
min) and football skills training (45 min).  Each was fully informed of the requirements 
and risks involved in the study before giving his written consent to participate.  The 
study was approved by an Ethics Committee from the University of Queensland.  
 
Experimental protocol 
The sole purpose was a compliance study rather than an experiment to determine the 
effectiveness of β-alanine supplementation.  The study examined compliance to β-
alanine or placebo supplementation over a 4 week rugby league pre-season training 
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period.  Training was not altered in any way for the purposes of this study.  At the first 
training session of each of the four weeks, participants were provided with a seven 
day supply of β-alanine or placebo capsules (56 in total) to consume over the week 
[282].   Participants were informed that they would be provided with a supplement that 
would assist their high intensity training.  Whilst participants were not blinded to the 
potential benefits of β-alanine they did receive either 6.4 g·d-1 sustained release β-
alanine tablets (High Intensity Sustained Release Beta Alanine, PowerBar, Nestlé, 
Switzerland) or an equivalent number of placebo tablets (6.4 g·d-1 maltodextrin) in a 
randomised, double blind fashion.  A sample of β-alanine tablets was tested by the 
manufacturer prior to the study to ensure no contamination with steroids or stimulants 
and that they conformed to the label claim for β-alanine content.  The supplementation 
regimen required participants to consume two 800 mg tablets, four times per day at 3 
– 4 hour intervals.  At the start of each of the four weeks, on the first day of training, 
players were required to return any capsules from the previous week that they had not 
consumed.  Players were informed that they would not be reprimanded for not taking 
any supplements and were requested to be honest with their level of compliance. 
Adherence to the supplementation protocol was assessed through weekly tablet 
counts and expressed as a percentage. 
 
At the conclusion of the four week supplementation period, participants completed a 
questionnaire adapted from the Morisky Medication Adherence Scale (MMAS-8) 
(Morisky, 1986); based on the responses to the eight items, a score was calculated to 
determine the level of adherence.  Participants were categorized into three levels of 
adherence groups depending on their responses in the adapted MMAS-8 scale; ‘high 
adherence’ (score of 8), ‘medium adherence’ (score of 6 or 7), and ‘low adherence’ 
(scores <6) [292].  A number of open ended questions relating to why and how each 
participant maintained their level of adherence and how this could be improved in the 
future were included.  Responses to open-ended questions were categorised to reflect 
common themes.  
 
Statistical analysis 
Data were analysed using SPSS (version 22.0).  Descriptive statistics including mean 
± SD and frequencies were used for the compliance data.  A two-way ANOVA with 
repeated measures and post-hoc Bonferroni correction was used to examine 
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differences in weekly compliance over time and between supplement groups.  Cross 
tabulation and chi-square tests examined differences in compliance between actual 
compliance and minimum accepted rates (80 or 90%) [293] and when chi-square 
analysis was performed, categories were collapsed to ensure that fewer than 20% of 
cells remained below minimum counts.  Statistical significance was reported at a p 
value of ≤ 0.05.   
 
Results 
Overall compliance 
Compliance over the 28 day period was 59% (± 24%)  Total compliance, measured 
via tablet count, was highest during the first week of supplementation (80.4 ± 21.3 %) 
and steadily declined with compliance rates of 63.2 ± 27.1 %, 51.4 ± 40.3 % and 39.4 
± 40.9 % during weeks 2, 3 and 4 respectively.  There was a significant main effect for 
time between week 1 and week 3 (p = 0.049) and also week 1 and week 4 (p = 0.020) 
(Figure 5.1).  There was no significant interaction between groups in total compliance 
(p = 0.836) or for any of the individual weeks.     
 
 
Figure 5.1 Combined compliance rates for β-alanine and placebo supplementation 
groups.  
* p < 0.05. 
 
Self-report adherence to the entire four weeks of the supplementation protocol rated 
by the MMAS-8 (Table 5.2) revealed that no players reported high levels of adherence, 
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five players (29%) report medium levels of adherence whilst the remaining 12 players 
(71%) reported low levels of adherence. 
 
To the question “Why did you not take all your supplements every day” the majority 
(11/17) reported “forgetfulness” as the primary reason.  Other responses to the same 
question included “side effects” (2/17), “not in routine on weekends” (1/17) and “too 
many tablets to fit in” (1/17). 
 
When asked “What made it easy to take all your supplements every day” the majority 
of responses (9/17) were categorised under “preparation”.  Another common response 
was “having routine” (4/17) with a small number using “reminders” (2/17) to assist them 
in adhering to the supplementation protocol.  
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Table 5.2 Response of patients to 8 questions in Morisky Medication Adherence Scale. 
Morisky item  Yes, n (%) No, n (%) 
Do you sometimes forget to take your supplements?  17 (100.0)  0 (0) 
People sometimes miss taking their supplements for reasons other than forgetting. 
Thinking over the past four weeks, were there any days when you did not take your 
supplements? 
12 (70.6)  5 (29.4) 
Have you ever cut back or stopped using your supplements without telling your strength 
and conditioning coach because you felt you were not getting any benefit from it? 
2 (11.8)  15 (88.2) 
When you travel or leave home, do you sometimes forget to bring along your 
supplements?  
13 (76.5)  4 (23.5) 
Did you take all your supplements on the last day of your 4 week period? 2 (11.8)  15 (88.2) 
When you feel you are not getting any benefit from your supplements, do you sometimes 
stop taking your supplements?  
7 (41.2)  10 (58.8) 
Taking supplements every day is a real inconvenience for some people. Do you ever feel 
hassled about sticking to your supplement plan? 
7 (41.2)  10 (58.8) 
How often do you have difficulty remembering to take all your supplements? 
          Never/rarely  
          Once in a while 4  
          Sometimes  
          Usually  
          Always  
 
2 (11.8) 
8 (47.1) 
4 (23.5) 
2 (11.8) 
1 (5.9) 
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Discussion 
The aim of this study was to evaluate the compliance to a 28 day evidence based β-
alanine supplementation protocol in semi-professional athletes.  Compliance was 
significantly lower to rates previously reported by others.  Mean adherence was 59%, 
which equates to approximately ~131 g of β-alanine consumed across the 28 day 
supplementation period; an amount which would be unlikely to provide an ergogenic 
benefit.  A meta-analysis recommended a total intake of 179 g consumed across 28 
days as the minimum amount of β-alanine required to produce improvements in high 
intensity exercise performance [2].  A number of studies that used β-alanine 
supplementation dosages <179 g over a similar time period, failed to show an 
improvement in exercise performance [52, 171, 174].  Currently, β-alanine studies vary 
widely in the way they assess compliance and future studies should report compliance 
to ensure valid study outcomes. 
 
The compliance over the 28 day period was likely less than the mean compliance rate 
previously reported (96%) (χ2 = 39.254, p < 0.0001), the minimum compliance rate 
previously reported (87%) (χ2 = 19.888, p < 0.0001), as well as the recommended 
minimum compliance rate 80% (χ2 = 10.402, p < 0.001) (Table 2.2).  A minimum 80% 
compliance rate would have been required in the present study to meet the 
recommended dose of β-alanine over the 28 day period; a supplementation dose that 
would support a potential ergogenic benefit.  It appears that compliance levels differ 
in a real world setting where athletes are provided with supplements to enhance 
performance with no specific pre-post testing compared to compliance in a controlled 
study.  In considering the behaviour that may influence compliance in semi-
professional athletes, it is important to distinguish between unintentional and 
intentional non-adherence.  Unintentional forgetfulness was the most commonly cited 
reason reported by respondents for non-adherence (question # 1 in Morisky scale) 
with 100% of participants reporting ‘forgetfulness’ and 76% of participants forgetting 
to take their supplements with them when they travelled away from home.  On the 
basis of these findings, attenuating this forgetfulness through the use of short message 
service (SMS) reminders [294] and electronic medication tracking devices [295] could 
improve compliance.  Additionally, sport science support staff might also help athletes 
in developing cues to remember time of supplementation by linking it to players’ 
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routine activity.  Intentional non-adherence is the result of a deliberate decision to not 
take supplements as prescribed.  A small number of participants (2/17) in the present 
study reported intentional non-adherence due to unwanted side effects.  The negative 
impact that unwanted side effects can have on adherence has been previously 
observed [292, 296].  Improving players’ understanding and knowledge of possible 
side effects and strategies to minimise their occurrence may reduce intentional non-
compliance. 
 
Beliefs about medication have been shown to be an important factor for adherence in 
patients across a range of diseases [297-299].  Also, the more information and 
understanding that a patient has regarding a disease and pharmacologic therapies, 
the more they are likely to adhere to their medications [300].  Greater adherence also 
correlates strongly with a patient’s knowledge of the disease and the therapy [6].  As 
found in Chapter 3, professional footballers have a poor knowledge of the benefits and 
correct dosages of β-alanine and this may have influenced adherence.  Therefore, 
athletes should be well informed about the long-term benefits of β-alanine 
supplementation and this education should be individualised based on athlete 
preferences instead of being uniformly applied.  
 
A limitation of the present study was that it was observational and therefore factors 
such as beliefs on the efficacy of β-alanine on performance could not be assessed. 
Also, medication beliefs vary across different cultural groups [301]; cultural factors 
were not investigated within the present study.  Similarly, the level of athlete – elite vs. 
sub-elite and perhaps level of education may influence compliance and should be 
investigated further.  Prospective longitudinal designs in a wide range of settings are 
needed to fully assess those factors that influence β-alanine compliance.  As no 
current valid and reliable measure of β-alanine compliance currently exists, a modified 
version of the MMAS-8 was used in the present study.  The MMAS-8 has previously 
been shown to have acceptable test–retest reliability and convergent and construct 
validity [302].  In future, the development of a valid and reliable tool to measure and 
report β-alanine compliance is warranted. 
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Conclusion  
The current study showed that compliance rates over a 28 day β-alanine 
supplementation period were lower than previously reported; there is a need for a 
better understanding of determinants of β-alanine (non-) compliance in athletes. 
Unintentional forgetfulness was the most commonly cited reason reported by 
respondents for non-adherence, therefore sport science support staff should assist 
athletes in developing cues to remember time of supplementation. Further quantitative 
and qualitative research could facilitate the development of athlete tailored 
supplementation protocols by exploring their beliefs, needs and underlying processes 
influencing supplement compliance. 
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CHAPTER 6. STUDY 4: THE INFLUENCE OF BODY COMPOSITION ON ACUTE 
SIDE EFFECTS FOLLOWING β-ALANINE SUPPLEMENTATION 
 
Abstract 
Oral β-alanine doses larger than 800 mg commonly result in paraesthesia. However, 
the side effects experienced when consuming β-alanine as an absolute dose or a dose 
relative to body mass have not been examined.  The primary aim of the present study 
was to determine if the acute side-effects resulting from β-alanine supplementation 
differed between absolute and relative doses.  A secondary aim was to determine if 
body mass and/or composition was related to reported side effects following 
supplementation.  Twenty-five healthy male participants completed three 
supplementation treatments: a placebo; β-alanine as a relative dose of 0.02 g·kgBM-1 
and β-alanine as an absolute dose of 1.6 g.  Data from 10 participants were removed 
from analysis (on the basis of their body mass) in order to stratify the participants into 
lower (< 75kg) and higher (> 85 kg) body mass groups.  For 90 min following 
supplementation in each condition, participants completed a questionnaire that sought 
responses to side effects.  Using a visual analogue scale (VAS), the mean perceived 
intensity of unusual sensations was significantly greater (p < 0.05) in the absolute dose 
condition for the lower body mass group and significantly greater (p < 0.05) in the 
relative dose condition in the higher body mass group.  There was a significant 
difference in maximal intensity score for ’pins and needles’ between the relative and 
absolute dose both in the lower (p = 0.008) and higher (p = 0.034) body mass groups.  
The incidence rates for ‘pins and needles’, ‘tickling and itching’ and ‘flush, shiver’ were 
significantly different between the relative and absolute β-alanine doses for both the 
lower and higher body mass groups.  There was a significant mode rate negative 
correlation (ρ = -0.534; p = 0.040) between VAS and body fat percentage and between 
body mass and QLSI(p&n-max) (ρ = -0.560; p = 0.030).  The results of the current 
investigation may be useful in providing guidelines to reduce side effects for specific 
individuals following β-alanine supplementation.  Lighter individuals are likely to 
experience fewer side effects if they supplement with β-alanine as a dose relative to 
body mass, while heavier individuals may benefit from supplementing β-alanine as an 
absolute dose.  
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Introduction 
β-alanine is an amino acid required for the synthesis of carnosine, an intramuscular 
compound that buffers pH; carnosine has been positively associated with high 
intensity exercise performance [282].  A range of symptoms following β-alanine 
supplementation have been reported; these include feelings of discomfort [117] and in 
doses exceeding 40 mg·kgBM-1 feelings of unpleasant steady burning and electric 
shock sensations [96] have been consistently experienced.  The symptoms following 
β-alanine supplementation have generally been under-reported, and conclusions 
relating to side effects and adverse events have been difficult to make [303].  In 
addition, not all individuals appear susceptible to side effects.  
 
Current recommendations relating to β-alanine supplementation generally involve 
absolute doses [282], rather than does relative to body mass; whether total body mass, 
or even body composition, is related to the extent or severity of symptoms following β-
alanine supplementation is not known.  Individual variations in fat mass and fat-free 
mass have been suggested to contribute to diverse absorption rates of several drugs 
[304].  When a relative caffeine dose was compared to body composition, obese 
individuals had significantly higher absorption rates than lean participants [305] .  As 
the intensity of β-alanine-related side effects are correlated with β-alanine plasma 
concentration [97], whether fat mass or fat free mass influence β-alanine absorption 
rate and consequently side effects, is of interest.  Similarly, there may be a relationship 
between a β-alanine dose relative to body mass and paraesthesia.  Stegen et al. [108] 
recently reported a wide variation in recommended daily β-alanine dose for both males 
and females.  For example a 56 kg female would require only 2.5 g·day-1 whereas an 
84 kg male would require up to 5.5 g·day-1 for a significant increase in M-Carn content 
to be achieved.  Given that the severity of paraesthesia episodes appears dose-
dependent [10], it is possible a lighter person consuming an absolute dose may 
experience more side effects.  Conversely, it is possible that heavier individuals 
ingesting the absolute recommended dose may experience few or no symptoms and 
may be able to tolerate higher dosages compared to lighter individuals.  They may be 
able to achieve the recommended daily amount of 4 – 6 g with a lower number of 
doses and this would improve compliance.  In studies involving medications, there is 
an inverse relationship between number of doses per day and rate of compliance 
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[115].  Understanding the highest doses that can be taken at once without acute side 
effects is important to optimise the capacity of individuals to consume the 
recommended daily doses. 
 
Mechanisms responsible for the paraesthesia experienced by many individuals 
following β-alanine supplementation have recently been investigated [141, 306, 307].  
These studies confirm that β-alanine is an activator of MrgprD which provokes itching 
in humans and provide evidence that β-alanine-induced itch-mediating neural activity 
originates in the peripheral and not the central nervous system [141].  Whilst the 
mechanism is understood, factors that influence the intensity of side effects and 
variations in the extent to which paraesthesia occurs between individuals following a 
comparable dose of β-alanine are yet to be examined.   
 
Whilst the incidence and severity of symptoms following β-alanine supplementation 
appear to be dose-dependent [117, 282], there have been differences in symptoms of 
paraesthesia in response to β-alanine supplementation found between Caucasians 
and Asians [128].  Following the ingestion of a single 3 g dose of β-alanine, Asians 
reported significantly fewer symptoms than Caucasians when the total of all symptoms 
were summed.  Caucasians reported more symptoms, despite having a greater 
average body weight (77.3 kg) than the Asians (63.2 kg).  This was unexpected, as 
side effects from other pharmaceuticals are typically greater in lighter individuals [128].  
However, the opposite was reported in females, with Asian females reporting more 
bothersome symptoms following β-alanine supplementation than the heavier 
Caucasian females.  In another study investigating the side-effects following acute 
ingestion of β-alanine supplementation, approximately 80% of participants were 
reported to have experienced some level of unusual sensation, however reasons why 
the remaining 20% of participants did not experience any symptoms were not 
discussed [97].  
 
The primary aim of the present study was to determine if the acute side-effects 
resulting from β-alanine supplementation differed between absolute and relative 
doses.  A secondary aim was to determine if body mass and composition were related 
to side effects experienced.  
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Methods 
Experimental approach to the problem 
The study followed a double-blind, randomized, triple-crossover design in which three 
different conditions (two β-alanine supplements and a placebo) were acutely 
administered once.  All dosage regimes were randomised and symptoms of 
paraesthesia were recorded after ingestion; a brief questionnaire was completed every 
10 min for a total of 90 min post-ingestion.  Each testing session began at either 7.00 
am or 8.00 am and was separated by a minimum of 48 hours.   
 
Participants 
To be accepted into the study, participants needed to be meat eaters (i.e. consumed 
meat at least once in the previous 7 days), and to have not taken any nutritional or 
dietary supplement in the previous three months or β-alanine for at least six months.  
None of the participants had previously taken β-alanine. A total of 25 healthy males 
volunteered to participate in the study.  In order to stratify the participants into two 
distinct groups (lower body mass, < 75 kg; higher body mass > 85 kg), 10 participants 
with intermediate body mass were excluded after volunteering to participate in the 
study.  These body mass limits were chosen to differentiate groups based on the 
relative to body mass dose.  The 10 participants with intermediate body mass were 
removed as the amount of β-alanine they consumed relative to body mass was not 
statistically different from the absolute dose. Data from the remaining 15 participants 
are shown in Table 6.1.  The two groups were significantly different (p >0.05) in height, 
body mass, bone-free lean mass and body fat (%). The study was approved by an 
ethics committee of The University of Queensland. 
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Table 6.1 Physical characteristics (mean ± SD) of participants. 
 Lower (n = 10) Higher (n = 5) 
Age (yrs) 23.7 ± 9.1 23.2 ± 4.2 
Height (cm) 173.3 ± 6.2 181.3 ± 4.1 
Body Mass (kg) 61.4 ± 17.7 91.9 ± 5.4 
Bone-free lean mass 
(kg) 
51.6 ± 2.3 68.0 ± 4.5 
Body fat (%) 15.9 ± 2.8 22.0 ± 7.4 
 
Body composition 
Upon arrival for the first supplementation session, participants had their stature 
(SE206, Seca, UK), and body mass (SE719, Seca, UK) measured.  Dual energy X-
ray absorptiometry (DXA) (Hologic QDR Discovery, MA, USA) was then used to 
determine bone mineral-free lean mass (LM), fat mass (FM), and % body fat.  The 
DXA operator was blinded to any treatment conditions.  The CV in our laboratory for 
LM, FM and % body fat are 0.3, 0.9 and 0.9%, respectively.  
 
Supplementation 
Participants were required to fast for 12 hours and refrain from consuming caffeine 
and alcohol for 48 hours.  All β-alanine (Musashi™, Notting Hill, Victoria, Australia) 
was supplied in a powdered form and mixed in 10 ml sugar-free cordial (Cottee’s, 
Tullamarine, VIC, Australia) and water to assist with blinding; the total adjusted volume 
was 250 ml.  Participants were given either an absolute dose (1.6g β-alanine), a 
relative dose (0.02 g.kgBM-1 β-alanine) or only cordial (placebo).  The solutions were 
identical in appearance and were provided in white cups marked with an identifying 
code.  The code was recorded by an experimenter not involved with data collection 
and only broken after data analysis was completed.  Participants were given 1 min to 
consume the solution after which they remained seated for 90 min.  
 
Sensory data 
Every 10 min for 90 min following consumption of each dose, participants completed 
parts of a questionnaire described previously by Decombaz et al. [97].  The 
questionnaire included questions from the Visual Analogue Score (VAS), Intensity of 
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Sensation Score (ISS), the Qualitative Light Symptoms Inventory (QLSI) and the body 
Sensitive Surface Score (SSS) sections used by Decombaz et al. [97].  The perceived 
intensity of symptoms was measured using the VAS and ISS.  The VAS was 
expressed as a percentage of scale length from the low end of a 9 cm line marked “no 
unusual sensation” to “most intense sensation imaginable” and participants drew a 
vertical line at the point that represented their perceived intensity.  The ISS was a 
discrete scale that consisted of 15 boxes (0 – 14) labelled “absent” to “unbearable” 
and was divided into levels of intensity (very low, low, moderate and intense).  The 
nature of the sensation was measured using the QLSI.  Participants recorded the most 
fitting level for five of the six descriptors used by Decombaz et al. [97].  These included: 
‘‘pins and needles and/or tingles’’, ‘‘tickling and/or itching’’, ‘‘flush and/or shiver’’, 
‘‘tactile hypersensitivity and/or irritation’’, and ‘‘numbness and/or insensitivity’’.  Next 
to each descriptor was a 5-point scale from 0 = ‘‘absent’’ to 4 = ‘‘extremely intense’’.  
Finally, the areas of the body most affected by symptoms (SSS) were reported by 
placing an “x” on either the front or back of a provided body image.  Marked areas 
were given a score of 1 and were totalled for the whole body (n = 23), higher body (n 
= 9), mid body (n = 6) and lower body (n = 8).  All questionaries were completed in the 
same order and the participants were not allowed to turn back pages to review 
previous answers.  
 
Statistical analysis 
For the QLSI and SSS questionnaires, maximal score (Smax), time to reach the 
maximal score and mean value over 90 min (excluding the time 0 value, Smean) were 
determined.  For nonparametric data within-group comparisons were examined using 
a Friedman test and Wilcoxon post hoc test, while the Mann-Whitney’s test was used 
for comparison of side effects between groups. Independent samples t-tests were 
used to determine differences in dosage in both the higher and lower body weight 
group. In addition, Spearman’s correlation analysis was performed between 
combinations of body composition variables and QLSI, VAS and ISS scores.  Analysis 
was completed using SPSS (Version 22) and data are presented as means ± SD with 
alpha set at p < 0.05.   
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Results 
Body composition and dosage  
There was a significant difference in body mass (p = 0.006), lean mass (p < 0.0001), 
and percentage body fat (p = 0.033) between the lower and higher body mass groups.  
There was also a significant difference in the mean dose consumed in the absolute 
and relative conditions for both the lower (1.60g vs. 1.33g; p < 0.0001) and higher 
body mass groups (1.6g vs. 1.84g; p < 0.001).  
 
Paraesthesia  
Two of the participants from the lower body mass group did not experience any side 
effects in any of the trial conditions.   
 
 Time course 
The time course of side-effects reported over the 90 minutes following 
supplementation is shown in Figure 6.1. Symptoms peaked around 20 to 30 min and 
then diminished.  Using the VAS scale, the mean perceived intensity of unusual 
sensations was significantly greater (p < 0.05) in the absolute dose condition at 20 – 
40 min and 60 – 70 min for the lower body mass group. In the higher body mass group 
the VAS scale was significantly greater in the relative dose condition at all time-points 
except for 10 min.   
 
Figure 6.1 Reported intensity of non-differentiated sensations of paraesthesia using 
a Visual Analogue Scale  
(%), from 0 = “no unusual sensation“ to 100 = “most intense sensations imaginable” 
following absolute or relative dose in the lower (A) and higher (B) body mass group. 
Mean ± SD. * p < 0.05. 
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Figure 6.2 Intensity of “pins and needles” sensations using the Qualitative Light 
Symptom Inventory  
(QLSIp&n, scale from 0 = absent to 4 = extremely intense) following absolute or relative 
dose in the lower (A) and higher (B) body mass group. Mean ± SD. * p < 0.05. 
 
Table 6.2 Maximal intensity scores of sensory descriptors in the low and higher body 
mass group. 
  Lower Body Mass Higher Body Mass 
Variable 
 
Score range Absolute Relative Absolute Relative 
VAS max 0–100% 39.9 ± 15.6  25.8 ± 9.2 
* 
20.6 ± 8.5 41.4 ± 13.9 
* 
ISS  0–14 9.6 ± 3.2 6.0 ± 1.4 * 3.2 ± 1.8 10.0 ± 1.6 
* 
QLSI  
(pins and 
needlesmax) 
0–4  2.9 ± 0.6 1.7 ± 0.7 * 1.0 ± 0.7 3.2 ± 0.8 
QLSI 
(ticking, 
itchingmax) 
0–4  1.4 ± 1.2 0.8 ± 0.7 * 0.2 ± 0.4 0.4 ± 0.5 
QLSI  
(flush, 
shivermax) 
0–4  1.4 ± 1.3 0.4 ± 0.8 * 0.2 ± 0.4 1.0 ± 1.2 
0 1 0 2 0 3 0 4 0 5 0 6 0 7 0 8 0 9 0
0
1
2
3
T im e  (m in )
In
te
n
s
it
y
 Q
L
S
I 
s
c
o
re
P la c e b o
R e la tive
A b so lu te
* *
** *
0 1 0 2 0 3 0 4 0 5 0 6 0 7 0 8 0 9 0
0
1
2
3
4
T im e  (m in )
In
te
n
s
it
y
 Q
L
S
I 
s
c
o
re
P la c e b o
R e la tive
A b so lu te
*
*
*
*
A B
 112 
 
SSS  
(whole 
bodymax) 
0 – 23  6.5 ± 4.6 5.0 ± 1.8 * 5.4 ± 4.9 7.4 ± 1.3 * 
      
Mean  ± SD;  
Absolute versus relative * p < 0.05. 
VAS, Visual Analogue Scale; ISS, Intensity of sensation score; QLSI, Qualitative light 
symptoms inventory; SSS, Body sensitive surface score. 
 
Severity and incidence of side effects  
The percentage of participants presenting at different levels of severity with respect to 
the categorical scale (ISS) throughout the 90 min period for both the absolute and 
relative doses in the lower and higher body mass groups are shown in Figures 6.3 and 
6.4 respectively.  There was a significant difference in ISS following the relative and 
absolute dose at all time-points expect for 10 min and 70 – 90 min in the lower body 
mass group and 70 – 90 min in the higher body mass group.  
 
The ISS unusual sensations were reported on 173 of a possible 405 occasions, 
resulting in a 43% incidence rate of response when both the placebo, absolute and 
relative treatments were grouped.  Low level symptoms were reported on only 4 
occasions in the placebo condition, in the other treatment conditions combined, the 
intense category symptoms were reported on 17 occasions all within 20 – 40 min of 
ingestion and there were 28 records in the moderate category between 10 – 50 min.  
From 60 – 90 min only, symptoms in the low and very low intensity category were 
reported.  
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Figure 6.3 Incidence (% of participants affected) and severity of symptoms follow a 
relative to body mass dose (A) and absolute dose (B) of β-alanine in the lower body 
mass group. Severity is shown with symptom intensity scores (ISS scale from 0 = 
absent to 14 = unbearable) and divided into categories. * Relative dose significantly 
different to absolute dose (p < 0.05). 
 
 
Figure 6.4 Incidence (% of participants affected) and severity of symptoms following 
a relative to body mass dose (A) and absolute dose (B) of β-alanine in the higher body 
mass group.  
Severity is shown with symptom intensity scores (ISS scale from 0 = absent to 14 = 
unbearable) and divided into categories.  * Relative dose significantly different to 
absolute dose (p < 0.05). 
 
Description of side effects 
Pins and needles was the descriptor that showed the highest maximal intensity score 
(Figure 6.5) and incidence rate (Figure 6.6) in both the lower and higher body mass 
groups.  There was a significant difference in maximal intensity score for pins and 
needles between the relative and absolute dose both the lower (p = 0.008) and higher 
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(p = 0.034) body mass groups.  A significant difference (p = 0.049) between the relative 
and absolute dose in maximal intensity score for the “tickling, itching” descriptor was 
found in the lower body mass group.  The incidence rate for “pins and needles”, 
“tickling, itching” and ‘‘flush, shiver’’ was significantly different between the relative and 
absolute dose for both the lower and higher body mass groups (Figure 6.6).  
 
 
Figure 6.5 Maximal intensity scores using the Qualitative Light Symptom Inventory 
(QLSI), following a relative to body mass dose and absolute dose of β-alanine in the 
lower (A) and higher (B) body mass group. 
  * p < 0.05. 
 
 
 
P i
n s
 &
 n
e e
d l
e s
, t
in
g l
in
g
T i
c k
lin
g ,
 it
c h
in
g
F l
u s
h ,
 s
h i
v e
r
T a
c t
ile
 h
y p
e r
s e
n s
it i
v i
ty
 
N u
m
b n
e s
s ,
 in
s e
n s
it i
v i
ty
0
1
2
3
4
In
te
n
s
it
y
 m
a
x
im
a
l 
s
c
o
re
s
R e la tive
A b so lu te
A
*
*
P i
n s
 &
 n
e e
d l
e s
, t
in
g l
in
g
T i
c k
lin
g ,
 it
c h
in
g
F l
u s
h ,
 s
h i
v e
r
T a
c t
ile
 h
y p
e r
s e
n s
it i
v i
ty
 
N u
m
b n
e s
s ,
 in
s e
n s
it i
v i
ty
0
1
2
3
4
In
te
n
s
it
y
 m
a
x
im
a
l 
s
c
o
re
s
R e la tive
A b so lu te
B
*
P i
n s
 &
 n
e e
d l
e s
, t
in
g l
in
g
T i
c k
lin
g ,
 it
c h
in
g
F l
u s
h ,
 s
h i
v e
r
T a
c t
ile
 h
y p
e r
s e
n s
it i
v i
ty
 
N u
m
b n
e s
s ,
 in
s e
n s
it i
v i
ty
0
2 0
4 0
6 0
8 0
In
c
id
e
n
c
e
 r
a
te
 (
%
)
R e la tive
A b so lu te
A
*
**
P i
n s
 &
 n
e e
d l
e s
, t
in
g l
in
g
T i
c k
lin
g ,
 it
c h
in
g
F l
u s
h ,
 s
h i
v e
r
T a
c t
ile
 h
y p
e r
s e
n s
it i
v i
ty
 
N u
m
b n
e s
s ,
 in
s e
n s
it i
v i
ty
0
2 0
4 0
6 0
8 0
In
c
id
e
n
c
e
 r
a
te
 (
%
)
R e la tive
A b so lu te
B
*
*
*
 115 
 
Figure 6.6 Incidence rate (% of reporting opportunities, 0 – 90 min) using the 
Qualitative light symptom inventory (QLSI) following a relative to body mass dose and 
absolute dose of β-alanine in the lower (A) and higher (B) body mass group.  
* p < 0.05. 
 
 
Topography of the symptoms 
The body sensitive area (SSSmax) for the whole body was significantly greater (p = 
0.02) following the absolute dose in the lower body mass group while in the higher 
body mass group the  SSSmax was greatest following the relative dose (p =  0.03) 
(Table 6.2).  There was no difference in SSSmax for the higher body (p = 0.35; p = 
0.94), mid body (p = 0.43; p = 0.94) or lower body (p = 0.72; p = 0.62) between the 
relative or absolute dose respectively.  Figure 6.3 shows a summary of the SSSmax 
expressed as a percentage of the number of areas per site.  The SSSmax expressed 
as a percentage showed that paraesthesia was experienced across 26% of the whole 
body while the trunk and arms (mid body) was the area where most paraesthesia was 
experienced followed by the upper body and finally lower body.  When expressed as 
a percentage, there was no difference in SSSmax following either the relative or 
absolute dose for the whole (p = 0.94), higher (p = 0.89), mid (p = 0.81) or lower body 
(p = 0.63).  When separated into lower, mid and higher body areas, the SSSmax 
expressed as a percentage was similar in both the lower and higher body mass groups 
(p > 0.05).  
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Figure 6.7 Topography of symptoms following β-alanine supplementation for both 
lower and higher body mass groups combined.  
The maximal body surface sensitive score (SSSmax) was expressed as a percentage 
of the number of areas per body section (whole body, 23 sites; higher body, 9 sites; 
mid body, 6 sites; lower body, 8 sites). Mean ± SD.  
 
Paraesthesia and body composition 
There was a significant moderate negative correlation (ρ = -0.534) between VAS and 
body fat percentage (p = 0.040).  This suggests that the less body fat, the more 
perceived unusual sensations.  There was a significant moderate positive correlation 
(ρ = -0.560, p = 0.030) between body mass and QLSI p&n(max).  There were no significant 
relationships between any of the paraesthesia symptoms and any other of the body 
composition measures. 
 
Discussion 
The primary aim of the study was to determine if absolute or relative doses of β-alanine 
resulted in different acute side-effects.  For participants weighing less than 75 kg, the 
absolute dose was associated with more side effects, whereas the opposite occurred 
for participants over 85 kg; for these participants, the relative dose elicited more side 
effects.  A secondary aim of the study was to determine whether body mass or body 
composition was related to side effects.  There was a moderate positive relationship 
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between body mass and reported symptoms of pins and needles and a moderate 
negative relationship between body fat and perceived unusual sensations following β-
alanine supplementation.  
 
The incidence rate of side effects following β-alanine supplementation has been 
inconsistently reported in previous ‘β-alanine‘ studies.  Several studies have reported 
no side effects at all following doses of 800 mg to 1600 mg  [52, 110, 171, 175]. In 
contrast, Harris et al. [10] reported “significant” symptoms in three out of their four male 
participants who had an average body mass of 80.2 ± 17.1 kg and supplemented with 
a 20 mg·kgBM-1 dose of β-alanine.  The same group reported an incidence rate of 
nearer 25% in their studies with over 50 participants who ingested a fixed dose of 800 
mg β-alanine.  Following ingestion of a 1.6 g dose, 20% of male participants reported 
“tingling” sensations [152], whilst 10 out of 22 (45%) elite swimmers reported mild 
paraesthesia following the acute intake of two 800 mg tablets [119].  In the present 
study, 84% of participants experienced side effects at some point during the 90 
minutes following supplementation.  This is consistent with the findings of Decombaz 
et al. [97] who reported 80% of all their 5 male (68.1 ± 8.0 kg) and 6 female (52.1 ± 
9.0 kg) participants experienced side effects following a 1.6 g dose.  When specifically 
monitored, the incidence rate of side effects following β-alanine supplementation 
appears to be higher than has generally been reported.  This is important for research 
design that considers monitoring symptoms to ensure participant blinding. Participants 
should specifically be asked to report side effects immediately after supplementation 
as opposed to recalling side effects after an extended period of suppkementation. 
 
The time-course of paraesthesia symptoms following intake in the present study was 
similar to that previously reported by Harris et al. [10] and Decombaz et al. [97].  
Following an early peak at around 20 – 30 min, sensations dissipated over time.  In 
addition, the level of intensity was dose-dependent, with significant differences in 
symptoms found between the lower and higher body mass groups.  In the current 
investigation, the intensity and severity of symptoms was greater than those reported 
by Decombaz et al. [97], who found that the symptoms experienced by their 
participants did not exceed the “very low” severity grade.  However, in the present 
study, when the relative dose was largest (higher body mass group), some symptoms 
were reported to be between “intense and very, very intense” with individual 
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sensations reported as “extremely strong’ which is similar to those recently reported 
by Bellinger and Minahan [117].  It is not entirely clear why individual responses vary 
and that some do not experience any symptoms at all following β-alanine 
supplementation.  One possible explanation could be a lack of or fewer G protein-
coupled receptors in the skin of certain individuals.  Another explanation, suggested 
by MacPhee et al. [128] relates to ethnic and gender differences; these differences 
were beyond the scope of the current study, and warrant further investigation.  The 
significant moderate negative correlation between symptom intensity (VAS) and body 
fat percentage and the moderate positive correlation (ρ = -0.560, p = 0.030) between 
body mass and QLSI(p&nmax) may provide further insight into explaining why individual 
differences may occur.  Similar to incidence rates, the difference in these symptoms, 
levels of intensity and severity rates between absolute and relative doses of β-alanine 
was significant between the lower and higher body mass groups. 
 
When paraesthesia was reported, the position on the body where they presented was 
not dose dependent; similar symptoms were reported on different sections of the body 
regardless of dose or group.  Consistent with the findings of Decombaz et al. [97], the 
greatest number of symptoms appeared on the trunk and arms, followed by the head 
and neck then the lower body.  Some participants reported that side effects worsened 
when their skin was in contact with another object, for example the back of a chair or 
clothing.  This further supports the work of Liu et al. [141] suggesting that β-alanine 
activated MrgprD in dorsal root ganglion neurons that innervate the skin.  
 
Both an absolute dose of 1.6 g β-alanine, 3 – 4 times per day, or a relative dose of 
0.02g·kgBMˉ¹, 3 – 4 times per day, have been found to be effective in increasing M-
Carn concentrations over 4 – 10 weeks of supplementation [52, 72, 144, 168].  Both 
doses are effective, yet they elicit different side effects for participants of different 
mass.  The results of the current investigation may therefore be useful in reducing the 
side effects for specific individuals.  Whilst a symptom-free, slow-release galenic β-
alanine formulae may improve compliance, it may not always be available [97].  To 
minimise side effects for a person weighing less than 75 kg, the relative dose should 
be used as it will be less than 1.6 g and the side effects seem to be dose dependent.  
Whilst these individuals will still be able to increase M-Carn levels with 1.6g.dayˉ¹ it 
may take a longer period of time. Therefore to increase M-Carn levels quicker they 
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may need to take more doses throughout the day to ensure they ingest sufficient β-
alanine to reach a daily dose of 3.2 – 6.4 g.  Future investigations could examine the 
time-course of changes in M-Carn using doses that minimise side effects.  For a 
person heavier than 85 kg, the absolute dose of 1.6 g could be used with few or no 
symptoms and individuals may even be able to tolerate higher dosages on each 
occasion.  Heavier individuals may be able to achieve the recommended daily dose of 
3.2 – 6.4 g with a lower number of doses and this would improve compliance; studies 
involving medications show an inverse relationship between number of doses per day 
and rate of compliance [115].   
 
Conclusion 
The present study found participants weighing less than 75 kg experienced a higher 
incidence and intensity of side effects when taking an absolute dose of β-alanine.  In 
contrast, with participants over 85 kg, the dose relative to body weight was associated 
with a greater incidence and intensity of side effects.  These findings may be useful in 
providing guidelines to reduce side effects and in turn improve compliance for specific 
individuals.   
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CHAPTER 7. STUDY 5: THE INFLUENCE OF PARAESTHESIA CAUSED BY β-
ALANINE SUPPLEMENTATION ON HIGH-INTENSITY CYCLING CAPACITY. 
 
Abstract 
β-alanine supplementation has been shown to improve high intensity exercise 
performance provided the supplementation period exceeds four weeks. However, 
some athletes believe that the paraesthesia experienced following acute β-alanine 
supplementation has an ergogenic effect – despite there being no supporting 
mechanistic evidence to explain a potential benefit.  The aim of the present study was 
to determine if the level of paraesthesia experienced following acute β-alanine 
supplementation was related to high intensity cycling performance.  On three separate 
occasions, 18 of 29 participants (mean ± SD; age: 21.1 ± 4.2 years, body mass: 72.9 
±8.9 kg, height: 182 ± 5 cm) who experienced paraesthesia in preliminary testing, 
ingested either an acute dose of 1.6 g pure β-alanine, 1.6 g sustained release β-
alanine or a placebo before completing a cycling test to exhaustion.  Sensory 
questionnaires were also completed by participants to determine of the extent of side 
effects in each trail.  There were no significant differences in total work done (p = 
0.743) or time to exhaustion (p = 0.794) between any of the three performance trials. 
Moreover, no relationship was found between the level of paraesthesia and exercise 
performance following acute β-alanine supplementation, despite participants 
experiencing significantly greater paraesthesia following supplementation of the pure 
β-alanine.  Six participants reported side effects in the preliminary testing but reported 
no side effects in any of the subsequent trials – suggesting inter-individual variation in 
the experiencing of side effects following β-alanine supplementation.  In conclusion, 
paraesthesia experienced following β-alanine supplementation did not influence to 
high intensity exercise performance.  
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Introduction 
Taking energy drinks and/or pre-workout supplements (many of which contain β-
alanine) is a popular practice among recreational and competitive athletes seeking to 
improve the quality of their training.  Pre-workout supplements that include β-alanine 
can improve multi-joint resistance exercise performance [308]. in addition to lower 
body muscular endurance and agility choice reaction performance [309] and time to 
exhaustion in a moderate-intensity treadmill run [310].  Given that several weeks of β-
alanine supplementation are required for intracellular carnosine concentrations to 
potentially increase, the performance improvements following acute pre-workout 
supplements that contain β-alanine are likely due to other ingredients (e.g. caffeine) 
and/or to a placebo effect.  
 
The influence of acute β-alanine supplementation on performance has been studied 
by a number of researchers; the aim being to determine whether there was a potential 
ergogenic effect independent of changes in muscle carnosine (M-Carn) levels.  Glenn 
and colleagues [123] examined the effects of acute β-alanine supplementation on 
anaerobic performance in trained female cyclists.  Participants received either a 1.6 g 
β-alanine dose or matched placebo 30 minutes prior to completing three repeated 
Wingate cycling tests.  No significant supplementation effect was observed for fatigue 
index, mean power, peak power, lactate or heart rate.  Consistent with these findings, 
no treatment effects on 6 x 35 m running performance, perceptual responses to 
exercise, blood lactate concentration, insulin, glucose and bicarbonate responses 
were observed following the acute supplementation of 1 g of β-alanine combined with 
1 g of L-carnosine in twelve young healthy active males [311].  However, in these 
studies, paraesthesia [97], was not measured and the possible effect of paraesthesia 
on performance was not considered.  Results from Chapter 4 show that athletes have 
reported that they believe β-alanine enhances performance when taken acutely (30 
min prior to exercise) [312] and this may be due to the paraesthesia many experience 
following β-alanine intake.  Athletes may be influenced by a placebo effect, defined as 
a positive impact on performance resulting solely from the belief that beneficial 
treatment has been received [280].  A placebo effect can influence performance with 
magnitudes varying from -1.9% to 50.7% of baseline performance, with the majority 
falling between 1% and 5% [281].  Although there is no current underlying mechanism 
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to explain how β-alanine-induced paraesthesia could acutely enhance performance, it 
is plausible that athletes believe that the sensations associated with supplementation 
are suggestive of an ergogenic aid and that this is sufficient to improve performance 
[117]. 
 
The influence of paraesthesia on perceived performance was recently examined by 
Bellinger and Minahan [117].  Using a balanced placebo design, eight competitive 
cyclists completed a 1 km cycling time trail under four conditions with varying 
information. In the informed β-alanine/received β-alanine condition, cyclists were 
correctly informed that they would receive β-alanine.  In the informed β-
alanine/received placebo condition, cyclists were informed that this condition would 
examine the effects of β-alanine and a new additive that would reduce the sensation 
of paraesthesia associated with β-alanine ingestion, but cyclists actually received a 
placebo. In the informed placebo/received β-alanine condition, cyclists were informed 
that they would receive a placebo that would mimic the effects of β-alanine, but cyclists 
actually received β-alanine.  Finally, in the informed placebo/received placebo 
condition, cyclists were correctly informed that they would receive a placebo [117].  
Though acute ingestion of β-alanine did not produce a clear benefit to 1 km cycling 
time trial performance, six of the eight cyclists believed their performance improved in 
the informed β-alanine/received β-alanine condition; feelings of paraesthesia were 
related to perception of how they felt during the time trial with five of the participants.  
Unfortunately, levels of paraesthesia and their relationship to time trial performance 
was not examined; a potential relationship between paraesthesia experienced after 
acute β-alanine ingestion, and exercise capacity is thus yet to be reported.  
Additionally the primary investigator has anecdotal experience in the field where 
athletes take β-alanine to experience the side effects which may in turn influence a 
placebo effect. The aim of the present study was therefore to determine if the level of 
paraesthesia experienced following acute β-alanine supplementation was related to 
exercise performance.  
 
Methods 
Participants 
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For inclusion in the present study, participants needed to be omnivores, had not 
ingested any dietary or nutritional supplements in the past three months, or taken β-
alanine in the previous six months.  Twenty-nine recreationally trained males 
completed preliminary testing which involved an assessment of side effects following 
consumption of pure and sustained release β-alanine on two separate occasions.  
Participants met the primary inclusion criterion for further involvement in the study if 
they experienced paraesthesia after taking pure β-alanine but did not experience side 
effects after ingesting sustained release β-alanine.  The 18 participants who met this 
criterion and were involved in the remainder of the study were 21.1 ± 4.2 years of age 
and weighed 72.9 ± 8.9 kg. Participants had no knowledge of β-alanine 
supplementation and subsequent side effects. Each was asked to continue their usual 
physical activity and maintain their normal diet throughout the duration of the study.  
The study was approved by an ethics committee of the University of Queensland. 
 
Experimental design 
The study involved a double-blind, randomised triple-crossover design, with three 
different treatments (two different β-alanine supplements and a placebo) each 
consumed acutely.  Each participant attended the laboratory on seven occasions 
(Figure 7.1).  The first two sessions were preliminary trials, in which the participants 
randomly ingested either 1.6 g of pure β-alanine (Musashi, Australia) or 1.6 g 
sustained-release β-alanine (High Intensity Sustained Release Beta Alanine, 
PowerBar, Nestlé, Switzerland) to determine whether or not they experienced 
paraesthesia.  Test administrators were blinded to the order of supplements and 
tablets were size, taste and texture matched.  The 18 participants who met the 
inclusion criterion completed five subsequent sessions.  The first of these involved 
completing an incremental cycling test to volitional fatigue (to determine maximal 
power output; Wmax); two high-intensity cycle test familiarisation trials followed.  The 
remaining three sessions involved performance trials following supplementation of 
pure β-alanine, sustained release β-alanine and a placebo supplement.  
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Figure 7.1 Overview of research design  
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 - 7
Pure β -alanine Slow-release β -alanine A) Pure β -alanine
Wmax test  & 1
st Familiarisation 2nd Familiarisation B) Slow-release β -alanine
Slow-release β -alanine Pure β -alanine C) Placebo
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Preliminary supplementation 
Participants ingested either 1.6 g pure β-alanine or 1.6 g sustained release β-alanine 
on separate occasions in a randomised order, with a minimum of 24 hours between 
trials. In both conditions, they consumed two tablets with 100 ml of water; each tablet 
contained 800 mg of β-alanine. During both preliminary tests, each completed a 
sensory questionnaire previously described by Decombaz et al, [97] at 10 minute 
intervals for 60 minutes.  Three main sections were used for data analysis, the Visual 
Analogue Score (VAS), the Intensity of Sensation Score (ISS), and the Qualitative 
Light Symptoms Inventory (QLSI).  
 
Preliminary testing and familiarisation 
Participants who reported on the QLSI that they experienced side effects, only after 
consuming the pure β-alanine, completed an incremental cycling test to volitional 
fatigue, in order to determine their maximal power output (Wmax).  Wmax was 
determined for each participant using a graded exercise test to exhaustion on an 
electronic ergometer (Lode Excalibur, Germany) using protocols previously reported 
by Sale et al. [162].  Each participant’s feet were securely attached to the pedals using 
straps and position (saddle height, angle, and handle bar vertical and horizontal 
position) on the cycle ergometer was selected by each participant.  The starting power 
output was 100 W and this increased by 6W every 15 seconds.  A cadence of 90rpm 
was maintained throughout the test, and the test was terminated volitionally or when 
cadence could not be maintained (determined by a drop to 70rpm).  Following the 
Wmax test and after 30 minutes recovery, participants completed their first 
familiarisation of the cycling capacity trial at 110% of their Wmax (CCT110%), which is 
commonly used to determine exercise capacity in studies investigating the effect of β-
alanine [4, 72, 162].  The coefficient of variation (CV) for time to exhaustion (TTE) and 
total work done (TWD) during the CCT110% is 4.4% and 4.9% respectively [247].  A 
second CCT110% familiarisation trial was completed by participants after at least 24 
hours rest. 
 
Performance trials 
Participants were required to abstain from vigorous exercise, caffeine and alcohol 
consumption and to complete a food record for the 48 hours prior to each performance 
trial. On three occasions, either 1.6 g of pure β-alanine tablets, 1.6 g of sustained 
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release β-alanine tablets or an equivalent number of placebo tablets (1.6g 
maltodextrin, GMP Pharmaceuticals, NSW, Australia) were consumed in a 
randomised order 30 minutes before exercise.  Participants completed a 5 minute 
cycle warm up, followed by self-selected stretching prior to completing the CCT110%.  
Time to exhaustion (TTE, sec) and total work done (TWD, kJ) were recorded from 
each test for later analysis.  A minimum of 24 hours separated each of the three trials. 
 
Sensory data 
Following supplementation, participants rested for 30 minutes before completing a 
sensory questionnaire described previously by Decombaz et al. [97].  The 
questionnaire included questions from the Visual Analogue Score (VAS), Intensity of 
Sensation Score (ISS), the Qualitative Light Symptoms Inventory (QLSI) sections used 
by Decombaz et al. [97].  The perceived intensity of symptoms was measured using 
the VAS and ISS.  The VAS was expressed as a percentage of scale length from the 
low end of a 9cm line marked “no unusual sensation” to “most intense sensation 
imaginable” and participants drew a vertical line at the point that represented their 
perceived intensity.  The ISS was a discrete scale that consisted of 15 boxes (0–14) 
labelled “absent” to “unbearable” and was divided into levels of intensity (very low, low, 
moderate and intense).  The nature of the sensation was measured using the QLSI.  
Participants recorded the most fitting level for the pins and needles and/or tingles 
descriptor used by Decombaz et al. [97].  Next to each descriptor was a 5-point scale 
from 0 = ‘‘absent’’ to 4 = ‘‘extremely intense’’.   
 
Dietary analyses 
Participants were asked to maintain a similar diet and to keep a record of their food 
intake 24 hours prior to the three performance tests.  The diet records were evaluated 
using the FoodWorks dietary assessment software program (Xyris Software, Qld, 
Australia) to determine average daily energy (kJ) and average daily fat (g), 
carbohydrate (g), and protein (g) intake.  
 
Statistical analysis 
A one-way analysis of variance with repeated-measures was used to identify potential 
differences between the three supplement conditions for performance outcome 
measures (TWD and TTE).  In addition, Tukey’s post-hoc multiple comparisons test 
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was employed to compare means and test all pairwise comparisons.  For the VAS, 
QLSI and ISS questionnaires, mean maximal score (Smax) was reported (excluding the 
time 0 value) were determined.  For nonparametric data, within-group comparisons 
were examined using a Friedman test and Wilcoxon post-hoc test. In addition, 
Spearman’s correlation analysis was performed between combinations of 
performance variables and VAS, QLSI, and ISS scores.  Analysis was completed 
using SPSS (Version 22) with alpha set at p < 0.05; data are presented as means ± 
SD.   
 
Results 
Despite experiencing side effects during the initial testing phase, during the treatment 
trials six participants reported no side effects for each of the three treatment trials.  
Data for these participants were removed from analysis; results for the remaining 12 
participants are presented below. 
 
Performance 
There were no significant differences in TWD (p = 0.743) or TTE (p = 0.794) between 
any of the trials (Table 7.1) nor was there a significant order effect for either TTE or 
TWD. 
 
Table 7.1 Values are mean ± SD for participants who experienced side effects (n=12) 
for each supplemented performance test. 
 Pure β-alanine 
Sustained release  
β-alanine 
Placebo 
TTE (s) 136.0 ± 18.5 137.4 ± 14.3 137.9 ± 17.0 
TWD (kJ) 44.4 ± 87.9 45.0 ± 7.9 45.0 ± 7.5 
TTE = time to exhaustion; TWD = total work done; (p < 0.05). 
 
Side effects 
Intensities and manifestations of side effects are shown in Figures 7.2 – 7.4.  In all 
trials, scores were highest in the pure β-alanine condition, followed by sustained 
release β-alanine condition, then placebo. VAS and ISS scores were significantly 
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different between placebo and sustained release β-alanine condition (p = 0.016, p = 
0.008) and pure β-alanine condition (p < 0.001, p < 0.001).  There was also a 
significant difference in QLSIpins&needles between the placebo and pure β-alanine 
condition (p < 0.001).  Significant differences in VAS and ISS and QLSIpins&needles were 
found between the sustained release and pure β-alanine conditions (p < 0.001, p = 
0.002, and p = 0.004 respectively).  
 
 
Figure 7.2 Reported intensity of non-differentiated sensations of paraesthesia using 
a Visual Analogue Scale  
(%), from 0 = “no unusual sensation“ to 100 = “most intense sensations imaginable” 
following each treatment. Mean ± SD. 
* = significantly different to placebo.  
** = significantly different to sustained release β-alanine.  
p < 0.05. 
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Figure 7.3 Severity of symptoms shown with symptom intensity scores (ISS scale from 
0 = absent to 14 = unbearable) following each treatment. 
* = significantly different to placebo.  
** = significantly different to sustained release β-alanine.  
p < 0.05. 
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Figure 7.4 Intensity of “pins and needles” sensations using the Qualitative Light 
Symptom Inventory  
(QLSIp&n, scale from 0 = absent to 4 = extremely intense) following each treatment. 
Mean ± SD. 
* = significantly different to placebo.  
** = significantly different to sustained release β-alanine.  
p < 0.05. 
 
Relationship between performance and side effects 
Table 7.2 shows the relationship between the difference in performance (TTE and 
TWD), between the placebo and β-alanine conditions, and side effects (VAS, ISS and 
QLSIp&n).  There were small to moderate relationships between side effects and 
performance, though none of the relationships reached statistical significance.    
 
Dietary analysis 
Table 7.3 shows the mean (± SD) values for energy (kJ∙day-1) and protein, 
carbohydrate and fat (g∙day-1) for the 24 hours prior to the three performance tests. 
The there was no significant difference in total energy intake, carbohydrate intake and 
fat intake between the three performance tests.  Protein intake was significantly 
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greater prior to the sustained release trial compared to the placebo and pure β-alanine 
trials (p = 0.014). 
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Table 7.2 Relationship (Spearman’s rho, ρ) between the difference in performance variables from placebo and side effects 
experienced. 
 Sustained β-alanine  Pure β-alanine 
 TTE difference TWD difference  TTE difference TWD difference 
VAS 0.400 0.325  0.493 0.518 
ISS 0.380 0.228  0.174 0.218 
QLSIpins&needles 0.407 0.369  0.006 0.098 
      
TTE = time to exhaustion 
TWD = total work done 
VAS = visual analogue score 
ISS = intensity of sensation score  
QLSIpins&needles = qualitative light symptoms inventory – pins and needles 
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Table 7.3 Mean (±SD) energy and macronutrient values of all participants’ dietary intake 24 hours prior to the three performance 
tests. 
Placebo   Sustained β-alanine  Pure β-alanine 
Energy 
(kJ) 
Protein 
(g) 
CHO 
(g) 
Fat  
(g) 
 Energy 
(kJ) 
Protein 
(g) 
CHO 
(g) 
Fat  
(g) 
 Energy 
(kJ) 
Protein 
(g) 
CHO 
(g) 
Fat  
(g) 
8793.1 104.9 225.2 81.2  8964.6 133.8** 202.9 79.8  8991.2 101.1* 234.2 84.6 
2009.6 32.1 71.9 30.7  1930.1 42.7 53.2 34.5  1840.8 25.9 64.4 36.9 
 
* Significantly different between pure and sustained β-alanine 
** Significantly different between placebo and sustained β-alanine 
p < 0.05 
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Discussion 
The aim of the present study was to examine whether paraesthesia experienced 
following acute β-alanine supplementation was related to high intensity exercise 
performance.  No relationship between the level of paraesthesia and high intensity 
exercise performance was found and there were no significant differences in TTE and 
TWD following acute supplementation of pure β-alanine, sustained release β-alanine, 
and a placebo.  
 
The incidence of paraesthesia experienced by participants following supplementation 
of the pure β-alanine condition was almost double that experienced following intake of 
the sustained release β-alanine.  That there was no significant difference in TTE and 
TWD across the three conditions in the present study is consistent with previous 
research showing no change in 1km cycle time-trial performance [117] or a running 
based anaerobic test [311] following acute β-alanine supplementation.  Therefore it 
appears that the paraesthesia experienced following acute β-alanine supplementation 
does not enhance exercise capacity.  The enhanced performance in longer term 
studies is most likely due to increased M-Carn levels despite athletes 
reporting/believing there are acute benefits. 
 
A novel finding of this investigation was the variation in paraesthesia responses after 
repeated acute consumption of β-alanine.  Of the 29 original participants, 18 
experienced paraesthesia and were included in the study.  However, six of these 18 
did not experience paraesthesia when they consumed either the pure or sustained 
release β-alanine prior to their exercise bouts in the second phase of the study.  
Stellingwerf et al. [101] reported that regular consumption of slow-release β-alanine 
over 8 weeks did not cause acute or chronic paraesthesia, however possible 
differences in paraesthesia responses across repeated occasions were not examined.  
Paraesthesia occurs when β-alanine activates MrgprD, provoking itching in neurons 
that innervate human skin [141].  Differences in paraesthesia between individuals have 
previously been shown to be related to size of dose [282], type of dose (solution vs. 
tablet) [97], ethnicity and gender [128] and body mass.  Whether there are inter-
individual differences in paraesthesia in response to repeated supplementation is yet 
to be reported.  The present findings suggest that there may be inconsistent responses 
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to acute dosing within some individuals.  Practitioners should monitor individual 
responses and educate athletes about these responses along with strategies to 
minimise side effects. 
 
Another novel finding of the current study was that paraesthesia following sustained 
release β-alanine ingestion was significantly greater than that following placebo. 
Previous research has suggested that ingestion of a sustained release β-alanine 
formula in tablet form results in negligible side effects compared to a placebo; indeed, 
sustained release β-alanine capsules have been used in studies, using participants of 
similar age, height and body mass as the current study, when blinding of participants 
was required [97, 101].  In future, if researches are using a slow release β-alanine 
formula to provide an asymptomatic dose to eliminate perceived side effects and 
ensure blinding of participants, it is recommended that they also monitor any side 
effects following acute supplementation.  Should participants experience side effects, 
researchers should consider removing their data from analysis as blinding may have 
been compromised.  Similarly, the recommendation to consume twice the dose of 
sustained release β-alanine (i.e. 1.6 g vs. 0.8 g of pure β-alanine) as an easier and 
more practical loading protocol [98] may need to be reassessed, as individual 
paraesthesia responses may vary. 
 
In this study participants were recruited who had no knowledge of β-alanine 
supplementation.  However, some admitted to researching β-alanine during the course 
of the study, and may have formed pre-conceived notions about what effect it may 
have, both in terms of performance and sensation.  The placebo effect is based in 
psychological, social, and neuro-physiological changes associated with expectation, 
reward, hope, reduced anxiety and stress [313].  Providing a placebo encourages 
belief that a treatment is effective.  This results in expectation in a clinical outcome 
and a research participant’s expectations and beliefs regarding the scientific 
intervention can influence results [314].  These expectations may vary substantially 
between individuals.  Some participants may have had high expectations to “feel” side 
effects, which may have caused a belief effect to occur resulting in them falsely 
experiencing side effects during the placebo and/or sustained release condition.  It is 
also possible that after researching the effects of β-alanine, some participants 
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discovered that it had no acute effects, which in turn may have negatively impacted 
their effort in any subsequent performance trials.  
 
Participants were only accepted into the present study if they had not consumed β-
alanine in the past six months; additional steps were taken to restrict participant 
knowledge of β-alanine.  Only two of 12 participants correctly guessed their individual 
supplement order, confirming that participants had little or no knowledge of β-alanine 
side effects, however this may have resulted in reduced ability to classify appropriate 
symptoms and potentially compromised the validity of the instruments used to 
measure the manifestations and intensity of the side effects.  Future investigations 
examining the acute effects of β-alanine should consider involving participants who 
have supplemented with β-alanine previously, so they are able to identify which 
sensations are attributable to β-alanine ingestion.  Furthermore, to determine the 
incidence of symptoms, participants completed the sensory questionnaire at 30 min, 
based on the findings of Decombaz et al. [97] and Harris et al. [10].  However, it is 
unclear if individual symptoms of paraesthesia had peaked at 30 min or before or after 
this time. In future, matching an individual’s exercise trial with the time their peak 
symptoms occur may provide a better opportunity to determine the influence of 
paraesthesia on exercise capacity.  
 
Conclusion 
In conclusion there was no relationship between the level of paraesthesia and high 
intensity exercise performance following acute β-alanine supplementation.  However, 
individual differences in side effects were evident after repeated doses of β-alanine 
and further understanding of the underlying mechanism of these differences is 
warranted.  Similarly, some participants experienced side effects after consuming the 
slow release formula and it is recommended that side effects should be monitored in 
future studies that wish to use this supplement when participant blinding is required.   
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SUMMARY AND CONCLUSIONS 
 
Review of findings 
This thesis first examined the combined influence of β-alanine supplementation and 
high intensity training (in addition to acute sodium bicarbonate supplementation) on 
high intensity exercise performance.  Factors that influence an athlete’s decision to 
use β-alanine and influence their decision to keep using it, such as side-effects and 
dosage compliance were also investigated.  Finally, how the practical applications of 
the research are likely to be translated into practice was considered.  Collectively, the 
studies described in the present thesis extend knowledge relating to β-alanine 
supplementation.  
 
Numerous studies have examined the benefits of β-alanine supplementation on 
exercise performance without including a training intervention.  This is unrealistic, as 
athletes would typically take a supplement to influence their performance in training 
and competition.  Chapter 3 (Study 1), showed that performance increased as a result 
of the sprint and interval intervention and that this may have outweighed any potential 
ergogenic effects of β-alanine and NaHCO3 (i.e., alone or in combination).  The 
findings of this study suggest that when β-alanine is supplemented to athletes who 
engage in sprint and interval training, the ergogenic potential of β-alanine may not be 
as significant as previous research findings suggest.   
 
The largest survey to date on ergogenic aids, with professional footballers (Chapter 4, 
Study 2) provides significant insight into the knowledge and behaviours of this under 
researched population.  The results suggest that over half the surveyed professional 
footballers are supplementing with β-alanine yet they rated their knowledge of β-
alanine as nil to limited and the majority of players were unsure of its benefits.  It 
appears that evidence from β-alanine research is not being clearly disseminated to 
athletes by the team dietitians and strength and conditioning coaches or if the 
information is being passed on to players they may not be completely understanding 
all the recommendations or adhering to the guidelines provided.  This has significant 
implications for staff wishing to translate research to practice in professional football. 
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As β-alanine is a relatively new ‘sports’ supplement, it is important that athletes are 
aware of the benefits of the supplement in addition to correct dosing strategies.  Given 
that greater adherence to a supplement correlates strongly with an individual’s 
knowledge of the therapy, poor knowledge of the benefits and correct dosages of β-
alanine may influence adherence and thus efficacy.  This is especially relevant to β-
alanine supplementation, as compliance rates (59%) found in Study 3 (Chapter 5) 
were significantly less than those previously reported in clinical investigations.  This is 
a pertinent finding for practitioners working with athletes to ensure recommended 
dosages are being achieved through individualised supplement education.  If athletes 
are to consume multiple daily doses of β-alanine over several weeks to achieve a 
potential increase in M-Carn levels; (non-) compliance needs to be monitored.   
 
Compliance may be improved by reducing side effects and Study 4 (Chapter 6) shows 
that this can be potentially achieved by manipulating the dose relative to body mass.  
To minimise side effects for lighter individuals, a dose relative to body mass is 
recommended.  Heavier individuals, with greater lean body mass and fat mass, may 
be able to achieve the recommended daily dose of 3.2 – 6.4 g with a lower number of 
doses and this would improve compliance. The findings of Study 5 highlight that 
individual differences in side effects were evident after repeated doses of β-alanine 
and further understanding of the underlying mechanism of these differences is 
warranted.  Results from Study 5 also showed that paraesthesia reported following 
sustained release β-alanine ingestion was significantly greater than that following 
placebo.  This is an important finding for future researchers who plan on using a slow 
release β-alanine formula to provide an asymptomatic dose to eliminate perceived 
side effects and to ‘blind’ participants in a study, it is recommended that they also 
monitor any side effects following acute supplementation.  There was no relationship 
between the level of paraesthesia experienced by participants following acute β-
alanine intake and exercise capacity; paraesthesia itself therefore does not appear to 
influence subsequent high intensity exercise performance.  
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Limitations 
Whilst the results of this thesis have several useful applications, the following 
limitations may apply; 
 
• The changes in intramuscular carnosine levels following β-alanine 
supplementation were not measured though the dosage strategy used has 
previously elicited increases muscle carnosine concentrations. Also 
intramuscular muscle buffer capacity was not measured and therefore the 
physiological changes contributing to performance improvements can only be 
theorised. 
• Compliance levels were only measured across one team and from one sport at 
the professional. Compliance levels may vary with athletes from different sports 
and with athletes from different performance levels (i.e. elite, sub-elite, 
recreational). 
• The sensory questionnaire used has not been assessed for validity or reliability, 
however, it has been used previously and no other known questionnaires have 
sought responses to paraesthesia-specific questions.  
 
Future considerations 
To expand on the findings of the studies presented in this thesis, it is recommended 
that further research investigates the following areas: 
 
• Future studies investigating the efficacy of β-alanine on performance should 
include a range of training interventions throughout the supplementation period. 
To date, the majority of studies that have shown performance benefits following 
β-alanine supplementation have not included a training intervention and the 
practical application to sport performance is limited.  Additionally, it is 
recommended that individuals with already well-developed intramuscular buffer 
capacities act as participants in such studies.  Alternatively, a high intensity 
training period to develop intramuscular buffer capacity prior to the 
supplementation period is recommended.   
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• It is unknown whether the relatively limited knowledge of β-alanine amongst 
professional footballers is due to poor supplement education programs or 
alternatively, if the knowledge of professional support staff may be insufficient.  
Therefore a review of the prevalence, knowledge and attitudes relating to β-
alanine use among support staff for professional footballers is recommended.  
In addition, research should examine the barriers in the translation of evidence-
based recommendations to footballers.  
• The rate of β-alanine adherence in ‘real world’ settings needs further 
investigation to determine the barriers to adherence with a view to improving 
long term adherence through individualised dosages recommendations based 
on body mass and education based on athlete preferences.  In future, the 
development of a valid and reliable tool to measure and report β-alanine 
compliance is warranted. 
• As some participants experienced side effects after consuming the slow release 
β-alanine, further research regarding side effects following ingestion of the slow 
release formula is recommended.  Also, side effects should be monitored in 
future studies that wish to use this supplement when participant blinding is 
required.   
 
Practical applications 
• For practitioners working with athletes who require enhanced buffering capacity 
for performance, SIT (rather than supplementation with NaHCO3 and/or β-
alanine) appears to be the most effective means of eliciting improvements in 
high intensity exercise performance.  Some individuals could derive further 
benefit from β-alanine supplementation; these ‘responders’ may wish to 
consider β-alanine supplementation to assist in performance enhancement.  
• Athletes should be provided with education regarding the efficacy of β-alanine 
supplementation in addition to individualised dosages recommendations based 
on body mass and personal preferences. 
• Individual side effects, even when supplementing with a slow release formula, 
should be monitored long term to enhance compliance.  However, aside from 
acute side effects there appears to be no long term harm in supplementing with 
β-alanine 
 141 
 
REFERENCES 
 
1. Saunders, B., et al., beta-alanine supplementation to improve exercise capacity 
and performance: a systematic review and meta-analysis. Br J Sports Med, 
2016. 
2. Hobson, R.M., et al., Effects of beta-alanine supplementation on exercise 
performance: a meta-analysis. Amino Acids, 2012. 43(1): p. 25-37. 
3. Gross, M., et al., Effects of beta-alanine supplementation and interval training 
on physiological determinants of severe exercise performance. Eur J Appl 
Physiol, 2014. 114(2): p. 221-34. 
4. Danaher, J., et al., The effect of beta-alanine and NaHCO3 co-ingestion on 
buffering capacity and exercise performance with high-intensity exercise in 
healthy males. Eur J Appl Physiol, 2014. 114(8): p. 1715-24. 
5. Cochran, A.J., et al., Beta-Alanine Supplementation Does Not Augment the 
Skeletal Muscle Adaptive Response to Six Weeks of Sprint Interval Training. 
Int J Sport Nutr Exerc Metab, 2015. 
6. Kirk, M.C. and C.A. Hudis, Insight into barriers against optimal adherence to 
oral hormonal therapy in women with breast cancer. Clin Breast Cancer, 2008. 
8(2): p. 155-61. 
7. Boldyrev, A., Carnosine: New concept for the function of an old molecule. 
Biochemistry (Moscow), 2012. 77(4): p. 313-326. 
8. Krimberg, R., Zur Kenntnis der Extraktivstoffe der muskelin. IV.Mutterlung. 
Uberdas vorkommen des carnosins, carnitins und methylguanidins im fleisch. 
Hoppe-Seyler’s Zeitschrift fur Physiologische Chemie, 1906. 48(412). 
9. Krimberg, R., Zur Kenntnis der Extraktivstoffe der muskelin. X. Mitteilung. Uber 
die identitat des novsains mit dem carnitin. Hoppe-Seyler’s Zeitschrift fur 
Physiologische Chemie, 1908. 55(466). 
10. Harris, R.C., et al., The absorption of orally supplied beta-alanine and its effect 
on muscle carnosine synthesis in human vastus lateralis. Amino Acids, 2006. 
30(3): p. 279-89. 
11. Harris, R.C., et al., Determinants of muscle carnosine content. Amino Acids, 
2012. 43(1): p. 5-12. 
12. Bate-Smith, E.C., The buffering of muscle in rigor; protein, phosphate and 
carnosine. The Journal of Physiology, 1938. 92(3): p. 336-343. 
13. Abe, H., Role of histidine-related compounds as intracellular proton buffering 
constituents in vertebrate muscle. Biochemistry (Mosc), 2000. 65(7): p. 757-65. 
14. Skulachev, V.P., Membrane-linked energy buffering as the biological function 
of Na+/K+ gradient. FEBS Letters, 1978. 87(2): p. 171-179. 
15. Davey, C.L., The significance of carnosine and anserine in striated skeletal 
muscle. Archives of Biochemistry and Biophysics, 1960. 89(2): p. 303-308. 
16. Peart, D.J., J.C. Siegler, and R.V. Vince, Practical Recommendations for 
Coaches and Athletes: A Meta-Analysis of Sodium Bicarbonate use for Athletic 
Performance. The Journal of Strength & Conditioning Research, 2012. Publish 
Ahead of Print: p. 10.1519/JSC.0b013e3182576f3d. 
17. Carr, A.J., W.G. Hopkins, and C.J. Gore, Effects of acute alkalosis and acidosis 
on performance: a meta-analysis. Sports Med, 2011. 41(10): p. 801-14. 
 142 
 
18. Sale, C., B. Saunders, and R.C. Harris, Effect of beta-alanine supplementation 
on muscle carnosine concentrations and exercise performance. Amino Acids, 
2010. 39(2): p. 321-33. 
19. Lamont, C. and D.J. Miller, Calcium sensitizing action of carnosine and other 
endogenous imidazoles in chemically skinned striated muscle. The Journal of 
Physiology, 1992. 454(1): p. 421-434. 
20. Dutka, T.L. and G.D. Lamb, Effect of Carnosine on Excitation–Contraction 
Coupling in Mechanically-Skinned Rat Skeletal Muscle. Journal of Muscle 
Research & Cell Motility, 2004. 25(3): p. 203-213. 
21. Dutka, T.L., et al., Effects of carnosine on contractile apparatus Ca2+ sensitivity 
and sarcoplasmic reticulum Ca2+ release in human skeletal muscle fibers. 
Journal of Applied Physiology, 2012. 112(5): p. 728-736. 
22. Everaert, I., et al., Effect of beta-alanine and carnosine supplementation on 
muscle contractility in mice. Med Sci Sports Exerc, 2013. 45(1): p. 43-51. 
23. Hannah, R., et al., beta-Alanine supplementation enhances human skeletal 
muscle relaxation speed but not force production capacity. J Appl Physiol 
(1985), 2015. 118(5): p. 604-12. 
24. Blancquaert, L., I. Everaert, and W. Derave, Beta-alanine supplementation, 
muscle carnosine and exercise performance. Curr Opin Clin Nutr Metab Care, 
2015. 18(1): p. 63-70. 
25. Swietach, P., et al., Coupled Ca2+/H+ transport by cytoplasmic buffers 
regulates local Ca2+ and H+ ion signaling. Proc Natl Acad Sci U S A, 2013. 
110(22): p. E2064-73. 
26. Swietach, P., et al., Pumping Ca2+ up H+ gradients: a Ca2(+)-H+ exchanger 
without a membrane. J Physiol, 2014. 592(15): p. 3179-88. 
27. Temperini, C., et al., Carbonic anhydrase activators: X-ray crystal structure of 
the adduct of human isozyme II with l-histidine as a platform for the design of 
stronger activators. Bioorganic &amp; Medicinal Chemistry Letters, 2005. 
15(23): p. 5136-5141. 
28. Chasovnikova, L.V., et al., The antioxidative properties of carnosine and other 
drugs. . Biochemistry International, 1990. 20: p. 1097-1103. 
29. MacFarlane, N., et al., Synergism of histidyl dipeptides as antioxidants. Journal 
of Molecular and Cellular Cardiology, 1991. 23(11): p. 1205-1207. 
30. Boldyrev, A., Does carnosine possess direct antioxidant activity? International 
Journal of Biochemistry, 1993. 25(8): p. 1101-1107. 
31. Mastaloudis, A., S.W. Leonard, and M.G. Traber, Oxidative stress in athletes 
during extreme endurance exercise. Free Radical Biology and Medicine, 2001. 
31(7): p. 911-922. 
32. Kohen, R., et al., Antioxidant activity of carnosine, homocarnosine, and 
anserine present in muscle and brain. Proceedings of the National Academy of 
Sciences, 1988. 85(9): p. 3175-3179. 
33. Pavlov, A.R., et al., The mechanism of interaction of carnosine with superoxide 
radicals in water solutions. Biochimica et Biophysica Acta (BBA) - General 
Subjects, 1993. 1157(2): p. 304-312. 
34. Gallant, S., A. Semyonova, and M. Yuneva, Carnosine as a potential anti-
senescence drug. Biochemistry (Mosc), 2000. 65(7): p. 866-8. 
35. Hipkiss, A.R., J. Michaelis, and P. Syrris, Non-enzymatic glycosylation of the 
dipeptide l-carnosine, a potential anti-protein-cross-linking agent. FEBS 
Letters, 1995. 371(1): p. 81-85. 
 143 
 
36. Johnson, P. and J. Aldstadt, Effects if carnosine and anserine on muscle and 
non-muscle phosphorylases. Comparative biochemistry and physiology. B, 
Biochemistry and molecular biology., 1984. 78: p. 331-333. 
37. Gualano, B., et al., Reduced muscle carnosine content in type 2, but not in type 
1 diabetic patients. Amino Acids, 2012. 43(1): p. 21-24. 
38. Janssen, B., et al., Carnosine as a Protective Factor in Diabetic Nephropathy: 
Association With a Leucine Repeat of the Carnosinase Gene CNDP1. 
Diabetes, 2005. 54(8): p. 2320-2327. 
39. Quinn, P.J., A.A. Boldyrev, and V.E. Formazuyk, Carnosine: Its properties, 
functions and potential therapeutic applications. Molecular Aspects of 
Medicine, 1992. 13(5): p. 379-444. 
40. Otani, H., et al., Colocalization of a carnosine-splitting enzyme, tissue 
carnosinase (CN2)/cytosolic non-specific dipeptidase 2 (CNDP2), with histidine 
decarboxylase in the tuberomammillary nucleus of the hypothalamus. 
Neuroscience Letters, 2008. 445(2): p. 166-169. 
41. Trombley, P.Q., M.S. Horning, and L.J. Blakemore, Interactions between 
carnosine and zinc and copper: implications for neuromodulation and 
neuroprotection. Biochemistry (Mosc), 2000. 65(7): p. 807-16. 
42. Bellia, F., G. Vecchio, and E. Rizzarelli, Carnosine derivatives: new 
multifunctional drug-like molecules. Amino Acids, 2012. 43(1): p. 153-163. 
43. Hipkiss, A.R., Glycation ageing and carnosine: Are carnivorous diets 
beneficial? Mechanisms of Ageing and Development, 2005. 126(10): p. 1034-
1039. 
44. Hipkiss, A.R., et al., Reaction of carnosine with aged proteins - Another 
protective process? Increasing Healthy Life Span: Conventional Measures and 
Slowing the Innate Aging Process, 2002. 959: p. 285-294. 
45. Begum, G., A. Cunliffe, and M. Leveritt, Physiological role of carnosine in 
contracting muscle. Int J Sport Nutr Exerc Metab, 2005. 15(5): p. 493-514. 
46. Suyama, M., et al., Quality of Wild and Cultured Ayu .1. Proximate Composition, 
Free Amino-Acids and Related Compounds. Bulletin of the Japanese Society 
of Scientific Fisheries, 1977. 43(5): p. 535-540. 
47. Crush, K.G., Carnosine and Related Substances in Animal Tissues. 
Comparative Biochemistry and Physiology, 1970. 34(1): p. 3-&. 
48. Dunnett, M., et al., Carnosine, anserine and taurine contents in individual fibres 
from the middle gluteal muscle of the camel. Research in Veterinary Science, 
1997. 62(3): p. 213-216. 
49. Harris, R.C., et al., Muscle buffering capacity and dipeptide content in the 
thoroughbred horse, greyhound dog and man. Comp Biochem Physiol A Comp 
Physiol, 1990. 97(2): p. 249-51. 
50. Dunnett, M. and R.C. Harris, High-performance liquid chromatographic 
determination of imidazole dipeptides, histidine, 1-methylhistidine and 3-
methylhistidine in equine and camel muscle and individual muscle fibres. 
Journal of Chromatography B, 1997. 688(1): p. 47-55. 
51. O'Dowd, J.J., D.J. Robins, and D.J. Miller, Detection, characterisation, and 
quantification of carnosine and other histidyl derivatives in cardiac and skeletal 
muscle. Biochim Biophys Acta, 1988. 967(2): p. 241-9. 
52. Derave, W., et al., beta-alanine supplementation augments muscle carnosine 
content and attenuates fatigue during repeated isokinetic contraction bouts in 
trained sprinters. Journal of Applied Physiology, 2007. 103(5): p. 1736-1743. 
 144 
 
53. Ozdemir, M.S.R., et al., Absolute quantification of carnosine in human calf 
muscle by proton magnetic resonance spectroscopy. Physics in Medicine and 
Biology, 2007. 52(23): p. 6781-6794. 
54. Pan, J.W., et al., Correlation of lactate and pH in human skeletal muscle after 
exercise by 1H NMR. Magn Reson Med, 1991. 20(1): p. 57-65. 
55. Johnson, P. and J.L. Hammer, Histidine Dipeptide Levels in Aging and 
Hypertensive Rat Skeletal and Cardiac Muscles. Comparative Biochemistry 
and Physiology B-Biochemistry & Molecular Biology, 1992. 103(4): p. 981-984. 
56. Stuerenburg, H.J. and K. Kunze, Concentrations of free carnosine (a putative 
membrane-protective antioxidant) in human muscle biopsies and rat muscles. 
Archives of Gerontology and Geriatrics, 1999. 29(2): p. 107-113. 
57. Derave, W., et al., Creatine supplementation augments skeletal muscle 
carnosine content in senescence-accelerated mice (SAMP8). Rejuvenation 
Research, 2008. 11(3): p. 641-647. 
58. Everaert, I., et al., Vegetarianism, female gender and increasing age, but not 
CNDP1 genotype, are associated with reduced muscle carnosine levels in 
humans. Amino Acids, 2011. 40(4): p. 1221-9. 
59. Baguet, A., et al., The influence of sex, age and heritability on human skeletal 
muscle carnosine content. Amino Acids, 2012. 43(1): p. 13-20. 
60. Tallon, M.J., et al., Carnosine, taurine and enzyme activities of human skeletal 
muscle fibres from elderly subjects with osteoarthritis and young moderately 
active subjects. Biogerontology, 2007. 8(2): p. 129-37. 
61. Kim, H.J., Comparison of the carnosine and taurine contents of vastus lateralis 
of elderly Korean males, with impaired glucose tolerance, and young elite 
Korean swimmers. Amino Acids, 2009. 36(2): p. 359-363. 
62. Penafiel, R., et al., Gender-related differences in carnosine, anserine and lysine 
content of murine skeletal muscle. Amino Acids, 2004. 26(1): p. 53-58. 
63. Tallon, M.J., et al., The carnosine content of vastus lateralis is elevated in 
resistance-trained bodybuilders. Journal of Strength and Conditioning 
Research, 2005. 19(4): p. 725-729. 
64. Marlin, D.J., et al., Carnosine Content of the Middle Gluteal Muscle in 
Thoroughbred Horses with Relation to Age, Sex and Training. Comparative 
Biochemistry and Physiology a-Physiology, 1989. 93(3): p. 629-632. 
65. Mannion, A.F., et al., Carnosine and anserine concentrations in the quadriceps 
femoris muscle of healthy humans. Eur J Appl Physiol Occup Physiol, 1992. 
64(1): p. 47-50. 
66. Ramos, E., et al., Muscle strength and hormonal levels in adolescents: Gender 
related differences. International Journal of Sports Medicine, 1998. 19(8): p. 
526-531. 
67. Vingren, J.L., et al., Testosterone Physiology in Resistance Exercise and 
Training The Up-Stream Regulatory Elements. Sports Medicine, 2010. 40(12): 
p. 1037-1053. 
68. Starka, L., H. Pospisilova, and M. Hill, Free testosterone and free 
dihydrotestosterone throughout the life span of men. Journal of Steroid 
Biochemistry and Molecular Biology, 2009. 116(1-2): p. 118-120. 
69. Simoneau, J.A. and C. Bouchard, Human Variation in Skeletal-Muscle Fiber-
Type Proportion and Enzyme-Activities. American Journal of Physiology, 1989. 
257(4): p. E567-E572. 
 145 
 
70. Staron, R.S., et al., Fiber type composition of the vastus lateralis muscle of 
young men and women. Journal of Histochemistry & Cytochemistry, 2000. 
48(5): p. 623-629. 
71. Harris, R.C., M. Dunnett, and P.L. Greenhaff, Carnosine and taurine contents 
in individual fibres of human vastus lateralis muscle. Journal of Sports 
Sciences, 1998. 16(7): p. 639-643. 
72. Hill, C.A., et al., Influence of beta-alanine supplementation on skeletal muscle 
carnosine concentrations and high intensity cycling capacity. Amino Acids, 
2007. 32(2): p. 225-33. 
73. Kendrick, I.P., et al., The effect of 4 weeks beta-alanine supplementation and 
isokinetic training on carnosine concentrations in type I and II human skeletal 
muscle fibres. European Journal of Applied Physiology, 2009. 106(1): p. 131-
138. 
74. Dunnett, M. and R.C. Harris, Carnosine and taurine contents of type I, IIA and 
IIB fibres in the middle gluteal muscle. Equine Veterinary Journal, 1995. 
27(S18): p. 214-217. 
75. Baguet, A., et al., A New Method for Non-Invasive Estimation of Human Muscle 
Fiber Type Composition. PLoS ONE, 2011. 6(7). 
76. Parkhouse, W.S., et al., Buffering Capacity of Deproteinized Human Vastus 
Lateralis Muscle. Journal of Applied Physiology, 1985. 58(1): p. 14-17. 
77. Bouchard, C., et al., Genetic effects in human skeletal muscle fiber type 
distribution and enzyme activities. Canadian Journal of Physiology and 
Pharmacology, 1986. 64(9): p. 1245-1251. 
78. Suzuki, Y., et al., The Effect of Sprint Training on Skeletal Muscle Carnosine in 
Humans. International Journal of Sport and Health Science, 2004. 2: p. 105-
110. 
79. Kendrick, I., et al., The effects of 10 weeks of resistance training combined with 
β-alanine supplementation on whole body strength, force production, muscular 
endurance and body composition. Amino Acids, 2008. 34(4): p. 547-554. 
80. Mannion, A.F., P.M. Jakeman, and P.L. Willan, Effects of isokinetic training of 
the knee extensors on high-intensity exercise performance and skeletal muscle 
buffering. Eur J Appl Physiol Occup Physiol, 1994. 68(4): p. 356-61. 
81. Gardner, M.L.G., et al., Intestinal-Absorption of the Intact Peptide Carnosine in 
Man, and Comparison with Intestinal Permeability to Lactulose. Journal of 
Physiology-London, 1991. 439: p. 411-422. 
82. Park, Y.J., S.L. Volpe, and E.A. Decker, Quantitation of carnosine in humans 
plasma after dietary consumption of beef. Journal of Agricultural and Food 
Chemistry, 2005. 53(12): p. 4736-4739. 
83. Harris, R.C., et al., The Carnosine Content of V Lateralis in Vegetarians and 
Omnivores. The FASEB Journal, 2007. 21(6): p. A944. 
84. Jones, G., M. Smith, and R. Harris, Imidazole dipeptide content of dietary 
sources commonly consumed within the British diet. Proceedings of the 
Nutrition Society, 2011. 70(OCE6): p. null-null. 
85. Tomonaga, S., M. Matsumoto, and M. Furuse, β-Alanine Enhances Brain and 
Muscle Carnosine Levels in Broiler Chicks. The Journal of Poultry Science, 
2012. 49(4): p. 308-312. 
86. Fritzson, P., The Catabolism of C-14-Labeled Uracil, Dihydrouracil, and Beta-
Ureidopropionic Acid in Rat Liver Slices. Journal of Biological Chemistry, 1957. 
226(1): p. 223-228. 
 146 
 
87. Matthews, M.M. and T.W. Traut, Regulation of N-Carbamoyl-Beta-Alanine 
Amidohydrolase, the Terminal Enzyme in Pyrimidine Catabolism, by Ligand-
Induced Change in Polymerization. Journal of Biological Chemistry, 1987. 
262(15): p. 7232-7237. 
88. Asatoor, A.M., et al., Intestinal absorption of carnosine and its constituent amino 
acids in man. Gut, 1970. 11(3): p. 250-4. 
89. Perry, T.L., et al., Carnosinemia - a New Metabolic Disorder Associated with 
Neurologic Disease and Mental Defect. New England Journal of Medicine, 
1967. 277(23): p. 1219-&. 
90. Bakardjiev, A. and K. Bauer, Transport of Beta-Alanine and Biosynthesis of 
Carnosine by Skeletal-Muscle Cells in Primary Culture. European Journal of 
Biochemistry, 1994. 225(2): p. 617-623. 
91. Miyamoto, Y., et al., Uphill Transport of Beta-Alanine in Intestinal Brush-Border 
Membrane-Vesicles. American Journal of Physiology, 1990. 259(3): p. G372-
G379. 
92. Ramamoorthy, S., et al., Functional-Characterization and Chromosomal 
Localization of a Cloned Taurine Transporter from Human Placenta. 
Biochemical Journal, 1994. 300: p. 893-900. 
93. Ng, R.H. and F.D. Marshall, Regional and Subcellular-Distribution of 
Homocarnosine-Carnosine Synthetase in Central Nervous-System of Rats. 
Journal of Neurochemistry, 1978. 30(1): p. 187-190. 
94. Skaper, S.D., S. Das, and F.D. Marshall, Some Properties of a Homocarnosine-
Carnosine Synthetase Isolated from Rat-Brain. Journal of Neurochemistry, 
1973. 21(6): p. 1429-1445. 
95. Dunnett, M. and R.C. Harris, Influence of oral ß-alanine and L-histidine 
supplementation on the carnosine content of the gluteus medius. Equine 
Veterinary Journal, 1999. 31(S30): p. 499-504. 
96. Harris, R.C., G. Jones, and J.A. Wise, The plasma concentration-time profile of 
beta-alanine using a controlled-release formulation (Carnosyn (R)). Faseb 
Journal, 2008. 22. 
97. Decombaz, J., et al., Effect of slow-release beta-alanine tablets on absorption 
kinetics and paresthesia. Amino Acids, 2012. 43(1): p. 67-76. 
98. Stellingwerff, T., et al., Optimizing human in vivo dosing and delivery of beta-
alanine supplements for muscle carnosine synthesis. Amino Acids, 2012. 43(1): 
p. 57-65. 
99. Baguet, A., et al., Carnosine loading and washout in human skeletal muscles. 
Journal of Applied Physiology, 2009. 106(3): p. 837-842. 
100. Baguet, A., et al., Important role of muscle carnosine in rowing performance. 
Journal of Applied Physiology, 2010. 109(4): p. 1096-1101. 
101. Stellingwerff, T., et al., Effect of two beta-alanine dosing protocols on muscle 
carnosine synthesis and washout. Amino Acids, 2012. 42(6): p. 2461-72. 
102. Harris, R.C., K. Soderlund, and E. Hultman, Elevation of Creatine in Resting 
and Exercised Muscle of Normal Subjects by Creatine Supplementation. 
Clinical Science, 1992. 83(3): p. 367-374. 
103. Greenhaff, P.L., et al., Effect of Oral Creatine Supplementation on Skeletal-
Muscle Phosphocreatine Resynthesis. American Journal of Physiology, 1994. 
266(5): p. E725-E730. 
104. Saunders, B., et al., Effect Of 24 Weeks beta-alanine Supplementation On 
High-intensity Cycling: 244 Board #81 June 1, 9: 30 AM - 11: 00 AM. Med Sci 
Sports Exerc, 2016. 48(5 Suppl 1): p. 55-6. 
 147 
 
105. Bex, T., et al., Muscle carnosine loading by beta-alanine supplementation is 
more pronounced in trained vs. untrained muscles. J Appl Physiol (1985), 2014. 
116(2): p. 204-9. 
106. Bex, T., et al., Exercise training and Beta-alanine-induced muscle carnosine 
loading. Front Nutr, 2015. 2: p. 13. 
107. Hoffman, J.R., et al., Short-duration beta-alanine supplementation increases 
training volume and reduces subjective feelings of fatigue in college football 
players. Nutr Res, 2008. 28(1): p. 31-5. 
108. Stegen, S., et al., beta-Alanine dose for maintaining moderately elevated 
muscle carnosine levels. Med Sci Sports Exerc, 2014. 46(7): p. 1426-32. 
109. Baguet, A., et al., Beta-alanine supplementation reduces acidosis but not 
oxygen uptake response during high-intensity cycling exercise. Eur J Appl 
Physiol, 2010. 108(3): p. 495-503. 
110. del Favero, S., et al., Beta-alanine (Carnosyn) supplementation in elderly 
subjects (60-80 years): effects on muscle carnosine content and physical 
capacity. Amino Acids, 2012. 43(1): p. 49-56. 
111. Artioli, G.G., et al., Role of [beta]-Alanine Supplementation on Muscle 
Carnosine and Exercise Performance. Medicine & Science in Sports & 
Exercise, 2010. 42(6): p. 1162-1173. 
112. Stegen, S., et al., Meal and beta-alanine coingestion enhances muscle 
carnosine loading. Med Sci Sports Exerc, 2013. 45(8): p. 1478-85. 
113. Hipkiss, A.R., Carnosine and protein carbonyl groups: A possible relationship. 
Biochemistry-Moscow, 2000. 65(7): p. 771-778. 
114. Guiotto, A., et al., Carnosine and carnosine-related antioxidants: A review. 
Current Medicinal Chemistry, 2005. 12(20): p. 2293-2315. 
115. Claxton, A.J., J. Cramer, and C. Pierce, A systematic review of the associations 
between dose regimens and medication compliance. Clinical Therapeutics, 
2001. 23(8): p. 1296-1310. 
116. Bellinger, P.M., et al., Effect of combined beta-alanine and sodium bicarbonate 
supplementation on cycling performance. Med Sci Sports Exerc, 2012. 44(8): 
p. 1545-51. 
117. Bellinger, P.M. and C.L. Minahan, Performance effects of acute beta-alanine 
induced paresthesia in competitive cyclists. Eur J Sport Sci, 2016. 16(1): p. 88-
95. 
118. Bellinger, P.M. and C.L. Minahan, The effect of beta-alanine supplementation 
on cycling time trials of different length. Eur J Sport Sci, 2015: p. 1-8. 
119. Chung, W., et al., Effect of 10 week beta-alanine supplementation on 
competition and training performance in elite swimmers. Nutrients, 2012. 4(10): 
p. 1441-53. 
120. de Salles Painelli, V., et al., The ergogenic effect of beta-alanine combined with 
sodium bicarbonate on high-intensity swimming performance. Appl Physiol Nutr 
Metab, 2013. 38(5): p. 525-32. 
121. de Salles Painelli, V., et al., Influence of training status on high-intensity 
intermittent performance in response to beta-alanine supplementation. Amino 
Acids, 2014. 46(5): p. 1207-15. 
122. Glenn, J.M., et al., Effects of longitudinal beta-alanine supplementation on 
isokinetic exercise performance and body composition in female masters 
athletes. J Strength Cond Res, 2015. 
 148 
 
123. Glenn, J.M., et al., Effects of Acute Beta-Alanine Supplementation on 
Anaerobic Performance in Trained Female Cyclists. J Nutr Sci Vitaminol 
(Tokyo), 2015. 61(2): p. 161-6. 
124. Gross, M., et al., Beta-alanine supplementation improves jumping power and 
affects severe-intensity performance in professional alpine skiers. Int J Sport 
Nutr Exerc Metab, 2014. 24(6): p. 665-73. 
125. Hoffman, J.R., et al., β-alanine supplementation improves tactical performance 
but not cognitive function in combat soldiers. Journal of the International Society 
of Sports Nutrition, 2014. 11(1): p. 1-8. 
126. Howe, S.T., et al., The effect of beta-alanine supplementation on isokinetic 
force and cycling performance in highly trained cyclists. Int J Sport Nutr Exerc 
Metab, 2013. 23(6): p. 562-70. 
127. Jordan, T., et al., Effect of beta-alanine supplementation on the onset of blood 
lactate accumulation (OBLA) during treadmill running: Pre/post 2 treatment 
experimental design. J Int Soc Sports Nutr, 2010. 7: p. 20. 
128. Macphee, S., I.N. Weaver, and D.F. Weaver, An Evaluation of Interindividual 
Responses to the Orally Administered Neurotransmitter beta -Alanine. J Amino 
Acids, 2013. 2013: p. 429847. 
129. McCormack, W.P., et al., Oral nutritional supplement fortified with beta-alanine 
improves physical working capacity in older adults: a randomized, placebo-
controlled study. Exp Gerontol, 2013. 48(9): p. 933-9. 
130. Mero, A.A., et al., Effect of sodium bicarbonate and beta-alanine 
supplementation on maximal sprint swimming. J Int Soc Sports Nutr, 2013. 
10(1): p. 52. 
131. Smith-Ryan, A.E., et al., High-velocity intermittent running: effects of beta-
alanine supplementation. J Strength Cond Res, 2012. 26(10): p. 2798-805. 
132. Sweeney, K.M., et al., The effect of beta-alanine supplementation on power 
performance during repeated sprint activity. J Strength Cond Res, 2010. 24(1): 
p. 79-87. 
133. Tobias, G., et al., Additive effects of beta-alanine and sodium bicarbonate on 
upper-body intermittent performance. Amino Acids, 2013. 45(2): p. 309-17. 
134. Hoffman, J.R., N.S. Emerson, and J.R. Stout, β-Alanine Supplementation. 
Current Sports Medicine Reports, 2012. 11(4): p. 189-195 
10.1249/JSR.0b013e3182604983. 
135. Donovan, T., et al., beta-alanine improves punch force and frequency in 
amateur boxers during a simulated contest. Int J Sport Nutr Exerc Metab, 2012. 
22(5): p. 331-7. 
136. Mori, M., B.H. Gahwiler, and U. Gerber, Beta-alanine and taurine as 
endogenous agonists at glycine receptors in rat hippocampus in vitro. J Physiol, 
2002. 539(Pt 1): p. 191-200. 
137. Wang, D.S., H.L. Zhu, and J.S. Li, Beta-alanine acts on glycine receptors in the 
rat sacral dorsal commissural neurons. Int J Neurosci, 2003. 113(3): p. 293-
305. 
138. Tiedje, K.E., et al., beta-Alanine as a small molecule neurotransmitter. 
Neurochemistry International, 2010. 57(3): p. 177-188. 
139. Shinohara, T., et al., Identification of a G protein-coupled receptor specifically 
responsive to beta-alanine. Journal of Biological Chemistry, 2004. 279(22): p. 
23559-23564. 
 149 
 
140. Zylka, M.J., F.L. Rice, and D.J. Anderson, Topographically distinct epidermal 
nociceptive circuits revealed by axonal tracers targeted to Mrgprd. Neuron, 
2005. 45(1): p. 17-25. 
141. Liu, Q., et al., Mechanisms of itch evoked by beta-alanine. J Neurosci, 2012. 
32(42): p. 14532-7. 
142. Bellinger, P.M. and C.L. Minahan, Additive Benefits of beta-Alanine 
Supplementation and Sprint-Interval Training. Med Sci Sports Exerc, 2016. 
143. Chung, W., et al., Doubling of muscle carnosine concentration does not improve 
laboratory 1-hr cycling time-trial performance. Int J Sport Nutr Exerc Metab, 
2014. 24(3): p. 315-24. 
144. Hoffman, J., et al., Beta-alanine and the hormonal response to exercise. Int J 
Sports Med, 2008. 29(12): p. 952-8. 
145. Sale, C., et al., beta-alanine supplementation improves isometric endurance of 
the knee extensor muscles. J Int Soc Sports Nutr, 2012. 9(1): p. 26. 
146. Saunders, B., et al., Effect of beta-alanine supplementation on repeated sprint 
performance during the Loughborough Intermittent Shuttle Test. Amino Acids, 
2012. 43(1): p. 39-47. 
147. Saunders, B., et al., Effect of sodium bicarbonate and Beta-alanine on repeated 
sprints during intermittent exercise performed in hypoxia. Int J Sport Nutr Exerc 
Metab, 2014. 24(2): p. 196-205. 
148. Saunders, B., et al., beta-alanine supplementation improves YoYo intermittent 
recovery test performance. J Int Soc Sports Nutr, 2012. 9(1): p. 39. 
149. Smith, A.E., et al., Exercise-induced oxidative stress: the effects of beta-alanine 
supplementation in women. Amino Acids, 2012. 43(1): p. 77-90. 
150. Smith-Ryan, A.E., et al., The effects of beta-alanine supplementation on 
physical working capacity at heart rate threshold. Clin Physiol Funct Imaging, 
2014. 34(5): p. 397-404. 
151. Solis, M.Y., et al., Effects of Beta-Alanine Supplementation on Brain 
Homocarnosine/Carnosine Signal and Cognitive Function: An Exploratory 
Study. PLoS ONE, 2015. 10(4): p. e0123857. 
152. Stout, J.R., et al., Effects of beta-alanine supplementation on the onset of 
neuromuscular fatigue and ventilatory threshold in women. Amino Acids, 2007. 
32(3): p. 381-6. 
153. Derave, W., et al., Muscle Carnosine Metabolism and beta-Alanine 
Supplementation in Relation to Exercise and Training. Sports Medicine, 2010. 
40(3): p. 247-263. 
154. Bishop, D., S. Lawrence, and M. Spencer, Predictors of repeated-sprint ability 
in elite female hockey players. Journal of Science and Medicine in Sport, 2003. 
6(2): p. 199-209. 
155. Bishop, D. and J. Edge, Determinants of repeated-sprint ability in females 
matched for single-sprint performance. European Journal of Applied 
Physiology, 2006. 97(4): p. 373-379. 
156. Rampinini, E., et al., Repeated-sprint ability in professional and amateur soccer 
players. Applied Physiology Nutrition and Metabolism-Physiologie Appliquee 
Nutrition Et Metabolisme, 2009. 34(6): p. 1048-1054. 
157. Bishop, D., J. Edge, and C. Goodman, Muscle buffer capacity and aerobic 
fitness are associated with repeated-sprint ability in women. Eur J Appl Physiol, 
2004. 92(4-5): p. 540-7. 
 150 
 
158. Suzuki, Y., et al., Carnosine and anserine ingestion enhances contribution of 
nonbicarbonate buffering. Medicine and Science in Sports and Exercise, 2006. 
38(2): p. 334-338. 
159. Suzuki, Y., et al., High level of skeletal muscle carnosine contributes to the latter 
half of exercise performance during 30-s maximal cycle ergometer sprinting. 
Japanese Journal of Physiology, 2002. 52(2): p. 199-205. 
160. Kern, B.D. and T.L. Robinson, Effects of beta-alanine supplementation on 
performance and body composition in collegiate wrestlers and football players. 
J Strength Cond Res, 2011. 25(7): p. 1804-15. 
161. Price, M., P. Moss, and S. Rance, Effects of sodium bicarbonate ingestion on 
prolonged intermittent exercise. Med Sci Sports Exerc, 2003. 35(8): p. 1303-8. 
162. Sale, C., et al., Effect of beta-alanine plus sodium bicarbonate on high-intensity 
cycling capacity. Med Sci Sports Exerc, 2011. 43(10): p. 1972-8. 
163. Jagim, A.R., et al., Effects of Beta-Alanine Supplementation on Sprint 
Endurance. Journal of Strength and Conditioning Research, 2013. 27(2): p. 
526-532. 
164. Jeukendrup, A., et al., A new validated endurance performance test. Medicine 
and Science in Sports and Exercise, 1996. 28(2): p. 266-270. 
165. Hinckson, E.A. and W.G. Hopkins, Reliability of time to exhaustion analyzed 
with critical-power and log-log modeling. Med Sci Sports Exerc, 2005. 37(4): p. 
696-701. 
166. Ducker, K.J., B. Dawson, and K.E. Wallman, Effect of Beta-Alanine 
Supplementation on 2000 m Rowing Ergometer Performance. Int J Sport Nutr 
Exerc Metab, 2012. 7: p. 7. 
167. Smith, A.E., et al., Effects of beta-alanine supplementation and high-intensity 
interval training on endurance performance and body composition in men; a 
double-blind trial. J Int Soc Sports Nutr, 2009. 6: p. 5. 
168. Hoffman, J., et al., Effect of creatine and beta-alanine supplementation on 
performance and endocrine responses in strength/power athletes. Int J Sport 
Nutr Exerc Metab, 2006. 16(4): p. 430-46. 
169. Stout, J.R., et al., Effects of twenty-eight days of beta-alanine and creatine 
monohydrate supplementation on the physical working capacity at 
neuromuscular fatigue threshold. Journal of Strength and Conditioning 
Research, 2006. 20(4): p. 928-931. 
170. Kresta, J., et al., Effects of 28 days of beta-alanine and creatine monohydrate 
supplementation on muscle carnosine, body composition and exercise 
performance in recreationally active females. Journal of the International 
Society of Sports Nutrition, 2012. 9(Suppl 1): p. P17. 
171. Zoeller, R.F., et al., Effects of 28 days of beta-alanine and creatine 
monohydrate supplementation on aerobic power, ventilatory and lactate 
thresholds, and time to exhaustion. Amino Acids, 2007. 33(3): p. 505-10. 
172. McNaughton, L.R., J. Siegler, and A. Midgley, Ergogenic effects of sodium 
bicarbonate. Curr Sports Med Rep, 2008. 7(4): p. 230-6. 
173. Stout, J.R., et al., The effect of beta-alanine supplementation on neuromuscular 
fatigue in elderly (55-92 Years): a double-blind randomized study. Journal of 
the International Society of Sports Nutrition, 2008. 5. 
174. Walter, A.A., et al., Six weeks of high-intensity interval training with and without 
beta-alanine supplementation for improving cardiovascular fitness in women. J 
Strength Cond Res, 2010. 24(5): p. 1199-207. 
 151 
 
175. Van Thienen, R., et al., Beta-alanine improves sprint performance in endurance 
cycling. Med Sci Sports Exerc, 2009. 41(4): p. 898-903. 
176. Bishop, D., O. Girard, and A. Mendez-Villanueva, Repeated-sprint ability - part 
II: recommendations for training. Sports Med, 2011. 41(9): p. 741-56. 
177. Girard, O., A. Mendez-Villanueva, and D. Bishop, Repeated-sprint ability - part 
I: factors contributing to fatigue. Sports Med, 2011. 41(8): p. 673-94. 
178. Thomas, C., et al., Effects of high-intensity training on MCT1, MCT4, and NBC 
expressions in rat skeletal muscles: influence of chronic metabolic alkalosis. 
American Journal of Physiology - Endocrinology And Metabolism, 2007. 293(4): 
p. E916-E922. 
179. Edge, J., D. Bishop, and C. Goodman, The effects of training intensity on 
muscle buffer capacity in females. Eur J Appl Physiol, 2006. 96(1): p. 97-105. 
180. Weston, A.R., et al., Skeletal muscle buffering capacity and endurance 
performance after high-intensity interval training by well-trained cyclists. Eur J 
Appl Physiol Occup Physiol, 1997. 75(1): p. 7-13. 
181. Mohr, M., et al., Effect of two different intense training regimens on skeletal 
muscle ion transport proteins and fatigue development. American Journal of 
Physiology - Regulatory, Integrative and Comparative Physiology, 2007. 
292(4): p. R1594-R1602. 
182. Dennig, H., et al., Effect of acidosis and alkalosis upon capacity for work. 
Journal of Clinical Investigation, 1931. 9(4): p. 601. 
183. Burke, L.M. and D.B. Pyne, Bicarbonate loading to enhance training and 
competitive performance. International Journal of Sports Physiology and 
Performance, 2007. 2(1): p. 93-97. 
184. Carr, A.J., et al., Effect of sodium bicarbonate on [HCO3-], pH, and 
gastrointestinal symptoms. Int J Sport Nutr Exerc Metab, 2011. 21(3): p. 189-
94. 
185. Renfree, A., The time course for changes in plasma [h+] after sodium 
bicarbonate ingestion. Int J Sports Physiol Perform, 2007. 2(3): p. 323-6. 
186. Siegler, J.C., et al., Effects of Various Sodium Bicarbonate Loading Protocols 
on the Time-Dependent Extracellular Buffering Profile. The Journal of Strength 
& Conditioning Research, 2010. 24(9): p. 2551-2557 
10.1519/JSC.0b013e3181aeb154. 
187. Baylis, A., D. Cameron-Smith, and L.M. Burke, Inadvertent doping through 
supplement use by athletes: assessment and management of the risk in 
Australia. Int J Sport Nutr Exerc Metab, 2001. 11(3): p. 365-83. 
188. Braun, H., et al., Dietary supplement use among elite young German athletes. 
Int J Sport Nutr Exerc Metab, 2009. 19(1): p. 97-109. 
189. Dascombe, B.J., et al., Nutritional supplementation habits and perceptions of 
elite athletes within a state-based sporting institute. Journal of Science and 
Medicine in Sport, 2010. 13(2): p. 274-280. 
190. Erdman, K.A., T.S. Fung, and R.A. Reimer, Influence of performance level on 
dietary supplementation in elite Canadian athletes. Med Sci Sports Exerc, 
2006. 38(2): p. 349-56. 
191. Krumbach, C.J., D.R. Ellis, and J.A. Driskell, A report of vitamin and mineral 
supplement use among university athletes in a division I institution. Int J Sport 
Nutr, 1999. 9(4): p. 416-25. 
192. Schroder, H., et al., The type, amount, frequency and timing of dietary 
supplement use by elite players in the First Spanish Basketball League. J 
Sports Sci, 2002. 20(4): p. 353-8. 
 152 
 
193. Slater, G., B. Tan, and K.C. Teh, Dietary supplementation practices of 
Singaporean athletes. International Journal of Sport Nutrition and Exercise 
Metabolism, 2003. 13(3): p. 320-332. 
194. Sobal, J. and L.F. Marquart, Vitamin/mineral supplement use among high 
school athletes. Adolescence, 1994. 29(116): p. 835-43. 
195. Sundgot-Borgen, J., B. Berglund, and M.K. Torstveit, Nutritional supplements 
in Norwegian elite athletes - impact of international ranking and advisors. 
Scandinavian Journal of Medicine & Science in Sports, 2003. 13(2): p. 138-144. 
196. Tian, H.H., W.S. Ong, and C.L. Tan, Nutritional supplement use among 
university athletes in Singapore. Singapore Medical Journal, 2009. 50(2): p. 
165-172. 
197. Kristiansen, M., et al., Dietary supplement use by varsity athletes at a Canadian 
university. Int J Sport Nutr Exerc Metab, 2005. 15(2): p. 195-210. 
198. Scofield, D.E. and S. Unruh, Dietary supplement use among adolescent 
athletes in central Nebraska and their sources of information. Journal of 
Strength and Conditioning Research, 2006. 20(2): p. 452-455. 
199. Petroczi, A., et al., Nutritional supplement use by elite young UK athletes: 
fallacies of advice regarding efficacy. Journal of the International Society of 
Sports Nutrition, 2008. 5. 
200. Jacobson, B.H., C. Sobonya, and J. Ransone, Nutrition practices and 
knowledge of college varsity athletes: A follow-up. Journal of Strength and 
Conditioning Research, 2001. 15(1): p. 63-68. 
201. Burns, R.D., et al., Intercollegiate student athlete use of nutritional supplements 
and the role of athletic trainers and dietitians in nutrition counseling. Journal of 
the American Dietetic Association, 2004. 104(2): p. 246-249. 
202. Malinauskas, B.M., et al., Supplements of interest for sport-related injury and 
sources of supplement information among college athletes. Advances in 
Medical Sciences, 2007. 52: p. 50-54. 
203. Tsitsimpikou, C., et al., The use of nutritional supplements among recreational 
athletes in Athens, Greece. International Journal of Sport Nutrition and Exercise 
Metabolism, 2011. 21: p. 377-384. 
204. Ronsen, O., J. Sundgot-Borgen, and S. Maehlum, Supplement use and 
nutritional habits in Norwegian elite athletes. Scandinavian Journal of Medicine 
& Science in Sports, 1999. 9(1): p. 28-35. 
205. Maughan, R.J., F. Depiesse, and H. Geyer, The use of dietary supplements by 
athletes (vol 25, suppl 1, pg S103, 2007). Journal of Sports Sciences, 2009. 
27(6): p. 667-667. 
206. Erdman, K.A., et al., Dietary supplementation of high-performance Canadian 
athletes by age and gender. Clinical Journal of Sport Medicine, 2007. 17(6): p. 
458-464. 
207. Tscholl, P., A. Junge, and J. Dvorak, The use of medication and nutritional 
supplements during FIFA World Cups 2002 and 2006. British Journal of Sports 
Medicine, 2008. 42(9): p. 725-730. 
208. Heikkinen, A., et al., Dietary Supplementation Habits and Perceptions of 
Supplement Use Among Elite Finnish Athletes. International Journal of Sport 
Nutrition and Exercise Metabolism, 2011. 21(4): p. 271-279. 
209. Nieper, A., Nutritional supplement practices in UK junior national track and field 
athletes. British Journal of Sports Medicine, 2005. 39(9): p. 645-649. 
 153 
 
210. Ayranci, U., N. Son, and O. Son, Prevalence of nonvitamin, nonmineral 
supplement usage among students in a Turkish university. Bmc Public Health, 
2005. 5. 
211. Sheppard, H.L., et al., Use of creatine and other supplements by members of 
civilian and military health clubs: a cross-sectional survey. Int J Sport Nutr Exerc 
Metab, 2000. 10(3): p. 245-59. 
212. Smith, J. and D.L. Dahm, Creatine use among a select population of high 
school athletes. Mayo Clinic Proceedings, 2000. 75(12): p. 1257-1263. 
213. Metzl, J.D., et al., Creatine Use Among Young Athletes. Pediatrics, 2001. 
108(2): p. 421-425. 
214. Juhn, M.S., J.W. O'Kane, and D.M. Vinci, Oral creatine supplementation in 
male collegiate athletes: A survey of dosing habits and side effects. Journal of 
the American Dietetic Association, 1999. 99(5): p. 593-595. 
215. LaBotz, M. and B.W. Smith, Creatine supplement use in an NCAA Division I 
athletic program. Clinical Journal of Sport Medicine, 1999. 9(3): p. 167-169. 
216. Bents, R.T. and E. Marsh, Patterns of ephedra and other stimulant use in 
collegiate hockey athletes. International Journal of Sport Nutrition and Exercise 
Metabolism, 2006. 16(6): p. 636-643. 
217. Duellman, M.C., et al., Protein Supplement Users among High School Athletes 
Have Misconceptions About Effectiveness. Journal of Strength and 
Conditioning Research, 2008. 22(4): p. 1124-1129. 
218. Desbrow, B. and M. Leveritt, Well-trained endurance athletes' knowledge, 
insight, and experience of caffeine use. International Journal of Sport Nutrition 
and Exercise Metabolism, 2007. 17(4): p. 328-339. 
219. Parr, R.B., M.A. Porter, and S.C. Hodgson, Nutrition Knowledge and Practice 
of Coaches, Trainers, and Athletes. The Physician and Sportsmedicine, 1984. 
12(3): p. 126-138. 
220. Wallimann, T., M. Tokarska-Schlattner, and U. Schlattner, The creatine kinase 
system and pleiotropic effects of creatine. Amino Acids, 2011. 40(5): p. 1271-
96. 
221. Del Coso, J., et al., Restoration of blood pH between repeated bouts of high-
intensity exercise: effects of various active-recovery protocols. Eur J Appl 
Physiol, 2010. 108(3): p. 523-32. 
222. Fitts, R.H., Muscle fatigue: the cellular aspects. Am J Sports Med, 1996. 24(6 
Suppl): p. S9-13. 
223. Robergs, R., et al., Influence of pre-exercise acidosis and alkalosis on the 
kinetics of acid-base recovery following intense exercise. Int J Sport Nutr Exerc 
Metab, 2005. 15(1): p. 59-74. 
224. Bishop, D., et al., Induced metabolic alkalosis affects muscle metabolism and 
repeated-sprint ability. Med Sci Sports Exerc, 2004. 36(5): p. 807-13. 
225. Donaldson, S.K., L. Hermansen, and L. Bolles, Differential, direct effects of H+ 
on Ca2+ -activated force of skinned fibers from the soleus, cardiac and 
adductor magnus muscles of rabbits. Pflugers Arch, 1978. 376(1): p. 55-65. 
226. Fabiato, A. and F. Fabiato, Effects of pH on the myofilaments and the 
sarcoplasmic reticulum of skinned cells from cardiace and skeletal muscles. J 
Physiol, 1978. 276: p. 233-55. 
227. Costill, D.L., et al., Acid-base balance during repeated bouts of exercise: 
influence of HCO3. Int J Sports Med, 1984. 5(5): p. 228-31. 
228. Sutton, J.R., N.L. Jones, and C.J. Toews, Effect of PH on muscle glycolysis 
during exercise. Clin Sci (Lond), 1981. 61(3): p. 331-8. 
 154 
 
229. Harris, R.C., et al., The time course of phosphorylcreatine resynthesis during 
recovery of the quadriceps muscle in man. Pflugers Arch, 1976. 367(2): p. 137-
42. 
230. Sahlin, K. and R.C. Harris, The creatine kinase reaction: a simple reaction with 
functional complexity. Amino Acids, 2011. 40(5): p. 1363-7. 
231. Gibala, M.J., et al., Short-term sprint interval versus traditional endurance 
training: similar initial adaptations in human skeletal muscle and exercise 
performance. J Physiol, 2006. 575(Pt 3): p. 901-11. 
232. Burgomaster, K.A., G.J. Heigenhauser, and M.J. Gibala, Effect of short-term 
sprint interval training on human skeletal muscle carbohydrate metabolism 
during exercise and time-trial performance. J Appl Physiol (1985), 2006. 100(6): 
p. 2041-7. 
233. Juel, C., Regulation of pH in human skeletal muscle: adaptations to physical 
activity. Acta Physiol (Oxf), 2008. 193(1): p. 17-24. 
234. Edge, J., D. Bishop, and C. Goodman, Effects of chronic NaHCO3 ingestion 
during interval training on changes to muscle buffer capacity, metabolism, and 
short-term endurance performance. J Appl Physiol (1985), 2006. 101(3): p. 
918-25. 
235. Hietavala, E.M., et al., Effect of diet composition on acid-base balance in 
adolescents, young adults and elderly at rest and during exercise. Eur J Clin 
Nutr, 2015. 69(3): p. 399-404. 
236. Boldyrev, A.A. and S.E. Severin, The histidine-containing dipeptides, carnosine 
and anserine: distribution, properties and biological significance. Adv Enzyme 
Regul, 1990. 30: p. 175-94. 
237. Smith, E.C.B., The buffering of muscle in rigor; protein, phosphate and 
carnosine. The Journal of Physiology, 1938. 92(3): p. 336-343. 
238. Ducker, K.J., B. Dawson, and K.E. Wallman, Effect of Beta alanine and sodium 
bicarbonate supplementation on repeated-sprint performance. J Strength Cond 
Res, 2013. 27(12): p. 3450-60. 
239. Bishop, D. and B. Claudius, Effects of induced metabolic alkalosis on prolonged 
intermittent-sprint performance. Med Sci Sports Exerc, 2005. 37(5): p. 759-67. 
240. Lavender, G. and S.R. Bird, Effect of sodium bicarbonate ingestion upon 
repeated sprints. Br J Sports Med, 1989. 23(1): p. 41-5. 
241. Linderman, J.K. and K.L. Gosselink, The effects of sodium bicarbonate 
ingestion on exercise performance. Sports Med, 1994. 18(2): p. 75-80. 
242. Hobson, R.M., et al., Effect of sodium bicarbonate supplementation on 2000-m 
rowing performance. Int J Sports Physiol Perform, 2014. 9(1): p. 139-44. 
243. McGawley, K. and D. Bishop, Reliability of a 5 x 6-s maximal cycling repeated-
sprint test in trained female team-sport athletes. Eur J Appl Physiol, 2006. 
98(4): p. 383-93. 
244. Fitzsimons, M., et al., Cycling and running tests of repeated sprint ability. 
Australian Journal of Science and Medicine in Sport, 1993. 25: p. 82-82. 
245. Baguet, A., et al., Effects of sprint training combined with vegetarian or mixed 
diet on muscle carnosine content and buffering capacity. Eur J Appl Physiol, 
2011. 111(10): p. 2571-80. 
246. Atkinson, G. and A.M. Nevill, Statistical methods for assessing measurement 
error (reliability) in variables relevant to sports medicine. Sports Med, 1998. 
26(4): p. 217-38. 
247. Saunders, B., et al., Reliability of a high-intensity cycling capacity test. J Sci 
Med Sport, 2013. 16(3): p. 286-9. 
 155 
 
248. Hopkins, W.G., et al., Progressive statistics for studies in sports medicine and 
exercise science. Med Sci Sports Exerc, 2009. 41(1): p. 3-13. 
249. Matson, L.G. and Z.V. Tran, Effects of sodium bicarbonate ingestion on 
anaerobic performance: a meta-analytic review. Int J Sport Nutr, 1993. 3(1): p. 
2-28. 
250. Galloway, S.D. and R.J. Maughan, The effects of induced alkalosis on the 
metabolic response to prolonged exercise in humans. Eur J Appl Physiol Occup 
Physiol, 1996. 74(4): p. 384-9. 
251. McNaughton, L.R., Bicarbonate ingestion: effects of dosage on 60 s cycle 
ergometry. J Sports Sci, 1992. 10(5): p. 415-23. 
252. Siegler, J.C., et al., Metabolic alkalosis, recovery and sprint performance. Int J 
Sports Med, 2010. 31(11): p. 797-802. 
253. Lindh, A.M., et al., Sodium bicarbonate improves swimming performance. Int J 
Sports Med, 2008. 29(6): p. 519-23. 
254. Froio de Araujo Dias, G., et al., (In)Consistencies in Responses to Sodium 
Bicarbonate Supplementation: A Randomised, Repeated Measures, 
Counterbalanced and Double-Blind Study. PLoS One, 2015. 10(11): p. 
e0143086. 
255. Sparks, A., et al., Sodium bicarbonate ingestion and individual variability in 
time-to-peak pH. Res Sports Med, 2017. 25(1): p. 58-66. 
256. Sahlin, K. and J.M. Ren, Relationship of contraction capacity to metabolic 
changes during recovery from a fatiguing contraction. J Appl Physiol (1985), 
1989. 67(2): p. 648-54. 
257. Bogdanis, G.C., et al., Recovery of power output and muscle metabolites 
following 30 s of maximal sprint cycling in man. J Physiol, 1995. 482 ( Pt 2): p. 
467-80. 
258. Dawson, B., et al., Muscle phosphocreatine repletion following single and 
repeated short sprint efforts. Scand J Med Sci Sports, 1997. 7(4): p. 206-13. 
259. Gaitanos, G.C., et al., Human muscle metabolism during intermittent maximal 
exercise. J Appl Physiol (1985), 1993. 75(2): p. 712-9. 
260. Tomlin, D.L. and H.A. Wenger, The relationship between aerobic fitness and 
recovery from high intensity intermittent exercise. Sports Med, 2001. 31(1): p. 
1-11. 
261. Bogdanis, G.C., et al., Contribution of phosphocreatine and aerobic metabolism 
to energy supply during repeated sprint exercise. J Appl Physiol (1985), 1996. 
80(3): p. 876-84. 
262. Chwalbinska-Moneta, J., et al., Threshold for muscle lactate accumulation 
during progressive exercise. J Appl Physiol (1985), 1989. 66(6): p. 2710-6. 
263. Faiss, R., et al., Significant molecular and systemic adaptations after repeated 
sprint training in hypoxia. PLoS One, 2013. 8(2): p. e56522. 
264. Messonnier, L., et al., Importance of pH regulation and lactate/H+ transport 
capacity for work production during supramaximal exercise in humans. J Appl 
Physiol (1985), 2007. 102(5): p. 1936-44. 
265. Weston, A.R., et al., Skeletal muscle buffering capacity is higher in the 
superficial vastus than in the soleus of spontaneously running rats. Acta 
Physiologica Scandinavica, 1996. 157(2): p. 211-216. 
266. Bell, G.J. and H.A. Wenger, The Effect of One-Legged Sprint Training on 
Intramuscular Ph and Nonbicarbonate Buffering Capacity. European Journal of 
Applied Physiology and Occupational Physiology, 1988. 58(1-2): p. 158-164. 
 156 
 
267. Lancha Junior, A.H., et al., Nutritional Strategies to Modulate Intracellular and 
Extracellular Buffering Capacity During High-Intensity Exercise. Sports Med, 
2015. 45 Suppl 1: p. S71-81. 
268. Percival, M.E., et al., Sodium bicarbonate ingestion augments the increase in 
PGC-1alpha mRNA expression during recovery from intense interval exercise 
in human skeletal muscle. J Appl Physiol (1985), 2015. 119(11): p. 1303-12. 
269. Driller, M.W., et al., The effects of chronic sodium bicarbonate ingestion and 
interval training in highly trained rowers. Int J Sport Nutr Exerc Metab, 2013. 
23(1): p. 40-7. 
270. Troup, J.P., J.M. Metzger, and R.H. Fitts, Effect of high-intensity exercise 
training on functional capacity of limb skeletal muscle. J Appl Physiol (1985), 
1986. 60(5): p. 1743-51. 
271. Demarle, A.P., et al., Whichever the initial training status, any increase in 
velocity at lactate threshold appears as a major factor in improved time to 
exhaustion at the same severe velocity after training. Arch Physiol Biochem, 
2003. 111(2): p. 167-76. 
272. Bayati, M., et al., A practical model of low-volume high-intensity interval training 
induces performance and metabolic adaptations that resemble 'all-out' sprint 
interval training. J Sports Sci Med, 2011. 10(3): p. 571-6. 
273. Burgomaster, K.A., et al., Six sessions of sprint interval training increases 
muscle oxidative potential and cycle endurance capacity in humans. J Appl 
Physiol (1985), 2005. 98(6): p. 1985-90. 
274. Sharp, R.L., et al., Effects of eight weeks of bicycle ergometer sprint training on 
human muscle buffer capacity. Int J Sports Med, 1986. 7(1): p. 13-7. 
275. Nevill, M.E., et al., Effect of training on muscle metabolism during treadmill 
sprinting. J Appl Physiol (1985), 1989. 67(6): p. 2376-82. 
276. Ghiasvand, R., et al., Effects of Six Weeks of beta-alanine Administration on 
VO(2) max, Time to Exhaustion and Lactate Concentrations in Physical 
Education Students. Int J Prev Med, 2012. 3(8): p. 559-63. 
277. Agency, W.A.-D. World anti-doping code 2015.  12 January 2015]; Available 
from: https://wada-main-prod.s3.amazonaws.com/resources/files/wada-2015-
world-anti-doping-code.pdf. 
278. Lun, V., et al., Dietary supplementation practices in Canadian high-
performance athletes. Int J Sport Nutr Exerc Metab, 2012. 22(1): p. 31-7. 
279. Finch, C.F. and A. Donaldson, A sports setting matrix for understanding the 
implementation context for community sport. Br J Sports Med, 2010. 44(13): p. 
973-8. 
280. Clark, V.R., et al., Placebo effect of carbohydrate feedings during a 40-km 
cycling time trial. Medicine and Science in Sports and Exercise, 2000. 32(9): p. 
1642-1647. 
281. Beedie, C.J. and A.J. Foad, The placebo effect in sports performance: a brief 
review. Sports Med, 2009. 39(4): p. 313-29. 
282. Trexler, E.T., et al., International society of sports nutrition position stand: Beta-
Alanine. J Int Soc Sports Nutr, 2015. 12: p. 30. 
283. Stellingwerff, T., Global Application of Beta-Alanine in sports practise. 14th 
Sport Nutrition Conference, London/Oxford 2012, 2012: p. 14. 
284. Cramer, J.A., et al., Medication compliance and persistence: terminology and 
definitions. Value Health, 2008. 11(1): p. 44-7. 
 157 
 
285. Urquhart, J. and E. De Klerk, Contending paradigms for the interpretation of 
data on patient compliance with therapeutic drug regimens. Stat Med, 1998. 
17(3): p. 251-67; discussion 387-9. 
286. Zeppetella, G., How do terminally ill patients at home take their medication? 
Palliat Med, 1999. 13(6): p. 469-75. 
287. Iskedjian, M., et al., Relationship between daily dose frequency and adherence 
to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin 
Ther, 2002. 24(2): p. 302-16. 
288. Mu, S. and T.M. Ludden, Estimation of population pharmacokinetic parameters 
in the presence of non-compliance. J Pharmacokinet Pharmacodyn, 2003. 
30(1): p. 53-81. 
289. Eisen, S.A., et al., The effect of prescribed daily dose frequency on patient 
medication compliance. Arch Intern Med, 1990. 150(9): p. 1881-4. 
290. Urquhart, J., The electronic medication event monitor. Lessons for 
pharmacotherapy. Clin Pharmacokinet, 1997. 32(5): p. 345-56. 
291. van Reijen, M., et al., Compliance with Sport Injury Prevention Interventions in 
Randomised Controlled Trials: A Systematic Review. Sports Med, 2016. 46(8): 
p. 1125-39. 
292. Morisky, D.E., et al., Predictive validity of a medication adherence measure in 
an outpatient setting. J Clin Hypertens (Greenwich), 2008. 10(5): p. 348-54. 
293. Sackett, D.L., et al., Randomised clinical trial of strategies for improving 
medication compliance in primary hypertension. Lancet, 1975. 1(7918): p. 
1205-7. 
294. Vervloet, M., et al., Short- and long-term effects of real-time medication 
monitoring with short message service (SMS) reminders for missed doses on 
the refill adherence of people with Type 2 diabetes: evidence from a 
randomized controlled trial. Diabet Med, 2014. 31(7): p. 821-8. 
295. Hayes, T.L., et al., An electronic pillbox for continuous monitoring of medication 
adherence. Conf Proc IEEE Eng Med Biol Soc, 2006. 1: p. 6400-3. 
296. Ammassari, A., et al., Self-reported symptoms and medication side effects 
influence adherence to highly active antiretroviral therapy in persons with HIV 
infection. J Acquir Immune Defic Syndr, 2001. 28(5): p. 445-9. 
297. Grunfeld, E.A., et al., Adherence beliefs among breast cancer patients taking 
tamoxifen. Patient Educ Couns, 2005. 59(1): p. 97-102. 
298. Chen, L.C., et al., Disease acceptance and adherence to imatinib in Taiwanese 
chronic myeloid leukaemia outpatients. Int J Clin Pharm, 2014. 36(1): p. 120-7. 
299. Berglund, E., P. Lytsy, and R. Westerling, Adherence to and beliefs in lipid-
lowering medical treatments: a structural equation modeling approach including 
the necessity-concern framework. Patient Educ Couns, 2013. 91(1): p. 105-12. 
300. Noens, L., et al., Prevalence, determinants, and outcomes of nonadherence to 
imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. 
Blood, 2009. 113(22): p. 5401-11. 
301. Horne, R., et al., Medicine in a multi-cultural society: the effect of cultural 
background on beliefs about medications. Soc Sci Med, 2004. 59(6): p. 1307-
13. 
302. Sakthong, P., R. Chabunthom, and R. Charoenvisuthiwongs, Psychometric 
properties of the Thai version of the 8-item Morisky Medication Adherence 
Scale in patients with type 2 diabetes. Ann Pharmacother, 2009. 43(5): p. 950-
7. 
 158 
 
303. Quesnele, J.J., et al., The effects of beta-alanine supplementation on 
performance: a systematic review of the literature. Int J Sport Nutr Exerc Metab, 
2014. 24(1): p. 14-27. 
304. Martinez, M.N. and G.L. Amidon, A mechanistic approach to understanding the 
factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol, 
2002. 42(6): p. 620-43. 
305. Kamimori, G.H., et al., The effects of obesity and exercise on the 
pharmacokinetics of caffeine in lean and obese volunteers. Eur J Clin 
Pharmacol, 1987. 31(5): p. 595-600. 
306. Han, L., et al., A subpopulation of nociceptors specifically linked to itch. Nat 
Neurosci, 2013. 16(2): p. 174-82. 
307. Qu, L., et al., Enhanced excitability of MRGPRA3- and MRGPRD-positive 
nociceptors in a model of inflammatory itch and pain. Brain, 2014. 137(Pt 4): p. 
1039-50. 
308. Gonzalez, A.M., et al., Effect of a pre-workout energy supplement on acute 
multi-joint resistance exercise. J Sports Sci Med, 2011. 10(2): p. 261-6. 
309. Spradley, B.D., et al., Ingesting a pre-workout supplement containing caffeine, 
B-vitamins, amino acids, creatine, and beta-alanine before exercise delays 
fatigue while improving reaction time and muscular endurance. Nutr Metab 
(Lond), 2012. 9: p. 28. 
310. Walsh, A.L., et al., Improved time to exhaustion following ingestion of the 
energy drink Amino Impact. J Int Soc Sports Nutr, 2010. 7: p. 14. 
311. Invernizzi, P.L., et al., The Acute Administration of Carnosine and Beta-Alanine 
Does Not Improve Running Anaerobic Performance and has No Effect on the 
Metabolic Response to Exercise. Advances in Physical Education, 2013. 
Vol.03No.04: p. 6. 
312. Kelly, V.G., et al., Prevalence, knowledge and attitudes relating to beta-alanine 
use among professional footballers. J Sci Med Sport, 2016. 
313. Benedetti, F. and M. Amanzio, Mechanisms of the placebo response. Pulm 
Pharmacol Ther, 2013. 26(5): p. 520-3. 
314. Halson, S.L. and D.T. Martin, Lying to win-placebos and sport science. Int J 
Sports Physiol Perform, 2013. 8(6): p. 597-9. 
 159 
 
APPENDICES 
 
APPENDIX A: Evaluation of the Prevalence, Knowledge and Attitudes Towards Beta-
Alanine Use Among Athletes Questionnaire  
 
 
 
 
 
Evaluation of the Prevalence, Knowledge and Attitudes Towards 
Beta-Alanine Use Among Athletes  
 
Please note that your responses are completely anonymous 
_________________________________________________________________________________ 
 
SECTION 1.0 DEMOGRAPHICS 
 
Date of Birth: ___________  Body Mass: ________kg  
 
Sport: _________________________________ 
 
Training for this sport involves training in which of the following disciplines?  
Tick ALL relevant boxes 
 
 Resistance Training e.g. weights, strength work  
 Aerobic Conditioning e.g. running, cycling, boxing ergometer work    
 Speed Training   
 Skills Training 
Other (please specify) _____________________________ 
 
What level do you currently participate in your particular sport?  
 
 Club-level   State-level   National-level   International-level  
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How many years have you participated at this level?      
 
 <1 year  
 1 year  
 2 years  
 3 years  
 >3 years  
 Other________________________ 
 
How many hours per week do you spend doing each of the following? 
 
Training   ________hours    
 
Competing  ________hours  
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SECTION 2.0 KNOWLEDGE OF BETA-ALANINE 
 
How would you rate your knowledge (potential benefits, when to take it, how much to take 
etc) of the supplement beta-alanine? 
 
 Nil   Limited  Average   Good  Excellent    
 
In general, how long do you have to take beta-alanine before a performance benefit occurs? 
 
 15-30min   1h   1 week   1-2 months  >2 months  
 Unsure    
    Other (please specify) ___________________________________________________ 
 
What dose of beta-alanine do you believe is needed to enhance performance? 
Tick ONE box only 
 
 Unsure    
 
 1-2 capsules/day  3-5 capsules/day  6+ capsules/day 
e.g. 1-2 capsules “Beta Blast”/day 3-5 capsules “Beta Blast”/day 6+ capsules “Beta Blast”/day 
 
 1-2 teaspoons/day  3-5 teaspoons/day  6+ teaspoons/day  
e.g. 1-2 tsp beta-alanine powder 3-5 tsp beta-alanine powder   6+ tsp beta-alanine powder 
 
 1-2 grams/day  3-5 grams/day  6+ grams/day  
 
 Other (please specify) ___________________________________________________ 
 
Do you think there are any risks of returning a positive drug test associated with beta-alanine 
use? 
 
 Yes   No     
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What effect do you think beta-alanine would have on the following aspects of exercise 
performance? 
 Improve endurance performance   
 Improve sprint performance  
 Improve repeated sprint performance (muscle buffer capacity) 
 Improve sport performance  
 Improve strength performance  
 Reduce fatigue 
 Build muscle 
 Lose fat  
 No effect  
 Other (please specify) ________________________________________ 
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SECTION 3.0 BETA-ALANINE USE 
 
Have you ever used beta-alanine or a product containing beta-alanine (e.g. Pure Beta-Alanine 
Powder, Beta-Blast, Reactivate Hardcore, etc) at any point in your athletic career? 
 Yes   No 
 
If you answered No what are your reasons for not taking beta-alanine? 
  
 Personal/religious beliefs  
 No knowledge of supplements 
 The cost is too high   
 I am healthy enough  
 Beta-alanine has no effect  
 I am afraid of the side effects of beta-alanine 
 I am afraid of doping issues 
 Other (please specify) ___________________________________________________ 
 
If you answered No above, please proceed to SECTION 5 on Page 7. 
 
If you answered Yes please continue below. 
 
If you answered YES above, why do/did you use beta-alanine?  
Tick ALL relevant boxes 
  
 Improve endurance performance   
 Improve sprint performance  
 Improve repeated sprint performance (muscle buffer capacity) 
 Improve sport performance  
 Improve strength performance  
 Reduce fatigue 
 Build muscle 
 Lose fat  
 Other (please specify) ________________________________________ 
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At what level of competition did you first use beta-alanine? 
 
 Club-level  State-level   National-level  International-level  
 
When was the last time you used beta-alanine? 
 
 Past 7 days         
 Past 30 days  
 Past 2-6 months  
 Past 7-12 months  
 > 1 year ago 
 
In which training phases do you generally use beta-alanine and how often? 
Tick ALL relevant boxes 
 
 Off season   
  Never 
  1-3 times/wk 
  4-6 times/wk 
  >6 times/wk 
 Pre-season training  
  Never 
  1-3 times/wk 
  4-6 times/wk 
  >6 times/wk 
 In-season/competition season 
  Never 
  1-3 times/wk 
  4-6 times/wk 
  >6 times/wk 
  Immediately before some matches/competitions  
  Immediately before priority matches/competitions 
  Immediately before all matches/competitions 
 
 Other (please specify) ________________________________________ 
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When do you usually take beta-alanine?  
Tick ALL relevant boxes 
  
 Before training   
 After training  
 Upon waking 
 With breakfast  
 With lunch  
 With dinner 
 Before bed 
 Other (please specify) ________________________________________ 
   
On average, what dose of beta-alanine do you take? 
 
 1-2 capsules/day  3-5 capsules/day  6+ capsules/day 
 1-2 teaspoons/day  3-5 teaspoons/day  6+ teaspoons/day  
 1-2 grams/day  3-5 grams/day  6+ grams/day  
 
 Other (please specify) ___________________________________________________ 
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In the table below please describe the brand of beta-alanine you generally use and how you 
use beta-alanine. (Please specify exact brand name, product name and dosages) 
 
Product Individual Dose Doses per Day Days per 
Week 
Example 1: Body Science – 
Beta Blast 
2 capsules 3 5 
Example 2: Musashi –  
Reactivate Hardcore 
1 scoop 1 3 
Example 3: Balance –  
Pure Beta-Alanine Powder 
Half a teaspoon 
(2 grams) 
3 4 
 
 
 
   
 
 
 
   
 
 
 
   
 
 
 
   
 
 
 
   
   
 
Please give details about where you obtained your beta-alanine? 
 
 Supplement store   
 Health food store  
 Online store 
 Provided by a team/club staff  
 Other (please specify) ________________________________________ 
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Please give details about how you obtained your beta-alanine? 
 
 I purchased it myself   
 It was provided by a team/club sponsor  
 It was provided by an individual sponsor 
 It was provided by a friend’s/team mate’s individual sponsorship 
 Other (please specify) ________________________________________ 
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SECTION 4.0 SIDE EFFECTS OF BETA-ALANINE USE 
 
Using the scale below, please note the severity of any side effects you have experienced as 
a result of using beta-alanine. 
                                                  
 
 
Absent Noticeable 
but minor 
Noticeable Severe Very 
Severe 
Unsure 
Pins & needles/tingly or 
prickly skin  
      
Tickling, itching       
Flushes, shiver       
Skin Irritation       
Numbness, insensitivity       
Pain, soreness       
Other________________       
 
In the diagram below mark with a large X, within each of the depicted framed zones, where 
you have experienced any of these sensations. 
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___________________________________________________ 
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SECTION 5.0 SOURCE OF INFORMATION 
From the following list, please select any individual(s) or information sources that have 
influenced your decision to use/not use beta-alanine within your sport?  
(Tick ALL relevant boxes). 
  
 I’ve never considered the use of beta-alanine with sport   
 
 Doctor/Physician 
 Strength & Conditioning Coach  
 Dietitian/Nutritionist  
 Coach  
 Trainer  
 Team mate  
 Physiotherapist 
 Sport Scientist 
 Manager 
 Massage Therapist 
 Health Food/Supplement Shop 
 Parent   
 Relative 
 Fellow athlete 
 Friend 
 Internet 
 TV/Radio  
 Magazine  
 Self-researched/experimented  
 Other (please specify) ________________________________________ 
 
How often do you read the labels of beta-alanine supplements before you take it? 
 
 Always  Sometimes  Never  Not applicable (i.e. I don’t take beta-alanine) 
 
Have you attempted to locate information on the side effects of beta-alanine? 
 
 Yes   No   Not applicable (i.e. I don’t take beta-alanine)   
Thank you for taking the time to complete this questionnaire.  
Good luck with your sport!  
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APPENDIX B: Sensory Questionnaire  
  STUDY…….. 
 
StudyTitle:…………………………………………………………………………… 
 
QUESTIONNAIRES 
on sensory perceptions and mood 
 
 
Volunteer:        ID#.……… 
 
Date of test: ………….………… 
 
 
 
The questionnaires to be filled today are listed in exact order.  
Therefore, please do NOT go back at any time  
to review a previous answer! 
 
 
NAME OF RESEARCHER 
ADMINSTERING THE QUESTIONNARE ……………………………………… 
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VAS 
 
 
 
 
 
Intensity of Sensation:  Visual Analogue Score (VAS) 
 
Explanation to the participant 
This is a linear, continuous scale to help you evaluate the intensity of your unusual 
sensations. 
1. First, identify the end of the line (either on the complete right or left side) that 
corresponds to zero sensations and mark an X in the square near the label  “No 
unusual sensation”. 
(This is being highlighted since some scales are presented to you from the left to 
right, but also sometimes from right to left). 
2. Then draw a vertical line at the spot that matches best the intensity of unusual 
sensations that you are perceiving at this very moment. 
 
Do not spend more than 5 seconds selecting the appropriate spot for the vertical 
line. 
 
 
Note: If you are unsure what to do, or have any questions throughout the questionnaire, 
please ask the person administering the questionnaire.  Also, please IGNORE any sensation 
that is cleary related to a known cause, such as the sting of a venous puncture or catheter. 
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VAS 
 
 
 
 
 
 
 
 
 
No unusual
sensation
Most intense
imaginable
sensation
Tick the zero sensation side , then
Mark with a vertical line the place on the scale that best reflects the
intensity with which you perceive unusual sensations at this moment. 
X
0 min
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ISS & QLSI 
 
 
 
 
 
Descriptions of unusual sensations: 
A) Intensity of Sensation Score (ISS) 
B) Qualitative Light Symptom Inventory (QLSI) 
C) Temporality 
D) Depth 
 
Explanation to the participant: 
 
If you perceive no unusual sensation at this moment, you fill in as follows: 
 
A)  =      absent 
B)  =   “0” for each of the 7 descriptors 
…and you cross out tables C) and D) 
 
 
 
Note: If you are unsure what to do, or have any questions throughout the questionnaire, 
please ask the person admistering the questionnaire.  Also, please IGNORE any sensation 
that is cleary related to a known cause, such as the sting of a venous puncture or catheter. 
. 
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Unusual sensations                    ISS & QLSI     0 min  
 
A) Intensity (ISS) 
Estimate the global intensity 
of your sensory perceptions 
at this very instant. 
 
Mark one box only with a X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C) Temporality 
Your dominant sensation at this 
instant is….? 
Mark one box only with an X 
 
 
 
 
 
 
 
 
 
 
B) Description (QSI) 
Which terms (multiple answers 
allowed) best match the nature 
of your sensations 
at this instant ? 
Circle ( Ο ) the score that best fits 
the perceived intensity 
(0=absent… 4=extremely 
strong). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D) Depth 
The location of the sensations is 
rather…(one box only X). 
absent
very very weak
very weak
weak
moderate, average
intense
very intense
very very intense
unbearable
brief, transient,
momentary
rhythmical, periodic,
intermittent, oscillating
continuous, constant,
regular, sustained
pins-and-needles, tingle
tickling, itching
flush, shiver
tactile hypersensitivity, irritation
numbness, insensitivity
pain, soreness
other ?.....................................
0  1  2  3  4
0  1  2  3  4
0  1  2  3  4
0  1  2  3  4
0  1  2  3  4
0  1  2  3  4
0  1  2  3  4
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EXTERNAL
INTERNAL
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SSS 
 
     0 min  
 
Explanation to the participant for describing the 
 
Sensitive body Surface Score (SSS) 
 
A scheme of the body helps you to designate sites on your body where you perceive 
unusual sensations at this very instant. 
 
Mark with a large X, within each of the depicted framed zones, where you are certain 
of the location/site of your sensations. 
 
Notes 
1. Multiple answers allowed: Draw as many X’s as there are sensitive zones (but 
only one X within each zone). The exact spot of the mark within a zone is not 
taken in consideration. 
2. Body sites remaining outside of the framed zones are not taken in 
consideration; you must use the nearest zone for marking. Do not mark outside 
of the framed zones. 
3. Do not take into account the nature of the sensation nor its perceived 
intensity, just consider the location. 
4. Carefully distinguish between the front and the back of the body using the 
appropriate body picture below. In particular, the inside of the arms is to be 
marked on the body picture viewed from the front (body image on the left side 
of the page) and the outside of the arms is to be marked on the body picture 
viewed from the back (body image on the right side of the page). 
5. If a sensation is perceived on both sides, you will draw marks on the left side 
and on the right side 
6. If you perceive no particular unusual sensation, please cross out the whole 
body scheme. 
 
Note: If you are unsure what to do, or have any questions throughout the 
questionnaire, please ask the person admistering the questionnaire.  Also, please 
IGNORE any sensation that is cleary related to a known cause, such as the sting of a 
venous puncture or catheter. 
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APPENDIX C: Compliance Questionnaire including modified Morisky scale. 
Please note that your responses are completely anonymous 
_________________________________________________________________________________ 
DEMOGRAPHICS 
 
Date of Birth: ___________   
 
Height: ________ cm  
 
Body Mass: ________ kg  
 
Position: ________________  
 
How many years have you been playing rugby league at senior level (FOGS &/or Qld Cup or 
above)?     ________________________ years 
 
Have you ever used beta-alanine or a product containing beta-alanine (e.g. Pure Beta-Alanine 
Powder, Beta-Blast, Reactivate Hardcore, etc) at any point?    Yes   No 
 
ADHERENCE TO TAKING YOUR SUPPLEMENTS 
 
Do you sometimes forget to take your supplements?   Yes   No 
 
People sometimes miss taking their supplements for reasons other than forgetting. Thinking 
over the past four weeks, were there any days when you did not take your supplements? 
              Yes   No 
 
Have you ever cut back or stopped using your supplements without telling your strength and 
conditioning coach because you felt you were not getting any benefit from it? 
             Yes   No 
 
When you travel or leave home, do you sometimes forget to bring along your supplements? 
             Yes   No 
 
Did you take all your supplements on the last day of your 4 week period?  
             Yes   No 
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When you feel you are not getting any benefit from your supplements, do you sometimes stop 
taking your supplements?             Yes   No 
 
Taking supplements every day is a real inconvenience for some people. Do you ever feel 
hassled about sticking to your supplement plan?     Yes   No 
 
How often do you have difficulty remembering to take all your supplements? 
 
 A. Never/rarely 
 
 B. Once in a while 
 
 C. Sometimes 
 
 D. Usually 
 
 E. All the time 
 
On which of the following days did you take the MOST supplements? 
 A. Weekdays 
 B. Weekends 
 C. Training days 
 D. Non-training days  
 E. I took all my supplements 
 
On which of the following days did you take the LEAST supplements? 
 A. Weekdays 
 B. Weekends 
 C. Training Days 
 D. Non-training days  
 E. I took all my supplements 
 
Did you take the supplements in each of the four weeks of the trial period?  
 Yes   No 
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If No, Why did you stop?  
 
 
 
 
 
 
Did you take the ALL of the supplements during the trial period?  Yes   No 
 
If No, Why did you not take all of your supplements every day? 
 
 
 
 
 
 
What made it easy to take all your supplements? What techniques did you use to make sure 
you took as many as possible on each day? 
 
 
 
 
 
 
 
 
 
In the future what methods/techniques/reminders would help you to ensure you take all your 
required supplements every day? 
 
 
 
 
 
 
